1. TITLE PAGE  
KemPhar
m Denmark  A/S 
CLINICAL S
TUDY PROTOCOL - CONFIDENTIAL  
Protocol Number:  CT-ORZY- NPC -002 
EudraCT Number:  2015-004438-93 
IND Number:   124547 
Title:  Arimoclomol prospective double -blind, randomi sed, 
placebo -controlled study in patients diagnosed with 
Niemann -Pick disease type C  
Version and Date:  Final Version  11.0 ‚Äì 21-Jun-2022 
Sponsor : KemPharm Denmark  A/S, Ole Maal√∏es Vej 3, DK -2200 
Copenhagen N, Denmark  
Clinicaltrials.gov ID: [STUDY_ID_REMOVED]
This document contains information which is the property of Zevra Denmark A/S and 
is provided here as part of the results registration on clinicaltrials.gov. It is understood 
that this information cannot and will not be disclosed to others without written 
approval from Zevra  Denmark A/S.
Protocol CT-ORZY-NPC-002 Arimoclomol in Niemann-Pick disease type C 
2. SIGNATURE PAGEPage 2 of 173 
Arimoclomol prospective double-blind, randomised, placebo-controlled study in 
patients diagnosed with Niemann -Pick disease type C 
Sponsor 
 
Chief Medical Officer 
Tel:  
e-mail: @KemPharm.com
Study Coordinating/Signatory Investigator: 
Dr. med.  
Tel: +  
e-mail: 
Final Version l 1.0; 21-Jun-2021 Signature 
Signature 
Date 
CONFIDENTIAL 

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 3 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  3. PROTOCOL AGREEMENT PAGE
I confirm that I have read and that I understand this protocol, and all other information provided 
by KemPharm Denmark  A/S.  
I agree to conduct this study in conformity with this protocol and also in accordance with the ethical principles that hav e their origin in the Declaration of Helsinki, the E6 International 
Conference on Harmonisation ( ICH) Harmonised Tripartite Guideline for Good Clinical 
Practice (GCP) , all applicable laws and regulations, including, without limitation, data privacy 
laws an d regulations, and the regulatory requirements for reporting serious adverse 
events  (SAEs) defined in Section  15.3 of this protocol. 
Pr
incipal Inve stigator 
Ti
tle and Name:  
Ho
spital Name : 
Signature: 
Date:  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 4 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  4. SYNOPSIS
Study title:  Arimoclomol prospective double blind, randomised, placebo- controlled 
study in patients diagnosed with Niemann -Pick disease type C.  
Protocol number:  CT-ORZY -NPC -002 
Type of study:  Phase II/III  
Sponsor:  KemPharm Denmark  A/S 
Principal Investigator: Prof. Dr. med.  
Study centres:  15-20 sites in 6-9 countries
Laboratories Central laboratories used for all samples:  
Clinical chemistry and haematology : Covance Indianapolis  (United States 
sites); Covance Geneva (European sites).  
Biomarker analysis : Covance Harrogate,  United Kingdom (c holesteryl 
esterification , oxysterol , unesterified cholesterol , heat shock pro tein 
70 [HSP70 ]); KemPharm Denmark , Denmark (g lycosphingolipid s [GSLs] , 
sphingoid bases ); Centogene, Germany (LysoSM509). 
Study design:  MAIN STUDY: 
A prospective, randomised, double -blind, placebo- controlled therapeutic 
study in patients with confirmed diagnosis of Niemann- Pick disease 
type C (NPC) on or not on miglustat therapy that either 1) have 
completed Visit 2 (end of study [EOS]) of the CT -ORZY- NPC -001 study 
or 2) meet the eligibility criteria of this study (CT -ORZY -NPC -001) 
including a requirement of stable treatment with miglustat for 6  months (if 
on miglustat therapy) prior to enrolment into CT -ORZY- NPC -002 study. 
It is anticipated that the majority of p atients for inclusion in the 
CT-ORZY -NPC -002 study would have comp leted the 
CT-ORZY -NPC -001 study. 
The purpose of this study is to assess the efficacy and safety of arimoclomol 
(compared to placebo) when it is administered as an add- on therapy to the 
patient‚Äôs current prescribed best standard of care; each patient‚Äôs stan dard 
of care may, or may not, include miglustat. 
Patients will be stratified into strata A (on miglustat therapy) and B (not on 
miglustat therapy). Hereafter , the patients will be randomised to receive 
placebo or arimoclomol (with an allocation ratio  of 1:2). 
To confirm the selected dose, patients less than 12 years of age will 
undergo an arimoclomol single -dose pharmacokinetic ( PK) evaluation 
before randomisation and the start of continuous (multiple dosing) 
treatment.  
The duration of the blinded phase study period will be 12 months.  
Following this , all patients will be offered to continue into the extension 
phase of the study where  every patient will receive arimoclomol and attend 
site visits at 18 months, and every 6 months thereafter until End of 
Extension Phase at 60 months ( after patient  randomisation) . The extension 
phase runs for 48 months or until arimoclomol has received European 
Union ( EU)/United States  (US)  marketing authori sation  (MA)  or until the 
analysis of data from the controlled , blinded phase  12-month study period 
does not support the efficacy and/or safety of arimoclomol.  If the EU /US 

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 5 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  MA is not obtained within this period, the duration of the study will be 
extended accordingly (amendment to protocol).  
Patients will be enrolled in the extension phase only if the investigator 
deem s that the patient is deriving clinical benefits from th e trial 
participation. 
The Investigator will contact the patient (or the patient's parent[s]/legal 
guardian[s]) by telephone (monthly calls during the first 6  months of the 
blinded phase and every 3 -4 months following the start of the extension 
phase) to follow up on the status of the patient, whether the patient has 
experienced any new AEs or the worsening of any existing AEs, whether 
the patient has had a change in any prescribed medication, whether the 
patient has experienced any difficulties in taking the investigational 
medicinal product  (IMP)  and to confirm the weight of the patient . Should 
the patient experience disease progression that is too severe and/or too fast 
or should there be any safety concerns , the patient may also attend the site 
for unscheduled visits. 
In order to perform an exploratory exposure -response analysis, sampling 
for Population Pharmacokinetics (POP PK) of arimoclomol and 
metabolites (if relevant) will be performed in all patients at Visits  3, 4, 5, 
and 6 (3, 6, 9 and 12 months respectively). 
A Data Safety Monitoring Board (DSMB) will review the safety data  
during the blinded phase of the study. 
Should a patient discontinue prematurely and choose to withdraw from the 
study, all effort should be made to have the patient attend the  site for a 
withdrawal visit during the blinded or the extension phase of the study 
(depending on the time point of withdrawal). 
In patients whose disease progression is too severe and/or too fast, the 
‚Äúearly escape clause‚Äù will allow the Investigator to a pply the escape route 
which implies that the patient can be treated with  arimoclomol during the 
blinded phase of the study. 
Early Escape Clause and Criteria:  
The ‚Äúearly escape clause‚Äù can be invoked when a set of criteria are met in 
the event that  a participating patient experiences  disease p rogression that is 
too severe and/or too fast . In such cases, the patient will:  
1)Stop receiving the IMP;
2)Be offered treatment with arimoclomol ;
3) Continue with their current protocol schedule.
For evaluation of a  potential early escape, the three relevant domains of the 
NPC  Clinical Severity Scale  (NPCCSS) to be assessed are: Ambulation, 
Swallowing and Fine Motor Skills. 
The investigator will assess the following criteria to determine if the ‚Äúearly -
escape clause‚Äù is to be invoked for the particular patient: 
EITHER  
‚Ä¢Criterion  1: An increase of at least 2  points simultaneously in two
out of the three relevant domains of the NPCCSS (for at least
4 points in total) within a period of 3 months;
OR 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 6 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢Criterion  2: An increase of 6  points simultaneously in two out of
the three relevant domains of the NPCCSS (for at least 6  points in
total) within a period of 6 months;
OR 
‚Ä¢Criterion  3: An increase of at least 2  points simultaneously in the
all of the three relevant domains of the NPCCSS (for at least
6 points in total) within a period of 6 months.
The Investigator will submit all requests for early escape to Worldwide 
Clinical Trials  for review and approval. 
Following the review of relevant juvenile toxicology data and 
PK information from 100% of the patients aged 2 to <12 years, t he 
CT-ORZY -NPC -002 study has now been expanded to include a paediatric 
substudy in patients aged 6 to < 24 months at study enrolment which will 
assess the safety and tolerability of 36 months of open -label arimoclomol 
when it is administered as an add -on therapy to the patient‚Äôs current 
prescribed best standard of care; each patient‚Äôs standard of care may, or 
may not, include miglustat. Data from the paediatric substudy will be 
analysed and reported separately from the data in the main study.  
PAEDIATRIC SUBSTUDY: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 7 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Study objectives:  MAIN STUDY: 
Primary:  
‚Ä¢To evaluate therapeutic response to arimoclomol versus placebo,
both in addition to best available standard of care, at 12 months.
Secondary:  
‚Ä¢To evaluate the therapeutic response to arimoclomol through
clinical, biological and imaging assessments at 6 and 12  months;
‚Ä¢To evaluate the long- term therapeutic response (clinical and
biological assessments) at 18 months and every 6 months
thereafter until End of Extension Phase at 60  months;
‚Ä¢To evaluate the safety of arimoclomol.
PAEDIATRIC SUBSTUDY: 
 
 
 
Study drug  and dosage 
form : MAIN STUDY:  
Blinded Phase Study Period 
Arimoclomol citrate or placebo in hard capsules  of 25  mg, 50 mg, and 
100 mg , which are supplied either in single -dose high density 
polyethylene ( HDPE ) bottles for the  initial single dose  PK evaluation  
(patients less than 12  years of age only) , or supplied in blister package s 
mounted within wallets which are packaged  within a box for the  placebo -
controlled part. 
Extension Phase  
Arimoclomol  citrate  in hard capsules of 25 mg and/or 50 mg and/or 100 mg 
are supplied in HDPE bottles. 
PAEDIATRIC SUBSTUDY:  
   
 
 
Dose s to be studied:  MAIN STUDY:  
Dosing is based on the patient‚Äôs body weight (BW): 
Patient Body Weight Arimoclomol C itrate Dose  
8-15 kg BW 50 mg t.i.d. (150 mg/day) 
>15-22 kg BW 75 mg t.i.d. (225 mg/day) 
>22-38 kg BW 100 mg t.i.d. (300 mg/day) 
>38-55 kg BW 150 mg t.i.d. (450 mg/day) 

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 8 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  >55 kg BW 200 mg t.i.d. (600 mg/day) 
The patient‚Äôs weight will be measured at each visit and the IMP dose is to 
be adjusted as required.  
In the event that a patient who is receiving 150 mg IMP per day requires a 
dose reduction, then a dose of 75 mg per day (25 mg t.i.d) should be 
administered.  
For individual patients less than 12  years of age, to confirm the 
corresponding dose, a single dose PK evaluation will be performed by an 
independent assessor following a single dose of arimoclomol to verify the 
area under the cur ve in 0-8 hours  (AUC 0-8). In the event that patient s require 
a dose reduction, the se patient s will be dispensed a further s ingle dose of 
arimoclomol, and a new single dose PK  evaluation will be performed to 
confirm the corresponding dose. Should further dose adjustments be 
required , based on the second single dose PK evaluation, the above 
procedure will be repeated until the c orrect dose level is found.  
Also, in the event that unexpected PK -profiles are obtained (from patients 
less than 12  years of age) which are clinical significant and could 
potentially impact the safety of the patient, the independent assessor can 
recommend additional PK sampling to be performed (in agreement with 
the Sponsor‚Äôs medical responsible person and the Principal Investigator). 
The results of this analysis might lead to dose adjustments as recommended 
by the independent assessor. 
This/these  dose reduction(s) will take place prior to randomisation and to 
commencing continuous dosing of IMP (arimoclomol or placebo, as per the 
study randomisation).  
PAEDIATRIC SUBSTUDY:  
 
 
 
Dosing route and 
regimen  MAIN STUDY:  
IMP (arimoclomol or placebo) will be administered orally t .i.d. 
If required, the IMP can be dispersed in 10-20 mL (i.e. 1-2 tablespoons) of 
liquid (water, apple juice) or soft foodstuff (yoghurt or apple sauce).  
In the dispersed state, the IMP capsules can also be administered via a 
gastric tube (as applicable). For full administration of the dose, flush the 
tube with 5 mL of water.  
PAEDIATRIC SUBSTUDY:  
 
 
 
 
 
 
 

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 9 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL   
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
Dose adjustment:  MAIN STUDY:  
Patients less than 12 years of age may have their dose adjusted (decrease) 
following a single oral dose of arimoclomol based on review of the 
following criteria by an independent assessor:  
‚Ä¢AUC 0-8
Also, in the event that unexpected PK -profiles are obtained (from patients 
less than 12 years of age) which are clinical significant and could 
potentially impact the safety of the patient, the independent assessor can 
recommend additional PK sampling to be performed (in agreement with 
the Sponsor‚Äôs medical responsible person and the Princi pal Investigator). 
The results of this analysis might lead to dose adjustments as recommended 
by the independent assessor.  
In addition to this, a patient who has commenced continuous dosing with 
the IMP is to be considered for dose reduction should the fol lowing criteria 
be met: 
‚Ä¢Serum creatinine above 1.5 x the patient‚Äôs baseline creatinine
value . Dose adjustment may be temporary  however, subsequent
dose increase  must be discussed with the KemPharm Denmark ‚Äôs
medical monitor (or delegate) ;
Note : Serum creatinine calculation  = Serum creatinine value /baseline
serum creatinine value. Result rounded to 1 decimal  point as per normal
rounding principles .
‚Ä¢Decrease in the patient‚Äôs weight  (as confirmed during a site visit)
meeting the lower weight range i n the  actual dose group .
Administration of IMP  will be stopped and the patient withdrawn from the 
study should the following criteria be met:  
‚Ä¢CTCAE* Grade  2 acute kidney injury considered related to the
IMP (which corresponds to the serum creatinine increase of above
2-3 x the patient‚Äôs baseline creatinine value);

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 10 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Note : Serum creatinine  calculation  = Serum creatinine value /baseline 
serum creatinine value. Resul t rounded to 1 decimal  point as per normal 
rounding principles . 
‚Ä¢CTCAE* Grade  3 hepatic related parameters ( aspartate
transaminase  [AST] and/or alanine transaminase [ALT] )
considered related to the IMP;
‚Ä¢Other CTCAE* Grade  3 AEs considered related to the IMP.
*National Cancer Institute Common Terminology Criteria for Adverse
Events  (CTCAE) Version 4.03.
The individual patient dose will be adapted if required upon patient‚Äôs 
weight changes at every visit . 
PAEDIATRIC SUBSTUDY:  
 
  
 
 
 
 
 
 
 
 
 
 
      
 
 
 
.

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 11 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Study population:  MAIN STUDY:  
Male and female patients with a confirmed diagnosis of NPC 1 or NPC2  on 
or not on  miglustat therapy that  either 1) have completed Visit  2 (EOS) of 
the CT -ORZY- NPC -001 study or 2) meet the eligibility criteria of this 
study (CT -ORZY- NPC -001) including a requirement of stable treatment 
with miglustat for 6  months (if on miglustat therapy) prior to enrolment 
into CT -ORZY- NPC -002 study. It is anticipated that the majority of 
patients for inclusion in the CT -ORZY- NPC -002 study would have 
completed the CT -ORZY- NPC -001 study. 
PAEDIATRIC SUBSTUDY:  
 
 
 
 
 
Diagnosis and main 
criteria for i nclusion:  Main inclusion criteria:  
‚Ä¢Diagnosis of NPC1 or NPC2;
‚Ä¢NPC diagnosis confirmed by:
Genetically confirmed (deoxyribonucleic acid [DNA] 
sequence analysis)  by mutations in both alleles of NPC1 or 
NPC2 , 
OR  
oMutation in only one allele of NPC1 or NPC2 plus either
positive filipin staining or elevated cholestane
triol/oxysterols (>2 x upper limit of normal [ULN]).
‚Ä¢Main study : Males and females aged from  2 years to  18 years and
11 months; 
‚Ä¢Paediatric substudy :
‚Ä¢Treated or no t treated with miglustat;
oMain study: If a patient is under prescribed treatment with
miglustat, it has to be under stable dose of the medication
for at least 6 continuous months prior to inclusion in the
CT-ORZY -NPC -002 study;
oMain study : If a patient has been discontinued from
prescribed treatment with miglustat, they must have been
discontinued for at least 3 continuous months prior to
inclusion in the CT- ORZ Y-NPC -002 study;
oPaediatric substudy : 

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 12 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  oPaediatric substudy : 
Main exclusion criteria:  
‚Ä¢Severe liver insufficiency (defined as hepatic laboratory
parameters, AST and /or ALT greater than three -times the ULN for
age and gender [ central laboratory assessment ]);
‚Ä¢Renal insuffici ency, with serum creatinine level greater than 1.5
times the ULN (central laboratory assessment);
‚Ä¢Paediatric substudy:  
 
‚Ä¢Paediatric substudy:  
‚Ä¢Paediatric substudy:  
‚Ä¢Paediatric substudy:  
Number  of planned 
visits:  MAIN STUDY:  
The trial includes the following visits:  
‚Ä¢Visit  1  (Site) :
oScreening;
oPK to confirm doses for patients less than 12  years of age;
oAdditional PK visits ( sit e) for patients less than 12 years of age
if required;
oRandomisation.
‚Ä¢Blinded Phase:
oTelephone follow up every month (¬±7 days) for 6 months after
the start of continuous treatment;
oVisit  2 (site): 7 -14 days after  the start of continuous treatment;
oV isit  3 (site): 3  months (¬±4 weeks) after patient randomisation;
oV isit  4 (site): 6  months (¬±4 weeks) after patient randomisation;
oV isit  5 (site): 9 months (¬±4 weeks) after patient randomisation;
oVisit  6 (site)/End of Blinded Phase: 12 months (¬±4  weeks)
after patient randomisation  or at patient withdrawal during the
blinded phase.
Visits  2 through 6 will include scoring for disease severity,
blood and skin biopsy sampling for biomarkers, as well as
assessment of safety, compliance, Scale for Assessment an d
Rating of Ataxia  (SARA), Nine -hole Peg Test (9HPT),
Clinical Global Impression Scale ‚Äì Severity  (CGI -S), Clinical
Global Impression Scale - Improvement (CGI -I) and Quality
of Life.
‚Ä¢Extension Phase :

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 13 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  oVisit  7 (site): 18 months  (¬±4 weeks) after patient 
randomisation ;
oVisit  8 (site): 24 months  (¬±8 weeks) after patient 
randomisation ;
oVisit  9 (site): 30  months  (¬±8 weeks) after patient 
randomisation;
oVisit  10 (site): 3 6 months (¬±8  weeks) after patient
randomisation;
oVisit  11 (site): 42  months (¬±8  weeks) after patient
randomisation;
oVisit  12 (site): 48  months (¬±8  weeks) after patient
randomisation;
oVisit  13 (site): 54 months (¬±8  weeks) after patient
randomisation;
oVisit  14 (site)/End of Extension Phase: 60 months (¬±8 weeks)
after patient randomisation or at patient withdrawal during the
extension phase.
Visits  7 to 14 will include scoring for disease severity, blood
sampling for biomarkers , as well as assessment of safety,
compliance, SARA, 9HPT , CGI -S, CGI -I and Quality of Life;
oTelephone follow up every 3-4 months .
PAEDIATRIC SUBSTUDY:  
 
     

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 14 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Total sample  size:  MAIN STUDY:  
Up to fifty -two (52) patients will be randomised in the study as the final 
target is to have at least forty  (40) evaluable patients (at least 30 of these 
should be paediatric patients less than 18 years of age).  
PAEDIATRIC SUBSTUDY:  
Primary  endpoint:  MAIN STUDY:  
‚Ä¢Change in the NPC disease severity based on the 5 domain NPCCSS
scores (ambulation, speech, swallow, fine motor skills and cognition)
from baseline  (V isit 1) to 12  months;
Clinical status endpoints:  MAIN STUDY:  
Key Secondary Endpoints: 
‚Ä¢Responder analysis of patient‚Äôs CGI-I score remains stable or shows
improvement at 12 months  (for the United States Food and Drug
Administration  [FDA ] submission, this endpoint is considered co-
primary);
‚Ä¢Responder analysis of patient‚Äôs 5 domain NPCCSS  score remains
stable or improves at 12 months compared to baseline;
‚Ä¢Time to worsening (as defined by reaching the minimal clinica lly
important difference [ MCID]  on patient's 5 domain NPCCSS ).  The
MCID will be determined and documented prior to unblinding the
study;
‚Ä¢Proportion of patients worsening (as defined by reaching the MCID on
patient‚Äôs 5 domain NPCCSS) at 6 and 12 months
‚Ä¢Change in full scale NPCCSS  score apart from hearing domains (i.e.
Hearing and Auditory Brainstem Response) at 12 months.
Other Secondary Endpoints: 
‚Ä¢Change in 5 dom ain NPCCSS score at 6  and 18 months and every
6 months thereafter until End of Extension Phase at 60 months;
‚Ä¢Change in full scale NPCCSS  score apart from hearing domains (i.e.
Hearing and Auditory Brainstem Response) at 6  and 18 months and
every 6  months thereafter until End of Extension Phase at 60 months;
‚Ä¢Responder analysis of the CGI -I score remains stable or shows
improvement at 6  and 18 months and every 6 months thereafter until
End of Extension Phase at 60 months;
‚Ä¢Responder analysis of 5 domain NPCCSS  score remains stable or
improves at 6  and 18 months and every 6 months thereafter until End
of Extension Phase at 60 months compared to baseline;
‚Ä¢Proportion of patients worsening (as defined by reaching the MCID on
patient‚Äôs 5 domain NPCCSS ) at 18 months and every 6 months
thereafter until End of Extension Phase at 60 months;
‚Ä¢Changes in each individual domain of the NPCCSS at 6, 12 and
18 months and every 6 months thereafter until End of Extension Phase
at 60 months;

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 15 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢Change in the Niemann Pi ck type C Clinical Database  (NPC -cdb)
score (modified "Stampfer Score" [Stampfer et al., 2013]) at 6, 12 and
18 months and every 6 months thereafter until End of Extension Phase
at 60 months;
‚Ä¢Change in Quality of Life (EQ -5D- Y) at 6, 12 and 18 months and every
6 months thereafter until End of Extension Phase at 60 months;
‚Ä¢Change in the SARA score at 6, 12 and 18 months and every 6  months
thereafter until End of Extension Phase at 60 months;
‚Ä¢Change in the 9HPT time at 6, 12  and 18 months , and every 6  months
thereafter until End of Extension Phase at 60 months;
‚Ä¢CGI-S score at 6, 12  and 18 months and every 6 months thereafter until
End of Extension Phase at 60 months ;
‚Ä¢CGI-I score at 6, 12 and 18 months and every 6  months thereafter until
End of Extension Phase at 60  months.
PAEDIATRIC SUBSTUDY:  
‚Ä¢
Exploratory Endpoints  MAIN STUDY:  
‚Ä¢NPC disease progression rate based on the NPCCSS scores from
baseline in the CT -ORZY- NPC -002 study to 6 and 12 months;
‚Ä¢The number of patients leaving the blinded phase of the study before
12 months as a result of early escape;
‚Ä¢The number of patients  who either withdraw from the study before
12 months, or who need to jump to escape therapy;
‚Ä¢Change in use of NPC medication/standard of care (including miglustat
therapy) at 12 and 18 months and every 6 months thereafter until End
of Extension Phase at 60 months.
Safety endpoints : MAIN STUDY AND PAEDIATRIC SUBSTUDY:  
‚Ä¢Adverse events ( AEs);
‚Ä¢Haematology;
‚Ä¢Clinical chemistry;
‚Ä¢Vital signs ;
Imaging endpoints:  MAIN STUDY:  
‚Ä¢Changes in the size of the liver and spleen (assessed by ultrasound).
Changes at 6 and 12  months.
PAEDIATRIC SUBSTUDY:  
‚Ä¢
Biomarker endpoints : MAIN STUDY:  
‚Ä¢NPC1 active protein;
‚Ä¢NPC1 protein function (cholesteryl esterification);
‚Ä¢Oxysterol (cholestane- 3Œ≤,5Œ±,6Œ≤ -triol);
‚Ä¢Un-esterified cholesterol;

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 16 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢HSP70 ;
‚Ä¢GSL s;
‚Ä¢Sphingoid bases;
‚Ä¢Lyso -SM-509.
Changes at 6 and 12  months (placebo versus arimoclomol) will be 
evaluated.  During the extension phase of the study, the following 
biomarkers will be analysed:  
‚Ä¢ Oxysterol (cholestane- 3Œ≤,5Œ±,6Œ≤ -triol);
‚Ä¢ Un-esterified cholesterol;
‚Ä¢ HSP70;
‚Ä¢ GSLs;
‚Ä¢ Lyso -SM-509.
PAEDIATRIC SUBSTUDY:
‚Ä¢
Other endpoints:  MAIN STUDY:  
‚Ä¢Patient acceptability/palatability of the IMP  (blinded phase study
period).
Statistical methods:  Descriptive analyses will be performed. Data will be summarised as 
follows: Continuous variables by descriptive statistics (number of 
patients [N], mean, SD, minimum, median and maximum); categorical data 
by absolute and relative frequencies (n and %). 
Unless indicated otherwise, summary statistics will be reported for 
observed data only. Missing data will not be imputed  for reporting 
summary statistics . If a baseline value is missi ng, no change from baseline 
will be calculated . 
MAIN STUDY:  
Evaluation of Primary Endpoint: 
The primary analysis is by a general linear mixed model for repeated 
measurements. The primary endpoint is the change from baseline to 
12 months in the 5  domain NPCCSS. The 5  domain NPCCSS  score is 
derived as the sum of scores from the ambulation, speech, swallow, fine 
motor skills and cognition domains.  
The model will be f itted with treatment, miglustat level and visit as fixed 
effects along with a treatment -by-visit interaction term. The estimated 
treatment effect will be taken from the treatment -by-visit interaction term 
at 12 months. 
The analysis model is:  
ùëåùëåùëñùëñùëñùëñùëñùëñ=ùõΩùõΩ0‚àôùë¶ùë¶ùëñùëñùëñùëñ0+ùëáùëáùëñùëñ+ùëÄùëÄùëôùëô+ùëâùëâùëñùëñ+ùëáùëáùëâùëâùëñùëñùëñùëñ+ùë†ùë†ùëñùëñùëñùëñ+ùëíùëíùëñùëñùëñùëñùëñùëñ 
where  
Yijk is the  5 domain  NPCCSS endpoint for the jth patient of treatment 
group i at visit k  
yij0 is the baseline value for the jth patient of treatment group i 

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 17 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ùõΩùõΩ0 is the unknown fixed slope for the baseline covariate  
Ti is the unknown fixed effect of treatment i 
Ml is the unknown fixed effect of miglustat level l  
Vk is the unknown fixed effect of visit k  
TVik is the unknown fixed interaction effect of treatment i  and visit k  
sij is the effect associated with the jth patient of treatment i  
eijk is the error (residual) associated with the jth patient of treatment i 
at visit k  
sij and eijk are assumed to be independent from each other and follow a 
multivariate normal distribution. Th e covariance matrix for e is chosen to 
be the unstructured variance -covariance matrix, it assumes pair -wise 
correlations are not constrained by the data.  
The estimated treatment effect is taken from the TVik interaction term at 
Visit  6 (i.e. 12 months). 
Missing data will not be imputed for the primary endpoint analysis. If a 
baseline value is missing, no change from baseline will be calculated.  
The model allows for the calculation of the 95% confidence interv al (CI) 
for the treatment effect, and a P -value to test the null hypothesis that the 
effect of arimoclomol  and placebo is the same.  
Evaluation of Secondary Endpoints:  
Key Secondary Endpoints: 
‚Ä¢Responder analysis of patient‚Äôs CGI -I score remains stable or shows
improvement at 12 months and descriptive summary of responder rate
at 12 months  (for the FDA submission, this endpoint is considered a
co-primary endpoint)
‚Ä¢Responder analysis of patient‚Äôs  5 domain NPCCSS  score remains
stable or improves at 12 months and descriptive summary of responder
rate at 12 months .
These will be analysed at 12  months using two- tailed chi -squared tests. If 
chi-squared conditions are not met, then a Fisher‚Äôs exact test will be used. 
A patient who disc ontinues before 12 months will be considered a non-
responder. 
‚Ä¢Time to worsening (as defined by reaching the  MCID in patient‚Äôs 5
domain NPCCSS)
Kaplan -Meier plots for time to worsening will be produced for each 
treatment group and compared via a log -rank te st, stratified for use of 
miglustat.   
‚Ä¢Proportion of patients worsening (as defined by reaching the MCID on
patient‚Äôs 5 domain NPCCSS) at 6 and 12 months
This will be analysed using two -tailed chi -squared tests . If chi -squared 
conditions are not met, then a Fisher‚Äôs exact test will be used. A patient 
who discontinues before 6 months (or 12 months, as appropriate) will be 
considered a patient who has worsened.  
‚Ä¢Change in full scale NPCCSS score apart from hearing domains (i.e.
Hearing and Auditory Brainstem Response) from baseline to 12
months : This will be analysed using an analysis of covariance model
including baseline full scale NPCCSS score (apart from heari ng
domains) , miglustat and randomised treatment as the only covariates.
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 18 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Other Secondary Endpoints : 
‚Ä¢Change in 5 domain NPCCSS at 6 and 18 months and every 6  months
thereafter until End of Extension Phase at 60 months:  The change in
5 domain NPCCSS at 6 months will be analysed using the same model
as for the change in the full NPCCSS ( apart from hearing domains ) at
6 months. Data from 18 months and beyond will be summarised
descriptively.
‚Ä¢Change in full scale NPCCSS sco re apart from hearing domains (i.e.
Hearing and Auditory Brainstem Response) at 6 and 18 months and
every 6  months thereafter until End of Extension Phase at 60 months :
This will be analysed descriptively.
‚Ä¢Responder analysis of the CGI -I score remains stable or shows
improvement at 6 and 18 months and every 6  months thereafter until
End of Extension Phase at 60 months.
‚Ä¢Responder analysis of 5 domain NPCCSS score remains stable or
improves at 6 and 18 months and every 6  months thereafter until En d
of Extension Phase at 60 months compared to baseline .
‚Ä¢Proportion of patients worsening (as defined by reaching the MCID on
patient‚Äôs 5 domain NPCCSS) at 18 months and every 6  months
thereafter until End of Extension Phase at 60 months .
‚Ä¢Changes in each individual domain of the NPCCSS at 6, 12 and
18 months and e v ery 6 months thereafter until End of Extension Phase
at 60 months : These will be tabulated and presented descriptively,
including each domain score and its change from baseline.
‚Ä¢Change in the NPC -cdb score (modified "Stampfer Score") at 6, 12 and
18 months and e v ery 6 months thereafter until End of Extension Phase
at 60 months : This will be analysed using the same model as for the
change in the full N PCCSS ( apart from hearing domains ) at 6  months.
‚Ä¢Change in Quality of Life (EQ 5D Y) at 6, 12 and 18 months and every
6 months thereafter until End of Extension Phase at 60 months : The
changes from baseline will be simply compared by a Mann Whitney
(independent samples) test and 95% CI at each of 6 and 12 months).
Data from 18 months and e very 6  months thereafter until End of
Extension Phase at 60 months will be summarised descriptively.
‚Ä¢Change in the SARA score at 6, 12  and 18 months and every 6  months
thereafter until End of Extension Phase at 60 months : This will be
analysed using the same model as for the change in the NPCCSS ( apart
from hearing domains ) at 6 months.
‚Ä¢Change in the 9HPT time at 6, 12 and 18 months and every 6  months
thereafter until End of Extension Phase at 60 months : This wil l be
analysed using the same model as for the change in the NPCCSS ( apart
from hearing domains ) at 6  months.
‚Ä¢CGI-S score at 6, 12  and 18 months and every 6  months thereafter until
End of Extension Phase at 60 months : This will be analysed
descriptively showing the distribution of scores for each treatment
group at 6 and 12 months and the overall distribution of scores at
18 months and every 6 months thereafter until End of Extension Phase
at 60 months.
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 19 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢CGI-I score at 6, 12  and 18 months  and every 6  months thereafter until
End of Extension Phase at 60 months:  This will be analysed
descriptively showing the distribution of scores for each treatment
group at 6 and 12 months and the overall distribution of scores at
18 months and every 6 months thereafter until End of Extension Phase
at 60 months.
Evaluation of Exploratory Endpoints: 
‚Ä¢NPC disease progression rate based on the NPCCSS (apart from
hearing domains) from baseline in the CT -ORZY- NPC -002 study to 6
and 12 months. This will be analysed using a similar model as for the
change in the N PCCSS score  at 6 months. Specifically, the analysis of
covariance models (2  models) will have as response variables: rate of
disease progression between Baseline and (1) 6  months in the
CT-ORZY- NP C-002  study and (2) 12 months in the
CT-ORZY- NPC-002  study. The covariates in each model (the same in
both analyses) will be rate of disease progression in study
CT-ORZY -NPC -001, miglustat use, and randomised treatment.
‚Ä¢The number of patients le aving the blinded phase of the study before
12 months as a result of early escape will be presented .
‚Ä¢The number of patients who either withdraw from the study before
12 months, or who need to jump to escape therapy  will be presented .
‚Ä¢Change in use of NPC m edication/standard of care (including
miglustat therapy) at 12 and 18 months and every 6  months thereafter
until End of Extension Phase at 60 months will be listed .
Subgroup Analyses:  
Exploratory subgroup analyses will be performed on the primary and three 
key secondary endpoints. Point estimates of treatment differences with 
95% CIs and proportions of treatment difference with 95% CIs will be 
presented for each subgroup where applicable. Exploratory subgroup 
analyses will be performed based upon: 
‚Ä¢Use (or not) of miglustat at randomis ation;
‚Ä¢Genotype;
‚Ä¢Age at diagnosis of first neurological symptom. Categories are:
oPre/peri -natal (onset at age <3  months);
oEarly -infantile (at age 3  months to <2  years);
oLate-infantile (at age 2 to <6  years);
oJuvenile (at age 6 -15 years);
oAdolescent/adult (at age >15  years).
‚Ä¢Age at entry to the study either <12 years or ‚â•12 years;
‚Ä¢Age at entry to the study either <4 years or ‚â•4  years);
‚Ä¢Disease severity defined as the 5 domain NPCCSS score at baseline
divided into 3 severity groups <4, 4- 22 and >22;
‚Ä¢Disease severity defined as the full scale NPCCSS ( apart from hearing
domains) at baseline divided into tertiles; 0 - ‚â§18, 19 - ‚â§36, 37 - ‚â§54);
‚Ä¢Change in full scale NPCCSS score (apart from hearing domains ) from
baseline to 3  months for patients with late infantile phenotype (age at
the start of neurological symptoms: 2 to <6  years).
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 20 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  PAEDIATRIC SUBSTUDY:  
 

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 21 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  5. TABLE OF CONTENTS
1. TITLE PAGE  ................................................................ ...............................1  
2. SIGNATURE PAGE  ................................................................ ....................2  
3. PROTOCOL AGREEMENT PAGE  .........................................................3  
4. SYNOPSIS  ................................................................................................ ....4 
5. TABLE OF CONTENTS ...........................................................................21  
6. LIST OF A BB REVIATIONS AND DEFINITIONS OF TERMS .........28  
7. INTRODUCTION ......................................................................................32  
7.1. NIEMANN -PICK DISEASE TYPE  C ........................................................32  
7.2. ARIMOCLOMOL  .......................................................................................32  
7.2.1.  Clinical Data ................................................................................................33  
7.3. RATIONALE FOR THE STUDY AND RISK- BENEFIT ASSESSMENT
 ......................................................................................................................34  
7.4. BIOBANK  ...................................................................................................38  
8. OBJECTIVES  ............................................................................................39  
8.1. PRIMARY OBJECTIVE  .............................................................................39  
8.2. SECONDARY OBJECTIVES  .....................................................................39  
9. INVESTIGATIONAL PLAN....................................................................40  
9.1. SUMMARY OF STUDY DESIGN  .............................................................40  
9.2. DISCUSSION OF TRIAL DESIGN ............................................................42  
9.3. STUDY ENDPOINTS  .................................................................................44  
9.3.1.  Primary Endpoint .........................................................................................44  
9.3.2.  Clinical Status Endpoints .............................................................................44  
9.3.3.  Exploratory Endpoints .................................................................................45  
9.3.4.  Safety Endpoints ..........................................................................................45  
9.3.5.  Imaging Endpoints .......................................................................................45  
9.3.6.  Biomarker Endpoints ...................................................................................45  
9.3.7.  Other Endpoints ...........................................................................................46  
9.4. TRIAL TIMETABLE (STUDY PERIODS) ................................................47  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 22 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  9.5. DATA SAFETY MONITORING COMMITTEE  .......................................48  
10. SELECTION AND WITHDRAWAL OF PATIENTS ...........................49  
10.1.  INFORMED CONSENT  .............................................................................49  
10.2.  INCLUSION CRITERIA .............................................................................49  
10.3.  EXCLUSION CRITERIA............................................................................51  
10.4.  ASSIGNMENT OF PATIENT NUMBER/ASSIGNING PATIENTS TO 
TREATMENT GROUPS  .............................................................................52  
10.5.  PREMATURE WITHDRAWAL OF PATIENTS FROM STUDY AND REPLACEMENT POLICY  .........................................................................52
 
10.5.1.  Discontinuation Criteria  ...............................................................................52  
10.5.2.  Early Escape Clause and Criteria .................................................................53  
10.5.3.  Replacement Policy ......................................................................................54  
11. STUDY MEDICATION ............................................................................55  
11.1.  INVESTIGATIONAL MEDICINAL PRODUCT  ......................................55  
11.1.1.  Presentation, Storage, Packaging and Labelling of Arimoclomol ...............55  
11.1.2.  Presentation, Storage, Packaging and Labelling of Placebo ........................56  
11.2.  INVESTIGATIONAL MEDICINAL PRODUCT DOSING SCHEDULE AND ROUTE OF ADMINISTRATION  .....................................................57
 
11.2.1.  Dose R ationale  .............................................................................................57  
11.2.2.  Dose  .............................................................................................................59  
11.2.3.  Dosing Route and Regimen .........................................................................59  
11.2.4.  Dose Adjustment ..........................................................................................60  
11.2.5.  Dose Interruption .........................................................................................61  
11.3.  BLINDING  ..................................................................................................62  
11.4.  EMERGENCY UNBLINDING  ...................................................................62  
11.5.  INVESTIGATIONAL MEDICINAL PRODUCT STABILITY DURING SHIPMENT  ..................................................................................................63
 
11.6.  INVESTIGATIONAL MEDICINAL PRODUCT ACCOUNTABILITY  ..63  
12. CONCOMITANT THERAPY/MEDICAL MANAGEMENT OFADVERS
E EVENTS ..................................................................................64  
12.1.  RECORDING OF CONCOMITANT THERAPY  ......................................64  
12.2.  MEDICATIONS THAT MUST BE ADMINISTERED .............................64  
12.3.  PROHIBITED MEDICATIONS  .................................................................64  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 23 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  13. SCHEDULE OF VISITS  ...........................................................................65  
13.1.  SCREENING AND ENROLMENT  ............................................................65  
13.1.1.  VISIT  1 ........................................................................................................65  
13.2.  BLINDED PHASE STUDY PERIOD  .........................................................69  
13.2.1.  Telephone Follow -up (Blinded Phase) ........................................................69  
13.2.2.  VISIT  2 ........................................................................................................69  
13.2.3.  VISIT  3 ........................................................................................................69  
13.2.4.  VISIT  4 ........................................................................................................70  
13.2.5.  VISIT  5 ........................................................................................................71  
13.2.6.  VISIT  6 (End of Blinded Phase/Withdrawal during Blinded Phase) ...........72  
13.3.  EXTENSION PHASE ..................................................................................73  
13.3.1.  Arimoclomol Dispensing  .............................................................................73  
13.3.2.  Telephone Follow -up (Extension Phase) .....................................................73  
13.3.3.  VISIT  7 ........................................................................................................73  
13.3.4.  VISIT 8  ........................................................................................................74  
13.3.5.  VISIT 9  ........................................................................................................75  
13.3.6.  VISIT 10  ......................................................................................................76  
13.3.7.  VISIT 11  ......................................................................................................76  
13.3.8.  VISIT 12  ......................................................................................................77  
13.3.9.  VISIT 13  ......................................................................................................78  
13.3.10.  VISIT  14 (End of Extension Phase/Withdrawal during Extension Phase) ..79  
13.4.  UNSCHEDULED VISIT  .............................................................................80  
13.5.  WITHDRAWAL/PREMATURE STUDY DISCONTINUATION  ............80  
14. ASSESSMENTS OF CLINICAL STATUS  .............................................82  
14.1.  SPECIFICATION OF CLINICAL STATUS PARAMETERS  ...................82  
14.2.  METHODS AND TIMING .........................................................................82  
14.2.1.  Niemann -Pick Disease Type C Disease Severity Scores  .............................82  
14.2.2.  Scale for Assessment and Rating of Ataxia .................................................82  
14.2.3.  Nine -hole Peg Test  .......................................................................................83  
14.2.4.  Clinical Global Impression Scale ‚Äì Severity and Clinical Global Impression 
Scale ‚Äì Improvement ...................................................................................83  
14.2.5.  Quality of Life  ..............................................................................................83  
15. ASSESSMENTS OF SAFETY  ..................................................................84  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 24 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  15.1.  SPECIFICATION OF SAFETY PARAMETERS  ......................................84  
15.2.  METHODS AND TIMING .........................................................................84  
15.2.1.  Adverse Events  ............................................................................................84  
15.2.2.  Haematology ................................................................................................84  
15.2.3.  Clinical Chemistry  .......................................................................................85  
15.2.4.  Physical Examination and Vital Signs .........................................................86  
15.2.5.  Electrocardiogram  ........................................................................................86  
15.3.  ADVERSE EVENT REPORTING  ..............................................................86  
15.3.1.  Definition of an Adverse Event ...................................................................86  
15.3.2.  Definition of a Serious Adverse Event ........................................................87  
15.3.3.  Recording and Reporting of Adverse Events ...............................................88  
15.3.4.  Adverse Event Reporting Period ..................................................................92  
16. ASSESSMENTS OF IMAGING ...............................................................93  
16.1.  SPECIFICATION OF IMAGING PARAMETERS  ....................................93  
16.2.  METHODS AND TIMING .........................................................................93  
17. ASSESSMENTS OF PHARMACOKINETICS  ......................................94  
17.1.  SPECIFICATION OF PHARMACOKINETIC PARAMETERS  ...............94  
17.2.  METHODS AND TIMING FOR ASSESSING, RECORDING AND 
ANALYSING PHARMACOKINETIC PARAMETERS  ...........................94  
17.2.1.  Patients less than 12  years of Age: Pharmacokinetic Profiling to confirm 
Dose Selection ..............................................................................................94  
17.2.2.  Population Pharmacokinetic Samples : All Patients aged >2  Years  .............95  
18. ASSESSMENTS OF BIOMARKERS  ......................................................96  
18.1.  SPECIFICATION OF BIOMARKER PARAMETERS ..............................96  
18.2.  METHODS AND TIMING .........................................................................96  
18.2.1.  Skin Punch Biopsy .......................................................................................97  
19. ASSE SSMENTS OF OTHER ENDPOINTS  ...........................................99  
19.1.  SPECIFICATION OF OTHER PARAMETERS  ........................................99  
19.2.  METHODS AND TIMING .........................................................................99  
20. EVALUATION OF RESULTS  ...............................................................100  
20.1.  SAMPLE SIZE AND STUDY POWER  ...................................................100  
20.2.  STATISTICAL METHODS  ......................................................................100  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 25 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  20.2.1.  General Considerations ..............................................................................100  
20.2.2.  Other Considerations..................................................................................100  
20.2.3.  Populations for Analysis ............................................................................101  
20.3.  BASELINE CHARACTERISTICS  ...........................................................101  
20.4.  EVALUATION OF PRIMARY ENDPOINT  ...........................................101  
20.5.  EVALUATION OF SECONDARY ENDPOINTS  ...................................102  
20.6.  EVALUATION OF EXPLORATORY ENDPOINTS  ..............................104  
20.7.  MISSING DATA AND SENSITIVITY ANALYSES  ..............................105  
20.8.  EVALUATION OF CLINICAL STATUS  ................................................106  
20.9.  EVALUATION OF SAFETY ...................................................................106  
20.10.  EVALUATION OF IMAGING  .................................................................106  
20.11.  EVALUATION OF PHARMACOKINETICS  ..........................................106  
20.12.  EVALUATION OF BIOMARKERS  ........................................................106  
20.13.  EVALUATION OF OTHER ENDPOINTS  ..............................................106  
20.14.  INTERIM ANALYSIS  ..............................................................................107  
21. OBLIGATIONS OF THE PRINCIPAL INVESTIGATOR  ................108  
21.1.  INDEPENDENT ETHICS COMMITTEE/ INSTITUTIONAL REVIEW 
BOARD ......................................................................................................108  
21.2.  REGULATORY BODY APPROVAL  ......................................................109  
21.3.  INFORMED CONSENT AND SCREENING DATA ..............................109  
21.4.  CASE REPORT FORMS AND SOURCE DOCUMENT VERIFICATION ....................................................................................................................109
 
21.5.  CONFIDENTIALITY  ................................................................................110  
21.6.  STAFF INFORMATION AND RESPONSIBILITIES  .............................110  
21.7.  ESSENTIAL DOCUMENT RETENTION  ...............................................110  
22. STUDY MANAGEMENT  .......................................................................112  
22.1.  MONITORING  ..........................................................................................112  
22.2.  QUALITY ASSURANCE AND QUALITY CONTROL  .........................112  
22.2.1.  Quality Control ..........................................................................................112  
22.2.2.  Quality Assurance ......................................................................................112  
22.2.3.  Audit...........................................................................................................112  
22.3.  DATA QUERY PROCESS  .......................................................................113  
22.4.  PROTOCOL DEVIATIONS/AMENDMENTS  ........................................113  
22.5.  DISCONTINUATION OF THE STUDY  ..................................................114  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 26 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  22.6.  PUBLICATIONS  .......................................................................................114  
23. STUDY TIMETABLE  .............................................................................115  
24. REFERENCES  .........................................................................................116  
25. APPENDICES  ..........................................................................................119  
25.1.  APPENDIX I: BMI FOR AGE - WORLD HEALTH ORGANISATION  119 
25.2.  APPENDIX II: STUDY FLOW CHART: BLINDED PHASE STUDY 
PERIOD: PATIENTS LESS THAN 12 YEARS OF AGE  .......................123  
25.3.  APPENDIX III: STUDY FLOW CHART: BLINDED PHASE STUDY PERIOD: PATIENTS 12  YEARS OF AGE AND OLDER  ......................129
 
25.4.  APPENDIX IV: STUDY FLOW CHART: EXTENSION PHASE: ALL PATIENTS  .................................................................................................133
 
25.5.  APPENDIX V: PAEDIATRIC SUBSTUDY  ............................................137  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 27 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  LIST OF TABLES  
Table 11 -1: Investigational Medicinal Product Description and Packaging .......56  
Table 11 -2: Recommended Dose Stratification based on a 2- fold  Safety Ratio to 
Juvenile Rat NOEL (400 mg/kg) .....................................................58  
Table 11 -3: Investigational Medicinal Dosing : Based on the Patient Body 
Weigh
t ..............................................................................................59  
Table 11 -4: Acceptance Criteria for Pharmacokinetic Evaluatio n foll owing 
Single Oral Dose of Arimoclomol (Patients Less than 12  years of 
Age)  ..................................................................................................60  
Table 14 -1: Niemann -Pick Disease Type C Disease Severity Scoring Models ..82  
Table 15 -1: Definition of Severity of Adverse Events ........................................89  
Table 18 -1: Niemann -Pick Disease Type C Biomarkers  .....................................96  
Table 25 -1: Investigational Medicinal Dosing: Based on the Patient Body 
Weight  ............................................................................................146  
TABLE OF
 FIGURES  
Figure 7-1: Proposed Mechanism of Arimoclomol of Ameliorating Niemann -
Pick
 Disease Type C Disease  ...........................................................35  
Figure 9-1:  Study Design ....................................................................................42  
Figure 11-1: Molecular Structure of Arimoclomol ...............................................55  
Figure 18-1: Biomarker Sampling Procedure .......................................................97  
Figure 18-2: Skin Punch Biopsy Procedure ..........................................................97  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 28 of 173 
Final Version 1 1.0; 21-Jun-2021 CONFIDENTIAL  6. LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS
ADME  Absorption, Distribution, Metabolism, Elimination  
AE Adverse Event  
ALS  Amyotrophic Lateral Sclerosis  
ALT  Alanine Transaminase  
ANC  Absolute Neutrophil Count 
AP Alkaline Phosphatase 
API Active Pharmaceutical Ingredient  
AST  Aspartate Transaminase  
AUC  Area under the Curve  
AUC 0-8 Area under the Curve in 0 -8 hours 
AUC 0-8,SS Area under the Curve in 0-8 hours at Steady State  
AUC 0-24 Area under the Curve in 0 -24 hours 
AUC tau Area under the Curve over the Dosing Interval at Steady State 
BBB  Blood B rain Barrier  
BMI  Body Mass I ndex  
BW Body Weight 
CAS  Completers Analysis Set  
CFS Cerebrospinal Fluid 
CGI-I Clinical Global Impression Scale  ‚Äì Improvement 
CGI-S Clinical Global Impression Scale ‚Äì Severity  
CI Confidence Interval 
CIOMS  Council for International Organizations of Medical Sciences 
CL Clearance  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 29 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  CL/F  Oral Clearance  
Cmax Peak Serum Concentration  
CNS  Central Nervous System 
CRA  Clinical Research Associate  
CRF  Case Report Form  
CRO  Clinical Research Organisation 
CT (Module) Clinical Trials (Module)  
CTCAE  (National Cancer Institute ) Common Terminology Criteria for Adverse 
Events 
CTFG  Clinical Trial Facilitation Group  
DNA  Deoxyribonucleic Acid  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
EMA/EMEA  European Medicines Agency 
EOS  End of Study 
EU European Union 
FAS Full Analysis Set 
FDA  United States Food and Drug Administration 
FPI First Patient  In 
GCP  Good Clinical Practice 
GGT  Gamma -glutamyltransferase  
GSL  Glycosphingolipid 
HDL  High -density Lipoprotein 
HDPE  High Density Polyethylene 
HPMC  Hydroxypropyl Methylc ellulose  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 30 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  9HPT  Nine -hole Peg Test  
HSP Heat Shock Protein  
HSP70  Heat Shock Protein 70 
HSR  Heat Shock Response 
IB Investigator Brochure 
ICH International Conference on Harmonisation 
IEC Independent Ethics Committee 
IMP Investigational Medicinal Product 
IRB Institutional Review Board  
IRT Interactive Response Technology  
IUD Intrauterine Device  
IUS Intrauterine Hormone -releasing System  
LAR  Legal Authorised Representative 
LDH  Lactate Dehydrogenase  
LDL  Low-density Lipoprotein 
LSD  Lysosomal Storage Disorder 
MA Marketing Authorisation 
MAR  Missing at Random 
  
MCID  Minimal Clinically Important Difference  
NOEL  No Observed Effect Level  
NPC  Niemann -Pick Disease Type C 
NPCCSS  NPC Clinical Severity Scale  
NPC -cdb Niemann -Pick T ype C Clinical Database  
PBMC  Peripheral B lood Mononuclear C ell 

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 31 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  PICD  Patient Informed Consent Document 
PK Pharmacokinetic  
POP PK  Population Pharmacokinetic 
PP Per Protocol 
QA Quality Assurance 
QC Quality Control 
RBC  Red Blood Cell 
RSI Reference Safety Information  
SAE  Serious Adverse Event 
SAP Statistical Analysis Plan  
SARA Scale for Assessment and Rating of Ataxia  
SD Standard D eviation  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
t.i.d. Three Times a Day  
Tmax Time to Peak Serum Concentration  
ULN  Upper Limit of Normal  
US/USA United States/United States of America  
WBC  White Blood Cell 
WHO  World Health Organisation 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 32 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  7. INTRODUCTION
7.1. NIEMANN- PICK DISEASE TYPE  C 
Niemann -Pick disease type C  (NPC ) is a very rare , fatal, neurovisceral, atypical lysosomal 
storage disorder  (LSD) presenting  impaired cellular functions in processing and transporting 
low-density lipoprotein- cholesterol ( Huang et al., 2011). The disease affects all organs and it 
is charact erised by a significant variety of progressive and disabling neurological symptoms 
(Vanier , 2010). NPC  presents an extremely heterogeneous clinical manifestation which 
progresses over varied periods of time ( Imrie  et al ., 2007; Patterson  et al. , 2012). 
The estimated incidence is 1:150,000 live births ( Wraith  et al. , 2009) or 0.1 in 10,000 people 
in the European Union (EU).  
NPC  is transmitted in an autosomal recessive manner and is caused by mutations of either the 
NPC1 (95% of families) or the NPC2  genes (in approximately 5% of cases) . Patients with 
NPC1 or NPC2 mutations are not clinica lly distinguishable. Undetected causal gene mutations 
may also exist.  
The broad clinical spectrum ranges from a neonatal rapidly fatal disorder to an adult onset 
chronic neurodegenerative disease. The neurological involvement defines the disease severity in most patients but is typically preceded by systemic signs (cholestatic jaundice in the neonatal 
period or isolated spleno- or hepatosplenomegaly in infancy or childhood).  
The disease progression largely correlates with the age at onset of the neurologic symptoms. Progressive neurological disease is the hallmark of NPC , and is responsible for disability and 
premature death in all cases. Classically, children with NPC  may initially present with delays 
in reaching normal developmental milestones before mani festing cognitive decline and 
dementia.  
Neurological signs and symptoms include cerebellar ataxia, dysarthria, dysphagia, tremor, 
epilepsy (both partial and generalized), vertical supranuclear palsy (up gaze palsy, down gaze palsy, saccadic palsy or paraly sis), sleep inversion, gelastic cataplexy, dystonia, spasticity, 
hypotonia, ptosis, microcephaly, psychosis, progressive dementia, progressive hearing loss, bipolar disorder, major and psychotic depression that can include hallucinations, delusions, mutism, or stupor. 
In the terminal stages of NPC , the patient is bedridden, with complete ophtalmoplegia, loss of 
volitional movement and severe dementia. 
7.2. ARIMOCLOMOL  
Arimoclomol acts as a c o-inducer of heat shock protein 70 ( HSP 70, a major component of the 
so-called  heat shock response  [HSR]) under conditions of cellular stress. The HSR has been 
established as therapeutic target in LSDs in several studies.   
Several previous studies have established the HSR as therapeutic target in NPC . In a recent 
study, HSP70 was shown to be critical for the proper folding and activity of the NPC1 protein, 
which is mutated in the majority of patients with NPC . Importantly, this study furthermore 
demonstrated that induction of HSP 70 can rescue the most common genetic defect i n the NPC1 
protein and the resulting cellular pathology. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 33 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Proof-of- concept for the use of arimoclomol has been established in vitro  and in vivo , in a 
mouse model of disease. In the NPC1-/- mouse model, arimoclomol was effective in improving 
neurological symptoms and reducing the accumulation of glycosphingolipids  (GSLs) which is 
a pathobiochemical hallmark of NPC . These results strongly suggest that arimoclomol may 
confer similar benefits to patients with NPC . Refer to the Investigator Brochure  (IB) for furt her 
information. 
7.2.1. Clinical Data  
Clinical experience on arimoclomol originates from 7  Phase I studies and 2 Phase II stud ies in 
Amyotrophic Lateral Sclerosis  (ALS) patients. Phase I studies with arimoclomol include a 
single- dose study, a multiple -dose study, an ascending multiple -dose study, two food effect 
studies, a mass balance study to determine absorption, distribution, metabolism, 
elimination  (ADME ), and a renal safety study. In addition, pharmacokinetic ( PK) parameters 
were assessed in one of the Phase II stud ies in ALS patients.  
Overall, arimoclomol was absorbed rapidly and arimoclomol exposure (based  on peak serum 
concentration  [C max] and are under the curv e [AUC ]) has been shown to increase in a nearly 
dose proportional manner. 
Steady  state appeared to  have been reached by  24 hours after the start  of three times a day  (t.i.d.) 
dosing for all dose levels.  
Across all clinical studies performed ( including the Phase  II stud ies in ALS patients) an 
average t 1/2 of 3.5 hours and a time to peak serum concentration  (Tmax) of 1-2 hours has been 
found.  Furthermore, the food effect was evaluated in 2  studies (single dose administration of 100 mg 
and 400 mg arimoclomol 
citrate ). No food effect (based upon AUC and C max) was observed 
following the administration of arimoclomol in the fed compared to the fasted state.  To date, a total of 106 healthy subjects received arim oclomol 
citrate  at doses ranging from 
50 mg  (single dose) to 1800 mg  (600 mg dosed t.i.d.). 
In the Phase  II study (Study AALS -001), 62 patients with ALS were administered 25 -100 mg 
arimoclomol citrate  t.i.d. for 3 months. A total of 69  patients from this study (previously treated 
with arimoclomol or placebo) continued in the open- label extension study (Study AALS -001-
OL), receiving 100 mg arimoclomol citrate  t.i.d. for an additional 6 months.  
In summary, safety data from the Phase  I studies and the Phase  II stud ies in ALS patients 
suggest that arimoclomol may lead  to a drug- related increase in serum creatinine, and a 
decrease in mean creatinine clearance. All observed changes in creatinine were reversible. 
Since there was no change in glomerular filtration rate and serum cystatin  C, this suggests an 
inhibitory effect of arimoclomol on tubular secretion of creatinine.  
In an in vitro  transporter study, arimoclomol was shown to be an inhibitor of OCT2 transporter 
(with initial inhibitory activity of this transporter at C max of individual human doses higher than 
400 mg ). OTC2 transports creatinine; thus, inhibition of this transporter could provide an 
explanation for the modest increases in serum creatinine found in clinical studies.  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 34 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Other adverse events  (AEs) related to arimoclomol were gastrointestinal disorders ( diarrhoea  
being most frequently reported) as well as dry mouth (this was the most frequently treatment 
related AE reported in the ALS studies). 
Refer to the IB for more information.  
7.3. RATIONALE FOR T HE STUDY AND RISK -BENEFIT ASSESSMENT 
NPC  is an extremely rare , progressive and life -threatening  disease. The clinical manifestation 
regarding symptoms, severity and progression is very heterogeneous amongst patients. There 
is no approved cure for NPC . In the absence of any curative treatment for  NPC , quality of life 
represents  the treatment goal in the management of the patients, and can be addressed by 
(Patterson  et al., 2012): 
‚Ä¢Rigorous sympt omatic treatment
‚Ä¢Miglustat therapy for existing neurological manifestations
Symptomatic treatments are targeting: 
‚Ä¢Neurological manifestations: such as seizures, cataplexy, dystonia and tremor,
dysphagia, drooling and sleep disturbances
‚Ä¢Cognitive impairment
‚Ä¢Psychiatric illness
‚Ä¢Systemic manifestations
In Europe, miglustat was approved in 2010  as disease modifying therapy for the treatment of 
progressive neurological symptoms in NPC  patients.  Miglustat reduces substrate load, intended 
to slow down the progressive neurological manifestations in adult and paediatric NPC  patients. 
The available data on miglustat support that at least some patients might benefit from treatment in that  the progression of disease is slowed down. The benefit of the treatment  should be 
evaluated on regular basis, e.g. every 6 months to monitor potential or expected AEs and the 
continuation of the therapy should be re -appraised after at least 1  year of treatment with 
miglustat.  
Several previous studies have established the HSR as therapeutic target in LSDs ( Ingemann  
and Kirkegaard, 2014). The HSR is a key homeostatic system, which is induced under conditions of metabolic stress (e.g. protein misfolding and aggregation, nutrient deprivation, oxidative or thermal stress). Its main components are the heat shock proteins  (HSPs), in 
particular HSP70, which have significant cytoprotective properties. HSP70 act as molecular chaperone,  assisting in the folding of newly synthesized or damaged proteins, preventing 
protein aggregation, and targeting severely damaged proteins for degradation. Notably, the cytoprotective actions of HSP70 also include protection against lysosomal dysfunction and cell death ( Ingemann  and Kirkegaard, 2014).  
Since most LSDs  are characterized by lysosomal dysfunction, cell death and significantly 
reduced enzyme activity due to missense mutations rather than complete loss of function, the LSDs are amenable to therapeutic approaches involving HSP70 ( Kirkegaard , 2013; Ingemann  
and Kirkegaard, 2014).  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 35 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Arimoclomol is a co -inducer of HSP70 expression which acts through the activation of heat 
shock factor- 1 (HSF -1), the major regulator of HSP gene transcription ( Neef  et al ., 2011).  
Through the induction of HSP70- proteins, arimoclomol aids the proper folding of otherwise 
misfolded NPC1 protein, hereby correcting the root cause of NPC  disease ( Figure 7-1). 
Additionally, HSP70 proteins improve lysosomal function, a key target in NPC  disease. The 
molecular actions of arimoclomol th us correct several aspects of the molecular pathology of 
NPC  disease in a concerted action, providing the mechanistic rationale for the hypothesized 
therapeut ic benefit of arimoclomol in NPC  patients.  
Another aspect related to the therapeutic potential of arimoclomol is its ability to cross the 
blood brain barrier  (BBB ). By penetration into the central nervous system  (CNS) arimoclomol 
is suggested to bring direct neurologic benefit also to the NPC  phenotype. 
Figure 7-1:  Proposed Mechanism of Arimoclomol of Ameliorating Niemann -Pick 
Disease Type C Disease  
Th
e observational (non- therapeutic, interventional)  study, CT -ORZY- NPC -001 was designed 
to better characterise the individual patient disease profile (disease burden) through the clinical, imaging, biological status, and Q uality of L ife prospectively recorded, together with the 
historic disease information collected from pati ent medical records. It also allowed the 
evaluation of the safety data of the disease- related therapy and to record every AE linked to the 
disease.  The study was categorized as interventional due to the nature and frequency of the 
study procedures, which are not necessarily performed as a standard of care. 

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 36 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  During the study CT -ORZY -NPC -001, the patients remained  on their prescribed disease 
related therapy (based on the choice of their treating physician) and did  not receive any 
investigational medicinal prod uct (IMP). All patient- care decisions, including diagnostic and 
therapeutic interventions, were made by and conducted at the discretion of the Investigators 
according to their clinical judgement and the local standard of medical care. 
The only standard of care limitation wa s that miglustat therapy was to  be stable for at least 
6 months before study participation (for those patients in treatment with miglustat), and that 
patients with three or more anticonvulsants were excluded from participation. For those 
patients who had  been discontinued from prescribed treatment with miglustat, they must have 
been discontinued for at least 3 continuous months prior to inclusion in the study. 
The procedures performed in the study CT -ORZY -NPC -001 are the same that the ones  which 
will be carried out in study CT -ORZY- NPC -002, apart from the Scale for Assessment and 
Rating of Ataxia  (SARA), Nine -hole Peg Test  (9HPT), Clinical Global Impression Scale ‚Äì 
Severity  (CGI -S), Clinical Global Impression Scale - Improvement (CGI- I), PK, Population 
Pharmacokinetics (POP  PK) and IMP related procedures which are exclusively performed in 
study CT -ORZY- NPC -002. The addition of the SARA , 9HPT , CGI -S and CGI -I will not add 
any burden to the study patients. Following on from the CT -ORZY- NPC -001 observational study, t his Phase  II/III  
interventional therapeutic study (CT -ORZY -NPC -002) will assess the efficacy and safety of 
arimoclomol (compared to placebo). This s tudy will allow for a thorough evaluation of the 
clinical (NPC Clinical Severity Scale  [NPCCSS], NPC Clinical Database [NPC -cdb], SARA, 
9HPT, Quality of Life , CGI -S and CGI -I), biological/biochemi cal (unesterified cholesterol, 
oxysterol, HSP70, NPC1 protei n, GSL s and sphingoid bases ), POP  PK and imaging 
(ultrasound of liver and spleen) markers in a randomised controlled setting ensuring the 
generation of reliable data for the assessment of therapeutic response of arimoclomol.  
In the CT -ORZY -NPC -002 study, t he IMP (arimoclomol or placebo) will be administered 
orally  t.i.d. as an add -on therapy to the patient‚Äôs current prescribed best standard of care. The 
duration of the controlled blinded phase study period will be 12 months; following this  period, 
every patient will continue into the extension stage of the study where they will receive 
arimoclomol in addition to the best standard of care  and be followed up at 18 months and every 
6 months thereafter until End of Extension Phase at 60 months (after patient randomisation) . 
The extension phase  runs for 48 months or until arimoclomol has received EU /United 
States  (US) marketing authorisation  (MA) or until the analysis of data from the controlled, 
12-month blinded phase study period does not support the efficacy and/or safety of
arimoclomol.  If the EU /US MA is not obtained within this period, the duration of the study
will be extended accordingly (amendment to protocol).
Following the review of relevant juvenile toxicology data  and PK  information f rom 100% of 
the patients aged 2 to <12 years, the CT -ORZY- NPC -002 study has now been expanded to 
include a paediatric substudy in patients aged 6 to <24 months at study enrolment which will 
assess the safety and tolerability of 36 months of open- label arimoclomol when it is 
administered as an add -on therapy to the patient‚Äôs current prescribed best standard of care; each 
patient‚Äôs  standard of care  may, or may not, include miglustat  (refer to APPENDIX V: 
Paediatric Substudy for description of the substudy). 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 37 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Arimoclomol has been shown to be well tolerated in healthy subjects and ALS  patients . To 
date, a total of 106 healthy subjects have received arimoclomol  citrate  at doses ranging from 
50 mg (single dose) to 1800 mg (600 mg dosed t.i.d.) and a total of 69 ALS patients have 
received 100  mg arimoclomol citrate t.i.d. for at least 6 months with no safety concerns.  
Refer to Section  11.2.1  for the rationale behind the dose recommendations for the 
CT-ORZY- NPC -002 study. 
The potential risks involved in this study concern those routinely linked to the interventional 
study procedures of skin punch biopsy procedure and blood draws for clinical haematology, 
biochemistry and biomarkers , and venous blood samples for the PK analysis (in patients less 
than 12 years of age ) and POP  PK analysis in all patients .  
One of the key requirements of a clinical trial is to assess as early and as reliable as possible 
any consistent pharmacodynamics effect of the drug being tested. KemPharm Denmark  A/S 
decided to perform in the participating NPC  patients in this study , the least invasive and best 
researched tissue (skin biopsy and blood sampling) instead of more invasive sampling 
assessment of cerebrospinal fluid  (CFS)  or the biopsy of other organs for this study. Skin 
biopsies are therefore required in this study to assess the effect of arimoclomol on lysosomal 
lipid sequestration as well as NPC1 protein expression.  
The key component of NPC  disease is the sequestration  of cholesterol and GSLs in the 
lysosomes. For this reason, Filipin staining of cultured fibroblast from skin biopsies is used as 
a diagnostic tool to confirm the accumulation of un- esterified cholesterol prior to sequencing 
of the NPC gene ( Vanier , 2010) . Likewise, the characterization of the NPC1 protein function 
and post translational glycosylation have been addressed in primary fibroblast cell cultures, which also show increased GSL accumulation  (Gelsthorpe  et al. , 2008) ( Sun et al. , 2001; 
Watanabe et al. , 1998; Yu  et al.,  2012; Zampieri  et al. , 2012). Therefore, the purpose of the 
skin punch biopsies is not to generate fibroblast cultures, but to directly measure the biomarkers in the fibroblasts from the skin homogenates. 
Lipid accumulation is pronounced in the brain, liver and spleen, organs that are severely 
affected in this neurovisceral , progressively debilitating and life -threatening disease. However, 
these tissues are not easily sampled in a clinical trial, even less justified in the paediatric population. Recently, GSL accumulation was also found to be elevated in purified CD19+ B 
cells ( Te Vruchte e
t al., 2014); but whether these cells are suitable for the diagnostic 
determination of cholesterol accumulation, remains to be investigated and confirmed. Whether 
the same observation can be shown in peripheral blood mononuclear cells  (PBMCs ) remains 
also to be investigated. For the ganglioside analysis, most publications rely on fibroblast or animal tissue but there are also a couple of publications on CD19+ cells. Upon these reasons it 
was decided not to rely solely on the PBMC results. 
Oxidation products of cholesterol, called Oxysterols, have been shown to be elevated in 
mu
ltiple tissue from NPC mutant mice and in -patient  blood samples ( Porter  et al. , 2010). 
Recently, a large clinical study demonstrated that the oxysterol cholestane -3Œ≤,5Œ±,6Œ≤ -triol can 
be used as a diagnostic marker for Niemann Pick type C disease ( McKay  Bounford et al ., 2014, 
Reunert  et al. , 2016). 
Accumulation of sphingoid bases  has been seen  in NPC patients as well as in mouse models of 
the disease ( Lloyd-Evans  and Platt, 2010; Vanier  et al. , 2015; Lloyd-Evans  et al., 2008). 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 38 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  The skin biopsies procedure is minimally invasive and represents a low risk in comparison to 
other diagnostic procedures that may imply a much higher risk of complication s. Other relevant 
target tissues such as brain, liver and spleen are not easily sample d in a clinical trial, and 
arguably are not ethically justifiable to sample if punch skin biopsies can be used instead. 
In order to perform an exploratory exposure -response analysis, sampling for POP PK will be 
performed in all patients at Visits  3, 4, 5, and 6 (3, 6, 9 and 12 months respectively). The 
maximum volume of blood collected for POP PK sampling will be 8 mL in total.  
Extensive assay development has  been performed  to confirm and validate the appropriate 
procedure/s and to  minimise the sampling vol umes . 
Upon regulations and guidelines, a  limited volume of blood will be drawn from each patient 
during this study (at baseline, 7 -14 days post the commencement of multiple dosing, and at the 
3, 6, 9, 12, 18, 24, 30, 36, 42, 48, 54 and 60- month visit s) that will not exceed the recommended 
maximum blood sampling volume for children in clinical trials which should not exceed 3 % of 
total blood volume in one draw ( Howie , 2011 ). 
7.4. BIOBANK  
If the patient or the patient's parent(s)/legal guardian(s) provide consent, the Sponsor will store 
the excess blood/plasma/serum collected during the study for future research use. The research 
may include analysis of biomarkers for NPC . This is optional for all patients entering the study 
and will involve a separate patient consent procedure. Consenting for the storage of excess blood/plasma/serum for future research use by the Sponsor is not a pre -requisite to participating 
in the study. Samples will be stored for a maximum of 15  years after the last patient has 
completed the study. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 39 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  8. OBJECTIV ES
8.1. PRIMARY OBJECTIVE  
‚Ä¢To evaluate therapeutic response to arimoclomol versus placebo, both in addition to
best available standard of care, at 12  months.
8.2. SECONDARY OBJECTIVE S 
‚Ä¢To evaluate the therapeutic response to arimoclomol through clinical, biological andimaging assessments  at 6 and 12 months;
‚Ä¢To evaluate the long- term therapeutic response (clinical and biological assessments) at
18 months and every 6 months thereafter until End of Extension Phase at 60 months;
‚Ä¢To evaluate the safety of arimoclomol.
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 40 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  9. INVESTIGATIONAL PLAN
9.1. SUMMARY OF STUDY DESIGN 
A prospective, randomised, double -blind, placebo- controlled therapeutic study in patients with 
confirmed diagnosis of NPC  1 or NPC  2 on or not on miglustat therapy that either 1) have 
completed Visit 2 (end of study [EOS]) of the CT -ORZY- NPC -001 study or 2) meet the 
eligibility criteria of this study (CT -ORZY- NPC -001) including a requirement of stable 
treatment with miglustat for 6  months (if on miglustat therapy) prior to enrolment int o 
CT-ORZY- NPC -002 study. It is anticipated that the majority of patients for inclusion in the 
CT-ORZY- NPC -002 study would have completed the CT- ORZY- NPC -001 study.  
The purpose of this study is to assess the efficacy and safety of arimoclomol (compared to 
placebo) when it is administered as an add -on therapy to the patient‚Äôs current prescribed best 
standard of care; each patient‚Äôs standard of care may, or may not, include miglustat . The study 
endpoints are documented in Section  9.3. 
Patients will be stratified into strata  A (on miglustat therapy) and B (not on miglustat therapy). 
Hereafter, the patients will be randomised to receive placebo or arimoclomol (with an allocation ratio of 1:2). 
To confirm the selected dose, patients less than 12 years of age will undergo an arimoclomol 
single- dose PK evaluation before randomisation and the start of continuous (multiple dosing) 
treatment.  
In order to perform an exploratory exposure -response analysis, sampling for POP PK will be 
performed in all patients at Visits  3, 4, 5, and 6 (3, 6, 9 and 12 months re spectively).  
The duration of the blinded phase study period will be 12  months. 
Following this, all patients will be offered to continue into the extension phase  of the study 
where every patient will receive arimoclomol and will attend site visits at 18, 24, 30, 36, 42, 
48, 54 and 60 months ( after patient randomisation ). The extension phase  runs for 48 months or 
until arimoclomol has received  EU/US MA or until the analysis of data from the controlled, 
12-month blinded phase study period does not support the efficacy and/or safety of
arimoclomol.  If the EU/US MA is not obtained within this period or if the study is stopped
prematurely (see S ection  22.5), the duration of the study will either be extended accordingly
(amendment to protocol) or patient s may be offered continued treatment with arimoclomol via
an early access program me as permitted by local regulation. Early access program mes may
vary depending on location and include: compassionate use, named patient, expanded accessand managed access program mes.
Continued access to treatment will be contingent on the continued favorable benefit/risk profile of arimoclomol in NPC as assessed by KemPharm  Denmark .  
Patients will be enrolled in the extension phase only if the investigator deem that the patient is deriving clinical benefits from the trial participation.  
Following the review of relevant juvenile toxicology data  and PK  information from 100% of  
the patients aged 2 to <12 years, the CT -ORZY- NPC -002 study has now been expanded to 
include a paediatric substudy in patients aged 6 to <24 months at study enrolment which will assess the safety and tolerability of 36 months of open- label arimoclomol whe n it is 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 41 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  administered as an add -on therapy to the patient‚Äôs current prescribed best standard of care; each 
patient‚Äôs standard of care may, or may not, include miglustat (refer to APPENDIX V: 
Paediatric Substudy for description of the substudy).  Data from the paediatric substudy will be 
analysed and reported separatel y from the data in the main study. 
Before undergoing any screening procedures or data collection, patients (and the patients' parent[s]/legal guardian[s]) will be required to sign the Patient Information and Informed Consent Document (PICD) for this study. 
Refer to Section  9.4 for the trial timetable/study visits. A schedule for the tests and evaluations 
to be conducted in this study is found in the flow chart s in APPENDIX II: Stu dy Flow Chart: 
Blinded Phase Study Period: Patients less than 12 years of age , APPENDIX III: Study Flow 
Chart: Blinded Phase Study Period: Patients 12 Years of Age and Older  an d APPENDIX IV: 
Study Flow Chart: Extension Phase: ALL Patients . 
The Investigator will contact the patient (or the patient's parent[s]/legal guardian[s]) by 
telephone (monthly calls during the first 6 months of the blinded phase and every 3-4 months 
following the start of the extension phase) to follow up on the status of the patient, whether the patient has experienced any new AEs or the worsening of any existing AEs, whether the patient has had a change in any prescribed medication, whether the patient has experienced any difficulties in taking the  IMP and to confirm the weight of the patient. Should the patient 
experience disease progression that is too severe and/or too fast or should there be any safety concerns  or should the patient‚Äôs weight require reassessment in the clinic (in order to confirm 
if a dose reduction is required), the patient may also attend the site for unscheduled visits. 
A Data Safety Monitoring Board (DSMB) will review the safety data (includ ing renal and 
hepatic data)  during the blinded phase of the study. 
In patients whose disease progression is too severe and/or too fast, the ‚Äúearly escape clause‚Äù 
(refer  also to Section  10.5.2) will allow the Investigator to apply the escape route which implies
 
that the patient can be treated with arimoclomol during the blinded phase of the study.  
Should a patient discontinue prematurely and choose to withdraw from the study, all effort 
should be made to have the patient attend the site for a withdrawal visit during the blinded or the extension phase of the study (depending on the time point of withdrawal). Should the patient 
(or the patient's parent[s]/legal guardian[s]) refuse to attend the withdrawal  visit, the date and 
reason for study discontinuation will be recorded in the electronic case report form  (eCRF) as 
minimum.  Refer to Section  10.5.1 for the discontinuation criteria. 
Approximately 15-20 sites in 6 -9 countries in Europe and US will participate in this study . Up 
to 52 NPC  patients  will be randomised , to have at least 40 evaluable patients  (at least 30 of 
these should be paediatric patients less than 1 8 years of age).  
The over all stu dy design is summarised in Figure 9-1. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 42 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Figure 9-1: Study Design  
9.2. DIS
CUSSION OF TRIAL DESIGN  
NPC  is a very rare disease in which patients  show progressive and significant neurological 
deterioration. There is no universally accepted marker of the disease. Inter- patient individual 
disease progression is heterogeneous.  
In this Phase  II/III study (CT -ORZY- NPC -002), a ll markers investigated dur ing the initial 
12-month placebo- controlled phase of the study will support the therapeutic response
evaluation of arimoclomol vs. placebo.Arimoclomol (or placebo) is given as an add- on therapy to the current best standard of care. 
Since none of the patie nts are deprived from their current available therapy it is considered 
ethically justified to use placebo in this study. In addition to this, the exposure to placebo has 
been minimised as much as statistically justifiable ( i.e. a randomisation scheme of 1:2 
[placebo:arimoclomol]) is applied. 
The 12-month duration of the blinded study phase is considered to be the minimal duration 
required in order to be able to identify changes in the disease severity (as assessed by the 
NPC CSS). In order to monitor the patient ‚Äôs disease progression and the safety of the IMP , as 
well as to maintain patient  motivation, improve patient compliance and minimise patient drop 
outs, the patient will visit  the site every 3  months.  
Although the potential  benefits of arimoclomol in this patient population still remains to be 
evaluated , an early escape clause has been implemented  in order to ensure that patients 
experiencing an unacceptable rate of  progression, than expected, can receive arimoclomol 

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 43 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  (active  treatment ) during the blinded phase of the study (as per the patient‚Äôs current protocol 
sche
dule) . To minimise bias introduced by the families (eager to get active drug), the decision 
of whether the early escape clause and criteria have  been met or not , is to be taken by the 
i
nvestigators and is based upon the NPCCSS score. Also, the frequent visits (every 3 months) 
are considered to minimise the risk of families requesting unscheduled visits to have the disease 
severity evaluated, since this could lead to  a bias in the estimate of time to ‚Äútreatment failure‚Äù. 
In general, with regard to the PK c haracteristics, the age group of 12-18 ye ars ( adolescent) i s 
considered t o hav e similar P K as adul ts, w hile the  lower age  g roups  are less pr edictable. 
Therefore the P K profile of  ar imoclomol is re quired t o be confirmed in patients below the age 
of 12 before multiple dosing can commence 
(ref:http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/
WC500003066.pdf
). 
In or der to perform an exploratory exposure -r esponse analysis, POP  PK will be performed in 
all patients at Visits  3, 4, 5, and 6 (3, 6, 9 and 12 months respectively). The maximum volume 
of blood collected for POP PK sampling will be 8 m L in total. Sampling times for POP  PK 
were selected based on the anticipated PK pr ofiles in children, robustness to uncertainty in PK 
and patient convenience. 
After the 12- month  blinded phase  of  the study, all patients will receive arimoclomol  (active 
drug) . Since the safety prof ile of arimoclomol in paediatric patients  will be well established at 
this time point , duri ng the extension phase of the study the patients will attend the site for  a 
visit at 18, 24, 30, 36, 4 2, 48, 54 and 60 m onths  (a fter patient randomisation) . In addition  to 
this, 
following the start of the extension phase of the study, the site will call the patient every 
3-
4 months to follow up on the status of the patient, whether the patient has experienced any
ne
w AEs or the worsening of any existing AEs, whet her  the patient has had a change in any
pre
scribed medication, whether the patient has experienced any difficulties in taking the IMP
a
nd to confirm the weight of the patient.
Patients will be enrolled in the extension phase only if the investigator deem that the  patient is 
de
riving  clini cal benefits f rom the  trial participation.  
F
ollowing the review of relevant juvenile toxicology data  and PK  information from 100%  of 
the patients aged 2 to <12 ye ar s, the CT -ORZY- NPC -002 study has now been expanded to 
include  a paediatric substudy in patients aged 6 to <24 m ont hs at study enrolment which will 
assess the safety and tolerability of 36 m onths of open- label arimoclomol when it is 
administered as an add-on therapy to the patient‚Äôs current prescribed best standard of care; each 
patient‚Äôs standard of care may, or may not, include miglustat (refer to APPENDIX V: 
P
aediatric Substudy for  a description of the substudy) . Patients below 2 ye ars of age will be 
tr
eated with open label arimoclomol and will be analysed and reported separately as compared 
to the main analysis of the 12 months placebo-controlled study. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 44 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  9.3. STUDY ENDPOINTS 
9.3.1. Primary Endpoint  
‚Ä¢Change in the NPC  disease severity  based on the 5 domain NPCCSS scores
(ambulation, speech, swallow, fine motor skills and cognition)  from baseline (Visit 1)
to 12 months;
9.3.2. Clinical Status Endpoints  
Key Secondary Endpoints: 
‚Ä¢Responder analysis of patient‚Äôs C GI-I score remains st able or shows improvement at
12 months (for the United States Food and Drug Administration [ FDA ] submission,
this endpoint is considered a co-primary endpoint);
‚Ä¢Responder analysis of patient‚Äôs 5 domain NPCCSS  score remains st able or improves at
12 months compared to baseline;
‚Ä¢Time to worsening (as define d by reaching the minimal clinically important
difference [ MCID ] on patient‚Äôs 5  domain NPCCSS);
‚Ä¢Proportion of patients worsening (as defined by reaching the MCID on patient‚Äôs 5
domain NPCCSS) at 6 and 12 months;
‚Ä¢Change in full scale NPCCSS  score apart from hearing domains (i.e. Hearing and
Auditory Brainstem Response) at 12  months.
Other Secondary Endpoints: 
‚Ä¢Change in 5 domain NPCCSS  score at 6  and 18 months and every 6  months thereafter
until End of Extension Phase at 60  months;
‚Ä¢Change in full scale NPCCSS  score apart from hearing domains (i.e. Hearing and
Auditory Brainstem Response)  at 6 and 18 months and every 6 months thereafter  until
End of Extension Phase at 60 months;
‚Ä¢Responder analysis of the CGI -I score remains st able or shows improvement at 6 and
18 months and every 6 months thereafter until End of Extension Phase at 60 months;
‚Ä¢Responder analysis of  5 domain NPCCSS  score remains st able or improves at 6 and
18 months and every 6 months thereafter until End of Extension Phase at 60 months
compared to baseline;
‚Ä¢Proportion of patients worsening (as defined by reaching the MCID on patient‚Äôs 5domain NPCCSS) at 18 months and every 6 months thereafter until End of Extension
Phase at 60  months;
‚Ä¢Changes in each individual domain of the NPCCSS at 6, 12 an
 d 18 months and every
6 months thereafter until End of Extension Phase at 60 months;
‚Ä¢Change in the NPC -cdb score (modified "Stampfer Score" [ Stampfer  et al., 2013]) at 6,
12 and 18 months and every 6 months thereafter until End of Extension Phase at
60 months;
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 45 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢Change in Quality of Life  (EQ -5D-Y) at 6 , 12 and 18 months and at every 6  months
thereafter until End of Extension Phase at 60 months;
‚Ä¢Change in the SARA score at 6, 12 and 18 months and every 6  months thereafter until
End of Extension Phase at 60 months;
‚Ä¢Change in the 9HPT time at 6, 12 and 18 months and every 6 months thereafter until
End of Extension Phase at 60 months;
‚Ä¢CGI-S score at 6, 12 and 18 months and every 6 months thereafter until End of
Extension Phase at 60 months;
‚Ä¢CGI-I score at 6, 12 and 18 months and every 6 months thereafter until End of
Extension Phase at 60 months.
9.3.3. Exploratory Endpoints 
‚Ä¢NPC disease progression rate based on the NPCCSS (apart from hearing domains)  from
baseline in the CT -ORZY- NPC -002 study to 6 and 12 months;
‚Ä¢The number of patients leaving the blinded phase of the study before 12 months as a
result of early escape;
‚Ä¢The number of patients who either withdraw from the study before 12 months, or who
need to jump to escape therapy ;
‚Ä¢Change in use of NPC medication/standard of care (including miglustat th erapy) at 12
and 18 months and every 6 months thereafter until End of Extension Phase at
60 months.
Exploratory subgroup analyses will be performed on the primary and three key secondary endpoints (refer to Sections  9.3.1 and 9.3.2, respectively ).  
9.3.4. Safety Endpoints  
‚Ä¢AEs (disease related and/or treatment/procedure related);
‚Ä¢Haematology;
‚Ä¢Clinical chemistry;
‚Ä¢Vital sign s.
9.3.5. Imaging Endpoints  
‚Ä¢Changes in the size of the liver and spleen (assessed by ultrasound). Changes at 6 and
12 months.
9.3.6. Biomarker Endpoints  
There are no validated b iomarkers in NPC  to evaluate disease progression burden and potential 
therapeutic response . The biomarkers listed (see also Table 18 -1) will be explorative  to confirm 
and support clinical observations and characterise the individual patient clinical status at baseline (Visit 1), 6 and 12 months ( Yanjanin  et al., 2010) . Absolute values  in the listed  
biomarkers will be recorded and analysed.  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 46 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢NPC1 active protein;
‚Ä¢NPC1 protein function (cholesteryl esterification) ;
‚Ä¢Oxysterol (cholestane- 3Œ≤,5Œ±,6Œ≤ -triol);
‚Ä¢Un-esterified cholesterol;
‚Ä¢HSP70 ;
‚Ä¢GSL s;
‚Ä¢Sphingoid bases ;
‚Ä¢Lyso -SM-509.
Cha
nges at 6 and 12 months (placebo versus arimoclomol) will be evaluated .  
During the extension phase of the study, the following biomarkers will be analysed: 
‚Ä¢Oxysterol (cholestane- 3Œ≤,5Œ±,6Œ≤ -triol);
‚Ä¢Un-esterified cholesterol;
‚Ä¢HSP70 ;
‚Ä¢GSL s;
‚Ä¢Lyso -SM-509.
9.3.7. O
ther Endpoints  
‚Ä¢Patient acceptability/palatability of the IMP  (blinded phase study period).
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 47 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  9.4. TRIAL TIMETABLE (STUDY PERIODS)  
The trial includes the following visits:  
‚Ä¢Visit 1 (Site):
oScreening;
oPK to confirm doses for patients less than 12 years of age;
oAdditional PK visits (site) for patients less than 12  years of age if required;
oRandomisation.
‚Ä¢Blinded Phase:
oTelephone follow up every month (¬±7 days) for 6 months after the start of
continuous treatment;
oVisit 2 (site): 7 -14 days after the start of continuous treatment;
oVisit 3 (site): 3  months (¬±4 weeks) after patient randomisation;
oVisit 4 (site): 6  months (¬±4 weeks) after patient randomisation;
oVisit 5 (site): 9 months (¬±4 weeks) after patient randomisation;
oVisit 6 (site)/End of Blinded Phase: 12 months (¬±4 weeks) after patient
randomisation or at patient withdrawal during the blinded phase.
Visits  2 through 6 will include scoring for disease severity, blood and skin
biopsy sampling for biomarkers, as well as assessment of safety, compliance ,
SARA, 9HPT,  CGI -S, CGI -I and Quality of Life.
‚Ä¢Extension Phase:
oVisit 7 (site): 18 months (¬± 4 weeks ) after patient randomisation ;
oVisit 8 (site): 24 months (¬±8 weeks) after patient randomisation ;
oVisit 9 (site): 30 months (¬±8 weeks) after patient randomisation;
oVisit 10 (site): 36 months (¬±8 weeks) after patient randomisation;
oVisit 11 (site): 42 months (¬±8 we eks) after patient randomisation;
oVisit 12 (site): 48 months (¬±8 weeks) after patient randomisation;
oVisit 13 (site): 54 months (¬±8 weeks) after patient randomisation;
oVisit 14 (site)/End of Extension Phase:  60 months (¬±8 weeks) after patient
randomisation or at patient withdrawal during the extension phase.Visits  7 to 14 will include  scoring for disease severity, blood sampling for
biomarkers, as well as assessment of safety, compliance, SARA, 9HPT , CGI-S,
CGI-I and Quality of Life;
oTelephone follow up every 3-4 months.
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 48 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  9.5. DATA SAFETY MONITORING COMMITTEE  
An independent DSMB consisting of at least 3 external independent members not associated 
with the conduct of the study or other study committees  will on a continuous basis assess the 
overall s afety of the study during the blinded phase of the study. This will include meet ing 
regularly to: 
‚Ä¢Review safety data, including the review of renal (e.g. serum creatinine) and hepatic
(e.g. aspartate transaminase [AST] and/or alanine transaminase [ALT] ) parameters ;
‚Ä¢Recommend on the stopping of IMP administration;
‚Ä¢Recommend the premature termination of the study if deemed necessary after a reviewof the latest available data.
All decisions will be documented in the form of minutes.  A DSMB charter will document in 
more detail the responsibilities, duties and objectives of the individuals and of the committee.  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 49 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  10. SELECTION AND WITHDRAWAL OF PATIENTS
Up to fifty -two (52) patients will be randomised in the study as the final target  is to have at 
least forty (40) evaluable patients  (at least 30 of these should be paediatric patients less than 
18 years of age) . Each patient should: 
‚Ä¢Meet all of the inclusion and none of the exclusion criteria specified below ( refer to
Sections  10.2 and 10.3) within the specified time -frame;
‚Ä¢Complete the required activities specified in this protocol;
‚Ä¢Have their data entered on the eCRF.
10.1. INFORMED C ONSENT  
Each potentially eligible patient (and /or their parent[s]/legal guardian[s] /legally authorised 
representative [ LAR ]) will be informed of the study‚Äô s objectives and overall requirements. 
Prior to conducting any tests not performed routinely in the treatment of the patient, the 
Investigator will exp lain the study fully to the patient and/or his/her parent(s)/legal guardian(s) 
using the PICD. If the parent/legal guardian is willing for the patient to participate in the study, (s)he will be requested to give written informed consent. The Informed Conse nt will be signed
and personally dated by the parent(s)/legal guardian(s) (according to local laws andregulations) and the Investigator. If capable, the patient should provide assent /consent to
participate in the study and also sign and personally date the Informed Consent if possible(according to local laws and regulations). A copy of the signed form (s) will be provided to the
parent(s)/legal guardian(s) and the original retained with the source documents. Although
nursing staff may be involved in describing the trial to a patient and his/her parent(s)/legal
guardian(s), the Investigator must participate  in discussions with the patient  and/or his/her
parent(s)/legal guardian(s) and sign and personally date the Informed Consent.
10.2. INCLUSION CRITERIA 
In order to ascertain efficacy, the patient population to be investigated should be as 
homogeneous as possible  in relation to metabolic parameters and clinical and biological disease 
status.  
In order to be eligible for inclusion into this study, each patient must fulfil all of the following inclusion criteria at enrolment (Visit 1): 
‚Ä¢EITHER
NPC  patients who have entered the CT -ORZY -NPC -001 study when aged from 2 years
to 18 years and 11 months; and who have completed Visit  2 (EOS) of the
CT-ORZY- NPC -001 study.
ORNPC  patients who did not enter or complete the CT -ORZY- NPC -001 study but are
fulfilling all of criteria listed below:
oDiagnosis of NPC1 or NPC2;
oNPC  diagnosis confirmed by:
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 50 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  -Genetically confirmed (deoxyribonucleic acid  [DNA] sequence
analysis)  by mutations in both alleles of NPC1 or NPC2,
OR 
-Mutation in only one allele of NPC1 or NPC2 plus either positive filipin
staining or elevated cholestane triol/oxysterols  (>2 x upper limit of
normal [ULN] ).
oMales and females aged from  2 years to  18 years and 11 months;
oTreated or not treated with miglustat;
oIf a patient is under prescribed treatment with miglustat, it has to be under stabledose of the medication for at least 6  continuous months prior to inclusion in the
CT-ORZY- NPC -002 study;
oIf a patient has been discontinued from prescribed treatment with miglustat, theymust have been discontinued for at least 3 continuous months prior to inclusionin the CT- ORZY- NPC -002 study;
oBody mass index (BMI) Z -score ‚â• -2 standard deviation  (SD) for age, according
to the World Health Organisation (WHO) standards ;
oPresenting at least one neurological symptom of the disease (for example, butnot limited to, hearing loss, vertical supranuclear gaze palsy, ataxia, dementia,dystonia, seizures, dysarthria, or dysphagia);
oAbility to walk either independently or with assistance.
‚Ä¢Written informed consent (and assent if appropriate to local laws and regulations) priorto any study- related procedures;
‚Ä¢Willing to participate in all aspects of trial design including blood sampling (PK, bloodbiomarkers and safety labs), skin biopsies and imaging (ultrasonography of the liverand spleen);
‚Ä¢Ability to travel to the corresponding clinical trial site at the scheduled visit times forevaluation and follow-up;
‚Ä¢All sexually active female patients of child -bearing potential (post -menarchal) must use
highly effective contraception during the study and until 3 week s after the last dose of
IMP.
Highly effective birth control methods include: Combined (oestrogen and progestogen
containing) hormonal contraception associated with inhibition of ovulation (oral,intravaginal or transdermal); progestogen -only hormonal contraception associated with
inhibition of ovulation (oral, injectable or implantable); intrauterine device  (IUD);
intrauterine hormone -releasing system  (IUS); bilateral tubal occlusion; and
vasectomised partner.
All sexually active male patients with female partners of child -bearing potential (post -
menarchal) must use a condom with or without spermicide in addition to the birth
control used by their partners during the study and until 3 months after the last dose ofIMP.
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 51 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Sexual absti nence is considered a highly effective birth control method only if it is 
defined as refraining from heterosexual intercourse during the study and for 3 week s 
after the last dose of IMP (for female patients of child -bearing potential) and for 
3 months afte r the last dose of IMP (for male patients with female partners of child -
bearing potential). The reliability of sexual abstinence needs to be evaluated by the 
Investigator in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.  
Based on recommendations from the Clinical Trial Facilitation Group  (CTFG , 2014). 
‚Ä¢Ability to comply with the protocol -specified procedures/evaluations and scheduled
visits.
10.3. EXCLUSION CRITERIA 
Each of the following criteria will be taken as reason for exclusion from participation in the trial: 
‚Ä¢Recipient of a liver transplant or planned liver transplantation;
‚Ä¢Severe liver insufficiency (defined as hepatic laboratory parameters, AST and /or ALT
greater than three- times the ULN for age and gender  (central laboratory assessment) ;
‚Ä¢Renal insufficiency, with serum creatinine level greater than 1.5 times the ULN (central
laboratory assessment) ;
‚Ä¢Known or suspected allergy or intolerance to the IMP (arimoclomol or constituents);
‚Ä¢In the opinion of the Investigator, the patient's clinical condition does not allow for therequired blood collection and/or skin biopsies as per the protocol -specified procedures;
‚Ä¢Treatment with any investigational drug during the study or in the 4 weeks  prior to
entering the study.
This includes treatment with  any investigational drug during the study in an attempt to
treat NPC ;
‚Ä¢Pregnancy or breastfeeding;
‚Ä¢Current participation in another trial is not permitted unless it is a non -interventional
study and the sole purpose of the trial is for long- term follow up/survival data (registry);
‚Ä¢For patients who have not completed the CT -ORZY -NPC -001 study, fulfilling any of
the criteria listed below:
oPatients with uncontrolled severe epileptic seizures period
a (at least
3 consecutive severe epileptic seizures that required medication) within
2 months prior to the written consent. This includes patients with ongoingseizures that are not stable in frequency or type or duration over a 2 -month
period prior to enrolment, requiring change in dose of antiepileptic medication(other than adjustment for weight) over a 2- month period prior to enrolment, or
requiring 3 or more antiepileptic medications to control seizures;
a An epileptic seizure is a transient symptom of  abnormal excessive or synchronous neuronal activity in 
the brain. The outward effect can be as dramatic as a thrashing movement (tonic -clonic seizure) or as 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 52 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  mild as a brief loss of awareness (absence seizure). It can manifest as an alteration in mental st ate, tonic 
or clonic movements, convulsions, and various other psychic symptoms. Sometimes it is not 
accompanied by convulsions but a full body slump, where the person simply will lose body control and 
slump to the ground. Seizures can occur in patients who do not have epilepsy. On the other hand, non-epileptic seizures are paroxysmal events that mimic an epileptic seizure but do not involve abnormal, rhythmic discharges of cortical neurons. These non -epileptic seizures are caused by either physiological 
or psychological conditions.  
oNeurologically asymptomatic patients;
oSevere manifestations of NPC  disease that would interfere with the patient‚Äôs
ability to comply with the requirements of this protocol;
oTreatment with any IMP within 4  weeks prior to the study enrolment.
10.4. ASSIGNMENT OF P ATIENT NUMBER /ASSIGNING PATIENTS TO 
TREATMENT GROUPS  
At screening, the Investigator will assign a patient number to the patient. 
Once the subject is considered by the Investigator to be eligible for the study, the Investigator 
will create a new patient in the eCRF. Patients will be stratified into strata A (on miglustat 
therapy) and B (not on miglustat therapy). Upon randomisation, the eCRF will assign a randomisation  number to the patient. The 
treatment assigned to each patient will be determined according to a computer -generated 
randomisation list.  Patients will be randomised to receive placebo or arimoclomol (with an 
allocation ratio of 1:2). 
10.5. PREMATURE WITHDRAWAL OF PATIENTS FROM STUDY AND 
REPLACEMENT POLICY 
10.5.1. Discontinuation C riteria  
Patients  (and their parent [s]/legal guardian[s]) will be informed that they have the right to 
withdraw from the study at any time, without prejudice to their medical care, and are not 
oblige d to state their reasons. Any withdrawals must be fully documented in the eCRF and 
should be followed up by the Investigator. 
Additionally, the Investigator may withdraw a patient at any time if he/she considers this to be 
in the patient‚Äôs best interest.  
Patients will be discontinued from the study if at least one of the following criteria has been 
met:  
‚Ä¢Patient ‚Äôs parents/legal guardian have withdrawn informed consent;
‚Ä¢Patient has withdrawn informed assent;
‚Ä¢Safety reasons (decision of the Investigators and/or Sponsor‚Äôs medical responsible
person and/or DSMB);
‚Ä¢Investigator‚Äôs decision;
‚Ä¢Patient has participated in another interventional clinical trial;
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 53 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢Patient ha s received a liver transplantation;
‚Ä¢Patient has died;
‚Ä¢Patient has become pregnant;
‚Ä¢Patient is lost to follow -up. This is defined as when the site is unable to contact the
patient (the patient ‚Äôs parents[s]/legal guardians[s]) and it is impossible to obtain any
further data ;
‚Ä¢Patient meets criteria for IMP administration to be stopped and subsequent withdrawal
(refer to Section  11.2.4);
‚Ä¢Patient is un -blinded during the blinded phase of the study due to an emergency (refer
to Section  11.4).
If a patient  fails to return for a scheduled visit, attempts should be made to contact the patient 
(or the patient ‚Äôs parent[s]/legal g uardian[s]) to ensure that the reason for not returning is not an 
AE. Likewise,  if a patient (and/or the patient ‚Äôs parent[s]/legal guardian[s]) declares his/her 
wish to discontinue prematurely and withdraw from the study e.g. for personal reasons, an attem pt should be made to establish that the true reason is not an AE (bearing in mind the 
patient is not obliged to state his/her reasons). 
Should the patient discontinue prematurely and choose to withdraw from the study, the patient 
will be asked to attend th e site for a withdrawal visit during the blinded or the extension phase 
of the study ( depending on the time point of withdrawal).  The visit should take place within 
4 weeks of patient withdrawal. The reason for study discontinuation (if known) should be 
documented in the eCRF, and any A Es followed up until resolution, until the condition 
stabilizes, until the event is otherwise expla ined or until the patient is lost to follow up. If the 
patient is lost to follow up, then this should be noted in the eCRF. 
10.5.2. Early Escape Clause and Criteria  
The ‚Äúearly escape clause‚Äù can be invoked when a set of criteria are met in the event that a partici pating patient experiences disease progression that is too severe and/or too fast. In such 
cases, the patient will: 
1) Stop receiving the IMP;
2)Be offered treatment with arimoclomol;
3)Continue with their current protocol schedule (see APPENDIX II: Study Flow Chart:Blinded Phase Study Period: Patients less than 12 years of age and APPENDIX III: Study
Flow Chart: Blinded Phase Study Period: Patients 12  Years of Age and Older ).
For evaluation of a potential early escape, the three relevant domains of the NPCCSS to be assessed are: Ambulation, Swallowing and Fine Motor Skills. 
The investigator will assess the following criteria to determine if the ‚Äúearly -escape clause‚Äù is 
to be invoked for the particular patient: 
EITHER  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 54 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢Criterion  1: An increase of at least 2  points simultaneously in two out of the three
relevant domains of the NPCCSS (for at least 4 points in total) within a period of
3 months;
OR 
‚Ä¢Criterion  2 : An increase of 6  points simultaneously in two out of the three relevant
domains of the NPCCSS (for at least 6 points in total) within a period of 6 months;
OR 
‚Ä¢Criterion  3 : An increase of at least 2  points simultaneously in the all of the three
relevant domains of the NPCCSS (for at least 6 points in total) within a pe riod of
6 months.
The Investigator will submit all requests for early escape to Worldwide Clinical Trials  for  
review and approval. 
10.5.3. Replacement P olicy  
At least f orty (40) patients planned to be evaluable in this study; at least  30 of these  should be  
paediatric patients less than 1 8 years of age. U p to fifty -two (52) NPC patients  will be 
randomised. No patient drop-outs will be replaced.  
An evaluable patient is defined as a patient who:  
‚Ä¢Met all of the inclusion and none of the exclusion cri teria specified in Sections 10.2 and
10.3 within the specified time -frame ,
‚Ä¢Completed Visit 1 and Visit 4 at 6  months, and
‚Ä¢Had his/her eCRF  completed.
Should a patient drop out or be withdrawn from the study, their patient study numbe r will not 
be reallocated.  A dropout rate of approximately 23% is estimated to ensure 40  evaluable 
patients to complete the study. During the study, recruitment may be increased based on an 
assessment on the number of evaluable patients in the study to dat e. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 55 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  11. STUDY MEDICATION
11.1. INVESTIGATIONAL MEDICINAL PRODUCT  
11.1.1. Presentation, Storage, Packaging and Labelling of Arimoclomol 
11.1.1.1. Presentation of Arimoclomol 
Arimoclomol (N-[(2R)-2-hydroxy-3- (1-piperidyl)propoxy]pyridine-3-carboximidoyl 
chl
oride, 1-oxide , citrate) is a hydroxim ic acid derivative.  
Arimoclomol is a small molecule that up-regul ates the HSPs in cells under stress and is a 
co-induc
er of the HSP70 expression. It has been demonstrated in experimental models for NPC  
tha
t arimoclomol offers the potential to ameliorate signs and symptoms of this severe 
neurological condition. 
Refer to Figure 11-1  for the molecular structure of arimoclomol. 
Fi
gure 11- 1:  Molecular Structure of  Arimoclomol 
11.1.1.2. Pac
kaging/Labelling of Arimoclomol 
Arimoclomol is an odourless, crystalline powder of white or off- white colour supplied in hard 
capsules  of 25 mg, 50 mg, and 100 mg . For each strength, capsule fill will be a powder mix of 
active pharmaceutical ingredient  (API), with the remainder made of  
 
 All strengths will have an 
identical capsule size (0), and capsule colour (white). Refer also to Table 11-1 for further 
information. 
For the initial PK evalu ation  (patients less than 12 years of age only) , the single-dose of 
arimoclomol selected for the patient will be presented in a sealed white  high-density 
polyethylene (HDPE) bottle. 

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 56 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  For the placebo -controlled part of the study, the capsules (25 mg, 50 mg, and 100 mg) will be 
supplied in blister packages mounted within wallets which will contain IMP treatment for 
7 days. Capsules are blistered into strips of 7 or 6 strips and are in a 42- capsule w allet. A total 
of 5 wallets will be packaged within a box.  
For the extension phase of the study, the capsules (25 mg and/or 50  mg and/or 100 mg) will be 
supplied in sealed HDPE bottles containing 84 capsules/bottle.  
At Visits  1, 3, 4 and 5 the pa tient will be provided with the required amount of IMP . 
At Visit 6  and thereafter in the extension phase of the study, the pat ient will be dispensed with 
sufficient arimoclomol to continue treatment.  
Each  wallet and  box, and bottle, will be labelle d according to local regulatory requirements. 
Table 11-1:  Investigational Medicinal Product  Description and Packaging  
Blinde d Phase  PK Evaluation Extension Phase  
Capsule T ype Hard g elatin capsule, 
white, size 0  Hard g elatin capsule, 
white, size 0  Hard HPMC capsule, 
white, size 0  
Packaging material Blister packages 
mounted within wallets 
which contain IMP 
treatment for 7 days. Capsules are blistered 
into strips and are in a 
42-capules wallet. A
total of 5 wallets are
packaged within a box.Capsules are packaged in 
HDP E bottles with a 
polypropylene child resistant cap , induction 
heat sealed with a foil 
liner at the neck opening. Capsules are packaged in 
HDP E bottles with a 
child resistant cap, induction heat sealed with a foil liner at the 
neck opening. Bottles 
contain 84 capsules  per 
bottle. 
HPMC: Hydroxypropyl  methylcellulose ; ; HD PE: H igh density polyethylene ; 
IMP: Investigational medicinal product  
11.1.1.3. Stor
age of Arimoclomol  
Arimoclomol must be stored in a secure, dry environment at room temperature. 
Any deviation from the recommended storage conditions should be immediately reported to 
the Sponsor. 
11.1.2. Presentation, Storage, Packaging and Labelling of Placebo 
The
 placebo capsule  is visually indistinguishable from the arimoclomol  capsule in size and 
appear
ance. The placebo will be presented with an identical  weight  capsule fill in identical 
whi
te hard capsules and packaged and labelled as described for arimoclomol (refer to 
Sect
ion 11.1.1.2 ). T he excipient composition, texture, appearance, solubility, smell and flavour 
of the placebo are carefully matched to mask the identity of the active capsule (arimoclomol).  
The storage of the placebo is as described for arimoclomol (refer to Section 11.1.1.3). 

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 57 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  11.2. INVESTIGATIONAL MEDICINAL PRODUCT  DOSING SCHEDULE 
AND ROUTE OF ADMINISTRATION 
11.2.1. Dose Rationale 
A simple allometric scaling method using PK data from Phase  I studies to relate size to 
predicted clearance (CL) (and total exposure), based on total body weight  (BW) has been 
selected as the most appropriate method to adjust dosage in paediatric patients with NPC  
because:  
1.Pharmacokinetics of arimoclomol are linear (proportional) and well characterised in
human adults;
2.Bioavailability of arimoclomol in human adults is high;
3.Renal clearance is expected to be a major contributor to overall elimination ofarimoclomol and metabolites;
4. Maturation of renal function is considered complete at 2 years of age.
The following equation was applied to predict CL ( Mahmood, 2006): 
CL in the child = adult CL√ó(weight of the child/70)
0.75 
Estimated CL values were used to predict exposure (AUC) over a dosing interval at steady state and an appropriate decrease in dose for children based on their total BW. Dose was adjusted based on a target daily exposure limit (AUC
0-24) of 12.9 ¬µg.h/mL ensuring a safety 
factor of 2 compared to daily exposure following repeated dosing at the No Observed Effect Level  (NOEL) (400  mg/kg/day) in juvenile rats. 
Predicted AUC
0-24 values at steady state in the patient population were also compared to 
observed AUC 0-24 at the NOEL in the most sensitive adult toxicological species to ensure a 
relevant safety margin was maintained.  
The final reco mmendation for dose stratification using a pragmatic choice of weight ranges to 
ensure a safety ratio of approximately 2 versus NOEL in juvenile rat are presented in Table 11-2. These recommendations are based on a t.i.d dose regime consistent with the dose regime used in adults. 
The following numerical assumptions were made for the completion of these predictions: 
1. Change in C
max and AUC with dose are proportional;
2. Bioavailability of arimoclomol is 100% in children and adults;3.CL in a healthy 70 kg human adult is 55 L/h - value pooled from available exposure
and demographic data in Phase I studies.
4. Protein binding is low (10%) and constant between adults and children.
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 58 of 173 
Final Version 11.0; 21- Jun-2022  CONFIDENTIAL  Table 11-2:  Recommended Dose Stratification based on a 2 -fold Safety Ratio to Juvenile Rat NOEL (400 mg/kg) 
Target safety ratio 2 versus NOEL rat juvenile  
Dose 
(mg 
per 
day) Dose (mg) per 
administration 
(t.i.d.) Weight 
range 
(kg)a Minimum 
predicted 
AUC (0-8) 
(¬µg.h/mL) Maximum 
predicted AUC (0-8) 
(¬µg.h/mL) Maximum 
predicted 
AUC 0-24 
(¬µg.h/mL)b Minimum safety 
ratio versus NOEL 
rat juvenile 
400 mg/kg/dayc Minimum safety ratio 
versus NOEL dog 
50 mg/kg/day 
16 weekd 
150 50 8-15 2.9 4.6 13.9 1.9 2.9 
225 75 >15-22 3.2 4.3 13.0 2.0 3.1 
300 100 >22-38 2.9 4.3 13.0 2.0 3.1 
450 150 >38-55 3.3 4.3 12.9 2.0 3.1 
600 200 >55 3.6 4.4 13.1 2.0 3.1 
AUC tau: AUC over the dosing interval at steady state (dosing interval 8 hours).  
a Calculations assuming maximum weight of 70 kg.  
b AUC (0-8) X 3. 
c Based on AUC (0-24) in juvenile rat of 25.7  ¬µg.h/mL.  
d Based on AUC (0-24) in dog of 40.2 ¬µg.h/mL.  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 59 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  11.2.2.  Do se 
IMP (arimoclomol and placebo) dosing is based on the patient‚Äôs BW (refer to Table 11-3 ): 
T
able 11- 3:  Investigational Medicinal Dosing : Based on the Patient Body Weight 
Patient Body Weight  (BW)  Investigational Medicinal Dosing  (IMP)  Dose  
8-15 kg BW 50 mg t.i.d. (150  mg/day)  
>15-22 kg BW 75 mg t.i.d. (225 mg/day)  
>22-38 kg BW 100 mg t.i.d.  (300 mg/day)  
>38-55 kg BW 150 mg t.i.d.  (450 mg/day)  
>55 kg BW 200 mg t.i.d.  (600 mg/day)  
The pa
tient‚Äôs weight will be measured at each visit and the IMP dose is to be adjusted as 
required.  
In the event that a patient who is receiving 150 mg IMP per day requires a dose reduction, then 
a dose of 75 mg per day (25 mg t.i.d) should be administere d (refer also to Section  11.2.4).  
For individual patients less than 12 years of age, to confirm the corresponding dose, a single dose PK evaluation will be performed by an independent assessor following a single dose of 
arimoclomol to verify the area under the curve in 0- 8 hours  (AUC
0-8). In the  event that patients 
require a dose reduction (refer also to Section  11.2.4), these patients will be dispensed a further 
single dose of arimoclomol, and a new single dose PK  evaluation will be performed to confirm 
the corresponding dose. Should further dose adjustments be required, based on the second single dose PK evaluation, the above procedure will be repeated until the correct dose level is found.  
Also, i n the event that unexpected PK -profiles are obtained (from patients less than 12 years of 
age) which are clin ical significant and could potentially impact the safety of the patient (e.g. 
risk of accumulation), the independent assessor can recommend additional PK sampling to be 
performed. If agreed by the Sponsor‚Äôs medical responsible person and the Principal Investigator , up to a maximum of 6 additional samples (corresponding to the full PK analysis 
set) can be taken at a subsequent visit prior to randomisation. The results of this analysis might 
lead to dose adjustments as recommended by the independent assessor. 
This/these dose reduction(s) will take place prior to randomisation and to commencing 
continuous dosing of IMP (arimoclomol or placebo, as per the study randomisation). 
11.2.3. Dosing Route and Regimen 
The IMP (arimoclomol and placebo) may be dispensed only by the Investigator or by a member 
of staff specifically authorized by the Investigator, as appropriate. The IMP will be dispensed 
to the patient during site visits or shipped to the patient‚Äôs house ( as appropriate) (refer to 
Section  13). 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 60 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Arimoclomol or placebo will be administered orally t.i.d. In the event that IMP administration 
during the blinded phase study period coincides with the administration of other concomitant medication, the IMP should be administered first. 
If required, the IMP can be dispersed in 10-20 mL (i.e. 1-2 tablespoons ) of liquid (water, apple 
juice) or soft foodstuff (yoghurt or apple sauce). In the dispersed state, the IMP  capsules can also be administered via a gastric tube (as 
applicable).  For full administration of the dose, flush the tube with 5 mL of water.  
The dispersed product is stable for 8 hours. 
11.2.4. Dose Adjustment  
Patients less than 12 years of age  may have their dose adjusted (decrease)  following a single 
oral dose of arimoclomol based on review of  the following criteria  by an independent assessor  
(see also Table 11 -4 and Section  11.2.1): 
‚Ä¢AUC
0-8
In 
addition, the dose can be adjusted (and subsequent repeated PK assessments performed)  
(refer to Section  11.2.2), if justified by the independent assessor (e.g. if an unexpected 
PK-profile is obtained and this could potentially impact the safety of the subject). 
In the event that a patient who is receiving 150 mg IMP per day requires a dose reduction, then 
a dose of 75 mg per day (25 mg t.i.d) should be administered. For this dose group (75 mg per day), the same AUC acceptance limit of 4.6 has to be adhered to ( Table 11 -4). 
Table 11-4: Acceptance Criteria for P harmacokinetic Evaluation following Single 
Oral Dose of Arimoclomol (Patients Less than 12 years of Age)  
Weight range (kg)
a Dose  
(mg per day) Dose (mg) per administration (t.i.d.) Acceptable exposure limit (AUC
0-8) to maintain an 
approx 2-fold safety ratio (¬µg.h/mL) 
8-15 150 50 4.6 
>15-22 225 75 4.6 
>22-38 300 100 4.6 
>38-55 450 150 4.6 
>55 600 200 4.6 
a Calculations assuming maximum weight of 70 kg.  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 61 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  In addition to this, a patient  who has commenced continuous dosing with the IMP  is to be 
considered for dose reduction should the following criteria be met: 
‚Ä¢Serum creatinine above 1.5 x the patient‚Äôs baseline creatinine value . Dose adjustment
may be temporary however, subsequent dose increase must be discussed with the KemPharm
Denmark ‚Äôs medical monitor (or delegate) ;
Note : Serum creatinine calculation  = Serum creatinine value/baseline serum creatinine value. Result
rounded to 1 decimal  point as per normal rounding principles .
‚Ä¢Decrease in the patient‚Äôs weight (as confirmed during a site visit) meeting the lower
weight range in the actual dose group (refer to Section  11.2.2 for dosing based on the
patients BW) .
Upon confirmation of a dose reduction, new IMP kits will be dispensed to the patient  at the 
confirmed lower dose . In the event that this does not coincide with a site visit, the IMP will be 
shipped to the patient‚Äôs home.  
In order to maintain blinding (refer to Section 11.3) in the event that a dose reduction is due to 
a patient‚Äôs elevated serum creatinine values  at Visit 2, 2 additio nal patients (selected at random 
from across all sites) will also be dispensed new IMP kits but their IMP dose will remain unchanged. 
Following confirmation of a dose reduction, the patient should continue their daily dosing at 
their current IMP dose, until they are in receipt of the new IMP kits, as per Investigator discretion and patient safety. 
Administration of IMP  will be stopped and the patient withdrawn from the study should the 
following criteria be met: 
‚Ä¢Common Terminology Criteria for Adverse Events  (CTCAE
) Grade 2  acute kidney
injury considered related to the IMP (which corresponds to the serum creatinine
increase of above 2-3 x the patient‚Äôs basel ine creatinine value) ;
Note : Serum creatinine calculation  = Serum creatinine value/baseline serum creatinine value. Result
rounded to 1 decimal  point as per normal rounding principles .
‚Ä¢CTCAE  Grade 3 hepatic related parameters (AST and/or ALT) considered related to
the IMP;
‚Ä¢Other CTCAE  Grade 3 AEs considered related to the IMP.
The individual patient dose will be adapted if required upon patient‚Äôs weight changes at every visit (refer to Section  11.2.1 for dosing based on the patients BW).  
Refer also to Section  11.3 for the review of the Visit 2 creatinine test results (central lab 
analysis).  
11.2.5. Dose Interruption  
If a patient experiences a clinically significant and/or unacceptable toxicity  (which is not a 
discontinuation criterion  as listed in Section  10.5.1 ), dosing may  be interrupted and supportive 
therapy administered as required. All dos ing interru ptions must be discussed with the 
KemPharm Denmark ‚Äôs medical monitor (or delegate).  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 62 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  An interruption of up to 4 weeks (calculated from AE start date) is permitted following 
discussion with the KemPharm Denmark ‚Äôs medical monitor (or delegate) prior to resuming 
IMP administration  at the same dose prior to interruption (unless the criteria are met for dose 
adjustment as specified in Section  11.2.4).  
11.3. BLINDING  
To maintain the integrity of the study, access to unblinded information will be restricted 
t
hroughout until final database lock. The treatment allocation for each patient will be managed  
vi
a Interactive Response Technology ( IRT). T reatment codes will not be  made available to 
anyone who could influence the ongoing treatment and evaluation of patients. 
Visit 2 creatinine test results (central lab analysis) will not be sent to the site; instead these 
r
esults will be reviewed by an independent expert in order to avoid the possible unblinding of 
the patient. Based upon the available data, any possible effects on the kidneys/creatinine levels 
will be detectable with 7 -14 da ys (at Visit 2) . Any possible changes are expected to be 
nor
malized within a period of 3-4 months. Visit  2 c reatinine test results will be transferred to 
Worldwide Clinical Trials  Data Management for inclusion in the study database following 
unbli
nding of the study data  after study completion. The independent expert will contact the 
investigator in the event that further safety follow up is required.  
In the event that a patient requires a dose reduction (refer to Section 11.2.4) at Visit 2, 
2 addi
tional patients (selected at random from across all sites) will also be dispensed new IMP 
ki
ts. Only the patient requiring a dose reduction will  r eceive a lower dose; the IMP dose for the 
a
dditional 2 patients will remain unchanged. 
The DSMB will be provided with unblinded data where appropriate , the DSMB will also have 
a
 specified unblinded statistician. Pharmacovigilance department can also requ e st unblinded 
data as per the requirements for safety reporting.  
To ensure blinding, all IMP (placebo, 25 mg, 50 mg, and 100 m g capsules) are identical in size 
and appearance. In the event the capsules are opened in order to mix or dissolve the contents 
i
nto liquid or foodstuff, the excipient composition, texture, appearance, solubility, smell  and 
flavour are carefully matched to mask the identity of the capsule fill.  
The IMP will be blinded by means of treatment c ode lists. The IMP packages will also be 
blinded: The number of capsules per container, and all container parts will be identical and 
f
rom the same parts batches, the label batches will be the same and the label print will be 
completed on the same print station, and the position of the label will be applied consistently 
be
tween treatment groups as well.  
11.4. E
MERGENCY UNBLINDING  
As a double -blind, placebo- controlled study, both the patients and the Investigators are blinded 
to the IMP assignment.  
In addition, all personnel from the CRO  and KemPharm Denmark  A/S (except for personnel 
in Product Supply depar tment) , laboratory personnel , and others are blinded to the IMP 
assignment and will remain blinded until the data for the 12-month blinded phase of the study 
has been validated and  locked . 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 63 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  In case of emergency, where knowledge of the blind treatment may influence further care of 
the patient , the investigator may determine the patient‚Äôs treatment using IRT . It is strongly 
encouraged that un- blinding should only take place after consultation with the study Medical 
Monitor, CRO  or KemPharm Denmark  A/S, provided that this does not compromise patient 
safety. If a treatment code is revealed for any reason, the Investigator must notify the CRO  
immediately and a record will be kept of when it was revealed , by whom and why. If a blind is 
broken due to an AE  or serious adverse event  (SAE ), a corresponding AE entry must be 
completed in the eCRF.  All SAEs must be reported as documented in Section 15.3.3.7. 
In the event of an emergency unblinding, the patient will be withdrawn (refer to Section  10.5). 
11.5. INVESTIGATIONAL MEDICINAL PRODUCT  STABILITY DURING 
SHIPMENT  
The IMP (arimoclomol and placebo) will be shipped to the centers  and to patients‚Äô  homes at 
room temperature.  
11.6. INVESTIGATIONAL MEDICINAL PRODUCT  ACCOUNTABILITY 
The Investigator (or pharmacist) is responsible for verifying accurate delivery of the IMP and 
acknowledging receipt of the IMP by signing (or initialling) and dating the document ation 
provided by or on behalf of Worldwide Clinical Trials  and returning it to Worldwide Clinical 
Trials . A copy will be retained for the Investigator Site File.  
The Investigator (or pharmacist) will maintain accountability records that must document all  
IMP received from the Sponsor, dispensed (as per the doses specified by the protocol/amendment[s]) to the patient, returned by the patient, and returned to the Sponsor (or alternative disposition of unused IMP) . In addition to this, the accountability records will 
document relevant information received by the Investigator (pharmacist) on the IMP shipped directly to the patients‚Äô homes. Records should include dates, quantities, batch numbers, expiration dates, and any unique code numbers assigned to the IMP  and/or patients. 
When IMP is shipped directly to the patient‚Äôs home, the confirmation of receipt will be documented via the tracking/documentation system of the courier supplying the IMP. 
Patients will be require d to return all unused IMP (and relevant packaging [used/empty blister 
packs  and used/empty bottles ]) to the site staff. The site staff should aim to follow up on the 
reasons for any missing IMP or other discrepancies noted after performing the relevant IM P 
accountability . 
IMP that has been dispensed to a patient and returned unused must not be re -dispensed for a 
different patient. Unused IMP must not be used for any purpose other than the present study. 
Patients should be instructed to return unused IMPs, preferably in their original packaging. 
The Worldwide Clinical Trials  Clinical Research Associate (CRA) will review the drug 
accountability forms and check all IMP returns  prior to making arrangements for their return 
to the Sponsor or authorising their destruction by the study site. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 64 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  12. CONCOMITANT THERAPY/MEDICAL MANAGEMENT OF
ADVERSE EVENTS
Any medication, w hich is considered necessary for the patient welfare, may be given at the 
discretion 
of the Investigator. Medications/therapies which should be administer ed as part of 
the study requirements are listed in Section 12.2. 
D
uring the study, patients will remain on their standard prescribed therapy (based on the choice 
of their treating physician), symptomatic medication (e.g.: corticosteroids, non- s teroidal anti-
inflammatories, anticonvulsants, tricyclic antidepressants, etc .) , vitamins, minerals and food 
s
upplements.  
There is the potential that arimoclomol could inhibit the elimination of cationic drugs (e.g. 
c
imetidine, ranitidine and trimethoprim) that are significantly eliminated by renal tubular 
s
ecretion, so concomitant administration of such drugs with the IMP should be done under 
careful observation. 
Medications 
that are prohibited during the course of this study are listed in Section 12.3. 
If a pa t ie nt experience s a c linica l significa nt and/or una cceptabl e toxicity, an interruption in 
IMP dos ing can t ake pl ace as pe r Se ction 11.2.5. 
Refer to Section  11.2.4 which lists the criteria/toxicities which will result in an IMP dose 
r
eduction. Section 11.2.4 also lists the criteria/toxicities which will result in the withdrawal of 
I
MP administration.
12.1. RE
CORDING OF CONCOMITANT THERAPY 
All medications  administered during the study and medical procedures (including any 
unplanned diagnostic, therapeutic or surgical procedures) ongoing at or starting after the time 
of written consent until the end of the extension phase of the study or patient withdrawal , must 
be reported in the appropriate section of the  case report form  (CRF)/ eCRF along with dosage 
information, dates of administration , frequency, route and reasons for use.  
12.2. MEDI CATIONS THAT MUST BE ADMINISTERED 
There is no mandatory therapy in this study. The patients should continue their standard therapy, which should remain unchanged as judged by the treating physician. Any changes to the patient ‚Äôs standard therapy should be recorded in the CRF/eCRF.  
12.3. PROHIBITED MEDICATIONS  
Any IMP or any product not approved by the European Medicines Agency ( EMA ) or the FDA.  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 65 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  13. SCHEDULE OF VISITS
Refer to APPENDIX II: Study Flow Chart: Blinded Phase Study Period: Patients less than 12 
years of age, APPENDIX III: Study Flow Chart: Blinded Phase Study Period: Patients 12  Y ears 
of Age and Older  and APPENDIX IV: Study Flow Chart: Extension Phase: ALL Patients .  
13.1. SCREENING AND E NROLMENT 
The Investigator will carry out the screening  and enrolment  for each patient ; eligibility criteria 
will be checked for compliance prior to enrolment in the study. 
The Investigator will explain the details of the study to the patient (and the patient ‚Äôs 
parent[s]/legal guardian[s]). The patient  (and the patient ‚Äôs parent[s]/legal guardian[s]) will be 
given a PICD to read for further information about the study (refer to Section 10.1 for more 
detail s regarding informed consent).  
The Investigator will maintain a Screening Log (as provided by the CRO ) for all patients who 
were screened for the study.  
13.1.1. VISIT  1 
13.1.1.1. Patients Less than 12 years of Age 
Once the patient (the patient ‚Äôs parent[s]/legal guardian[s]) has signed the PICD, the formal 
screening evaluations and procedures to determine the patient ‚Äôs study eligibility must be 
completed. Where appropriate, data will be taken from the CT -ORZY- NPC -001 study. 
Most patients are anticipated to have completed Visit  2 (EOS) in the CT -ORZY- NPC -001 
study. These evaluations include the following: 
‚Ä¢Date of signed informed consent;
‚Ä¢Demographics ‚Äì date of birth, sex and race;
‚Ä¢Diagnosis:
oDate of initial symptoms and initial symptom/s description;
oDate of clinical diagnosis and symptoms/clinical status;
oFillipin staining result (if applicable );
oCholestane triol/oxysterols (if applicable);
oDate of confirmed genetic NPC  diagnosis;
oDate and details of the results of the DNA  sequence analy sis.
‚Ä¢NPC  disease history including date of first NPC  symptom, history of neurological
manifestations and past treatments;
‚Ä¢Medical history (including all concomitant disease[s]);
‚Ä¢Confirmation of study eligibility (inclusion and exclusion criteria);
‚Ä¢SARA (re fer to Section  14);
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 66 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢9HPT (refer to Section 14);
‚Ä¢CGI
-S and CGI-I (refer to Section 14) ;
‚Ä¢Pregnancy test (urine) for post-m enarchal  female patients;
‚Ä¢Review of concomitant therapy (refer to Section 12);
‚Ä¢Review
 of AEs that may have occurred since PICD signature (refer to Section  15.3).
The
 following assessments do not need to be repeated at Visit  1 i f these assessments have been 
performed within 7 days of  Visit 1 (e.g. performed at Visit  2 [ EOS ] for the 
CT-ORZY- NPC -001 study): 
‚Ä¢Physical examination including height (refer to Section  15.2.4 for the list of  
parameters);
‚Ä¢Vital
 signs (refer to Section 15.2.4 for  the list of parameters);
‚Ä¢Patient weight;
‚Ä¢Electrocardiogram (ECG ) (refer to Section 15.2.5);
‚Ä¢Skin punch biopsy for 
biomarkers analysis (refer to Section  18);
‚Ä¢Blood sample for:
oHaematology (refer to Section 15.2.2 fo r the list of parameters);
oClinical chemistry (refer to Section 15.2.3 fo r the  list of parameters);
oBiomarkers analysis (refer to Section 18).
‚Ä¢Ultrasound of the 
spleen and liver (refer to Section  16);
‚Ä¢NPCCSS
 (refer to Section 14);
‚Ä¢NPC
-cdb score (refer to Section 14) ;
‚Ä¢Quality of Life scoring 
(refer to Section 14).
PK
 evaluation: 
‚Ä¢Patients less than 12 years of age will be dispensed and administered a single dose of
arimoclomol based on their BW (refer to Section  11.2.1);
‚Ä¢PK sampling for patients less than 12 years of age will be performed at the following
time-points:
oPre-dose and 30 min (¬±5  min), 1 hour (¬±10  min), 2 hours (¬±10  min),
4 hours (¬±30  min) and 8 hours (¬±30 min) following dosing.
‚Ä¢The PK results will be reviewed by an independent assessor  to confirm  the
corresponding dose or advise on adjusting the dose of arimoclomol. In the event that
the patient requires a dose reduction (refer also to Section  11.2.4) , the patient will be
dispensed a further single dose of arimoclomol. Single dose PK  evaluation will be
performed following this single dose of arimoclomol in order to confirm the
corresponding dose.
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 67 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Should further dose adjustments be required based on the single dose PK evaluation, 
the above procedure will be repeated.  
Patient Randomisation and IMP Dispensing and Administration 
‚Ä¢Following confirmation of corresponding dose, the Investigator (or delegate) willrandomise the patient;
‚Ä¢The patient will be dispensed enough IMP (arimoclomol or placebo, as per the studyrandomisation) for treatment. The IMP (arimoclomol or placebo, as per the studyrandomisation) will be shipped to the patient, who will commence dosing upon receiptof it. W ithin 1  week following randomisation, the investigator will contact the patient
(or patient‚Äôs parent[s]/legal guardian[s]) by telephone to confirm that the IMP has beenreceived, the date that the patient has commenced IMP dosing and whether the patient
has experienced any difficulties in taking the IMP.
Results of all the screening evaluations and procedures must be reviewed by the Investigator to ensure that all eligibility criteria ha ve been satisfied prior to patient enrolment. Care should 
be taken to ensure that the maximum amount of blood drawn does not exceed what is stated in the PICD . 
13.1.1.2. Patients 12  years of A ge and Older 
Once the patient (the patient‚Äôs parent[s]/legal guardian[s]) has signed the PICD, the formal screening evaluations and procedures to determine the patient‚Äôs study eligibility must be completed. Where appropriate, data will be taken from the CT -ORZY- NPC -001 study. 
Most patients are anticipated to have completed Visit  2 (EOS) in the CT -ORZY- NPC -001 
study. 
These evaluations include the following: 
‚Ä¢Date of signed informed consent;
‚Ä¢Demographics ‚Äì date of birth, sex and race;
‚Ä¢Diagnosis:
oDate of initial symptoms and initial symptom/s description;
oDate of clinical diagnosis and symptoms/clinical status;
oFillipin staining result (if applicable );
oCholestane triol/oxysterols (if applicable);
oDate of confirmed genetic NPC  diagnosis;
oDate and details of the results of the DNA  sequence analysis
‚Ä¢NPC  disease history including date of f irst NPC  symptom, history of neurological
manifestations and past treatments;
‚Ä¢Medical history (including all concomitant disease[s]);
‚Ä¢Confirmation of study eligibility (inclusion and exclusion criteria);
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 68 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢Pregnancy test (urine) for post-m enarchal female patients;
‚Ä¢SARA (refer to Section 14);
‚Ä¢9HPT (refer to Section 14);
‚Ä¢CGI
-S and CGI-I (refer to Section 14) ;
‚Ä¢Review of concomitant therapy (refer to Section 12);
‚Ä¢Review
 of AEs that may have occurred since PICD signature (refer to Section 15.3).
The
 following assessments do not need to be repeated at Visit  1 i f these assessments have been 
performed within 7 days of Visit 1: 
‚Ä¢Physical examination including height (refer to Section 15.2.4 for the list of  
parameters);
‚Ä¢Vital
 signs (refer to Section 15.2.4 for  the list of parameters);
‚Ä¢Patient weight;
‚Ä¢ECG (refer to Section 15.2.5);
‚Ä¢Skin punch biopsy for 
biomarkers a nalysis (refer to Section 18);
‚Ä¢Blood sample for:
oHaematology (refer to Section 15.2.2  for the list of parameters);
oClinical chemistry (refer to Section 15.2.3 fo r the  list of parameters);
oBiomarkers analysis (refer to Section 18).
‚Ä¢Ultrasound of the 
spleen and liver (refer to Section  16);
‚Ä¢NPCCSS
 (refer to Section 14);
‚Ä¢NPC-cdb  s core (refer to Section 14) ;
‚Ä¢Quality of Life scoring (refer to Section 14);
Pa
tient Randomisation and IMP Dispensing and Administration 
‚Ä¢Patient randomisation;
‚Ä¢IMP dispensing and administration: Patients ‚â• 12 years old will be dispensed enough
IMP (arimoclomol or pla cebo, as per the study randomisation) for treatment. Patients
will commence continuous dosing with IMP (arimoclomol or placebo) as per the study
randomisation upon receipt of the IMP.
Confirmation of eligibility will be dependent on the availability of the  relevant central
lab results  (refer to Section  10.3) . In the event that confirmation of eligibility and
subsequent randomisation of a patient occur s after the screening site visit, IMP
(arimoclomol or placebo, as per the study randomisation) will be shipped to the patient,
who will commence dosing upon receipt of it. Within 1 week following randomisation,
the investigator will contact the patient (or patient‚Äôs parent[s]/legal guardian[s]) bytelephone to confirm that the IMP has been received, the date that the patient has
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 69 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  commenced dosing and whether the patient has experienced any difficulties in taking 
the IMP.  
Results of all the screening evaluations and procedures must be reviewed by the Investigator to ensure that all eligibility criteria have been satisfied prior to patient enrolment. Care should be taken to ensure that the maximum amou nt of blood drawn does not exceed what is stated in 
the PICD.  
13.2. BLINDED PHASE  STUDY PERIOD  
13.2.1. Telephone Follow -up (Blinded Phase)  
During the first 6 months of the blinded phase of the study, the Investigator will contact the patient (or patient‚Äôs parent[s]/lega l guardian[s]) by telephone every month (¬±7 days) in order 
to follow up on the status of the patient, whether the patient has experienced any new AEs or the worsening of any existing AEs, whether the patient has had a change in any prescribed medication, whether the patient has experienced any difficulties in taking the IMP  and to 
confirm the weight of the patient. Telephone follow up will commence 1 month following the commencement of continuous dosing. If required, the Investigator should follow up with t he 
patient more frequently. The Investigator will document the telephone contact and information received in the patient‚Äôs medical notes and update the relevant sections of the eCRF.  
13.2.2. VISIT  2 
Visit 2 should take place 7-14 days after the start of continuous treatment with the IMP 
(arimoclomol or placebo). 
The following procedures should be performed: 
‚Ä¢Vital signs (refer to Section 15.2.4 for the list of  parameters);
‚Ä¢Blood sample for:
oHaematology (refer to Section  15.2.2 for the list of parameters);
oClinical chemistry (refer to Section 15.2.3 f or the list of parameters).
‚Ä¢Review
 of concomitant therapy;
‚Ä¢Review of AEs that may have occurred following the PICD signature;
‚Ä¢IMP (arimoclomol or placebo) administration;
‚Ä¢Patient acceptability/palatability
 of the IMP (refer to Section 19).
Shoul
d any of the blood samples collected for the purposes of the study be compromised or 
destroyed in error, a repeat sample should be taken during the visit. Care should be taken to 
ensure that the maximum amount of blood drawn does not exceed what is st ated in the PICD.  
13.2.3. VISIT  3 
Visit 3 should take place at the site  3 months (¬±4  weeks) after patient randomisation . 
The following procedures should be performed: 
‚Ä¢Patient weight;
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 70 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢Vital signs (refer to Section 15.2.4 for the list of parameters);
‚Ä¢Blood sample for:
oHaematology (refer to Section  15.2.2 for the list of parameters);
oClinical chemistry (refer to Section 15.2.3 for the list of parameters).
‚Ä¢NPCCSS
 (refer to Section 14);
‚Ä¢CGI
-S and CGI-I (refer to Section 14) ;
‚Ä¢Review of concomitant therapy;
‚Ä¢Review of AEs that may have occurred following the PICD signature;
‚Ä¢IMP dispensing: Patients will be dispensed enough IMP (arimoclomol or placebo) for
treatment;
‚Ä¢IMP
 (arimoclomol or placebo) administration;
‚Ä¢Blood sample for POP
 PK (refer to Section 17.2.2);
‚Ä¢Patient acceptability/palatability
 of the IMP (refer to Section 19).
Shoul
d any of the blood samples collected for the purposes of the study be compromised or 
destroyed in error, a repeat sample should be taken during the visit. Care should be taken to 
ensure that the maximum amount of blood drawn does not exceed what is stated in the PICD.  
13.2.4. VISIT  4 
Visit 4 should take place at the site  6 months (¬±4 weeks) after patient randomisation . 
The following procedures should be performed: 
‚Ä¢Physical examination (refer to Section 15.2.4 f or the  list of parameters);
‚Ä¢Patient weight;
‚Ä¢Vital signs (refer to Section 15.2.4 fo r the list of parameters);
‚Ä¢ECG
 (refer to Section 15.2.5);
‚Ä¢Skin punch biopsy for biomarkers analysis  
(refer to Section 18);
‚Ä¢Blood sample for:
oHaematology (refer to Section 15.2.2 f or the list of parameters);
oClinical chemistry (refer to Section 15.2.3 f or the  list of parameters);
oBiomarkers
 analysis ( refer to Section 18).
‚Ä¢Ultrasound of the spleen and liver (refer to Section  16);
‚Ä¢NPCCSS (refer to Section 14);
‚Ä¢NPC-cd b score (refer to Section 14);
‚Ä¢SARA
 (refer to Section  14);
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 71 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢9HPT (refer to Section 14);
‚Ä¢CGI
-S and CGI-I (refer to Section 14) ;
‚Ä¢Quality of Life scoring (refer to Section 14);
‚Ä¢Revie
w of concomitant therapy;
‚Ä¢Review of AEs that may have occurred following the PICD signature;
‚Ä¢IMP return: Patients will be required to return all unused IMP (and relevant packaging
[used/e mpty blister packs]) to the site staff. The site staff should aim to follow up on
the reasons for any missing IMP or other discrepancies noted after performing the
relevant 
IMP accountability;
‚Ä¢IMP dispensing: Patients will be dispensed enough IMP (arimoclomol or placebo) for
treatment;
‚Ä¢IMP (arimoclomol or placebo) administration;
‚Ä¢Blood samples 
for POP PK (refer to Section  17.2.2);
‚Ä¢Patient acceptability/palatability
 of the IMP (refer to Section 19).
Shoul
d any of the blood samples collected for the purposes of the study be compromised or 
destroyed in error, a repeat sample should be taken during the visit. Care should be taken to 
ensure that the maximum amount of blood drawn does not exceed what is st ated in the PICD.  
13.2.5. VISIT  5 
Visit 5 should take place at the site  9 months (¬±4 weeks) after patient randomisation . 
The following procedures should be performed: 
‚Ä¢Patient weight;
‚Ä¢Vital signs (refer to Section 15.2.4 for the list of parameters);
‚Ä¢NPCCSS
 (refer to Section 14);
‚Ä¢CGI
-S and CGI-I (refer t o Section 14) ;
‚Ä¢Review
 of concomitant therapy;
‚Ä¢Review of AEs that may have occurred following the PICD signature;
‚Ä¢IMP dispensing: Patients will be dispensed enough IMP (arimoclomol or placebo) for 
treatment;
‚Ä¢IMP (arimoclomol or placebo) administration;
‚Ä¢Blood sample for POP
 PK (refer to Section 17.2.2).
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 72 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  13.2.6. VISIT  6 (End of Blinded Phase /Withdrawal during B linded Phase ) 
Visit 6 should take place at the site 12 months (¬±4 weeks) after patient randomisation or within 
4 weeks of patient withdrawal during the blinded phase of the study. 
The following procedures should be performed: 
‚Ä¢Physical examination (refer to  Section 15.2.4 fo r the  list of parameters);
‚Ä¢Patient
 weight;
‚Ä¢Vital signs (refer to Section 15.2.4 for the list of parameters);
‚Ä¢ECG (refer to Section 15.2.5);
‚Ä¢Skin punch biopsy for biomarkers analysis (refer to Section  18);
‚Ä¢Blood sample for:
oHaematology (refer to Section 15.2.2 fo r the list of parameters);
oClinical chemistry (refer to Section 15.2.3 fo r the  list of parameters);
oBiomarkers analysis (refer to Section 18).
‚Ä¢Pregnancy test (urine) for post-men archal female patients;
‚Ä¢Ultrasound of the spleen and liver (refer to Section  16);
‚Ä¢NPCCSS
 (refer to Section 14);
‚Ä¢NPC-cdb  s core (refer to Section 14);
‚Ä¢SARA
 (refer to Section 14);
‚Ä¢9HPT (refer to Section 14);
‚Ä¢CGI
-S and CGI-I (refer to Section 14);
‚Ä¢Quality of Life scoring 
(refer to Section 14);
‚Ä¢Review
 of concomitant therapy;
‚Ä¢Review of AEs that may have occurred following the PICD signature;
‚Ä¢IMP return: Patients will be required to return all unused IMP (and relevant  
packaging [used/empty blister packs]) 
to the site staff. The site staff should aim to  
follow 
up on the reasons for any missing IMP or other discrepancies noted after 
performing the relevant IMP accountability;
‚Ä¢Dispensing 
of sufficient arimoclomol  to continue treatment (for patients who have not 
withdrawn from the study);
‚Ä¢Arim oclomol administration (for patients who have not withdrawn from the study);
‚Ä¢Blood samples for POP PK (refer to Section 17.2.2 );
‚Ä¢Patient acceptability/palatability of the IMP (refer to  Section 19).
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 73 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Should any of the blood samples collected for the purposes of the study be compromised or 
destroyed in error, a repeat sample should be taken during the visit. Care should be taken to ensure that the maximum amount of blood drawn does not exceed what is stated in the PICD.  
13.3. EXTENSION  PHASE  
13.3.1. Arimoclomol Dispensing  
Following Visit 6 (end of the blinded phase of the study), patients will be dispensed with 
sufficient arimoclomol to continue treatment.  
When this dispensing does not coincide with a site visit, this supply of arimoclomol will be 
shipped to the patient‚Äôs home. 
13.3.2. Telephone Follow -up (Extension Phase) 
Following the start of the extension phase of the study, t he Investigator will contact the patient 
(or patient‚Äôs parent[s]/legal guardian[s]) by telephone every 3 -4 months in order to follow up 
on the status of the patient , whether the patient has experienced any new AEs or the worsening 
of any existing AEs , whether the patient has had a change in any prescribed medication , 
whether the patient has experienced any difficulties in taking arimoclomol and to confirm the weight of the patient. If required, the Investigator should follow up with the patient more frequently. The Investigator will document the telephone contact and information received in the patient‚Äôs  medical notes and update the relevant sections of the eCRF.  
13.3.3. VISIT  7 
Visit 7 should take place at the site  18 months (¬±4 weeks) after patient randomisation . 
The following procedures should be performed: 
‚Ä¢Physical examination (refer to Section 15.2.4 for the list of parameters);
‚Ä¢Patient weight;
‚Ä¢Vital signs
 (refer to Section 15.2.4 f or the list of parameters);
‚Ä¢Blood sample for:
oHaematology (refer to Section 15.2.2 f or the list of parameters);
oClinical chemistry (refer to Section 15.2.3 f or the list of parameters);
oBiomarkers
 analysis (refer to Section 18).
‚Ä¢Pregnancy test (urine) for post-m enarchal
 female patients;
‚Ä¢NPCCSS (refer to Section 14) ;
‚Ä¢NPC-c db score (refer to Section 14);
‚Ä¢SARA
 (refer to Section 14);
‚Ä¢9HPT (refer to Section 14);
‚Ä¢CGI
-S and CGI-I (refer to Section 14);
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 74 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢Quality of Life scoring (refer to Section 14);
‚Ä¢Review of concomitant therapy;
‚Ä¢Review of AEs that may have occurred following the PICD signature;
‚Ä¢IMP return: Patients will be required to return all unused IMP (and relevant
packaging [used/empty bottles ]) to the site staff. The site staff should aim to follow up
on the reasons for any missing IMP or other discrepancies noted after performing therelevant IMP accountability
‚Ä¢Dispensing of sufficient arimoclomol to continue treatment;
‚Ä¢Arimoclomol administration.
Should any of the blood samples collected for the purposes of the study be compromised or destroyed in error, a repeat sample should be taken during the visit. Care should be taken to ensure that the maximum amount of blood drawn does not exceed what is st ated in the PICD.  
13.3.4. VISIT 8  
Visit 8 should take place at the site 24 months (¬±8 weeks) after patient randomisation . 
The following procedures should be performed: 
‚Ä¢Physical examination (refer to Section 15.2.4 for the list of parameters);
‚Ä¢Patient weight;
‚Ä¢Vital signs
 (refer to Section 15.2.4 f or the list of parameters);
‚Ä¢Blood sample for:
oHaematology (refer to Section  15.2.2 for the list of parameters);
oClinical chemistry (refer to Section 15.2.3 for the list of parameters);
oBiomarkers
 analysis (refer to Section 18).
‚Ä¢Pregnancy test (urine) for post-m enarchal
 female patients;
‚Ä¢NPCCSS (refer to Section 14);
‚Ä¢NPC-c db score (refer to Section 14);
‚Ä¢SARA
 (refer to Section 14);
‚Ä¢9HPT (refer to Section 14);
‚Ä¢CGI
-S and CGI-I (refer to Section 14);
‚Ä¢Quality of Life scoring (refer to Section  14);
‚Ä¢Review
 of concomitant therapy;
‚Ä¢Re
view of AEs that may have occurred following the PICD signature;
‚Ä¢IMP return: Patients will be required to return all unused IMP (and relevant  
packaging [used/empty b ottles]) to the site staff. The site staff should aim to follow up
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 75 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  on the reasons for any missing IMP or other discrepancies noted after performing the 
relevant IMP accountability ; 
‚Ä¢Dispensing of sufficient arimoclomol to continue treatment;
‚Ä¢Arimoclomol administration ;
‚Ä¢Blood samples for POP  PK (refer to Section  17.2.2 ).
Should any of the blood samples collected for the purposes of the study be compromised or destroyed in error, a repeat sample should be taken during the visit. Care should be taken to ensure that the maximum amount of blood drawn does not exceed what is stated in the PICD. 
13.3.5. VISIT 9 
Visit 9 should take place at the site 30 months (¬±8 weeks) after patient randomisation.  
The following procedures should be performed: 
‚Ä¢Physical examination (refer to  Section 15.2.4 for the list of parameters);
‚Ä¢Patient weight;
‚Ä¢Vital signs
 (refer to Section 15.2.4 f or the list of parameters);
‚Ä¢Blood sample for:
oHaematology (refer to Section  15.2.2 for the list of parameters);
oClinical chemistry (refer to Section 15.2.3 for the list of parameters);
oBiomarkers
 analysis (refer to Section 18).
‚Ä¢Pregnancy test (urine) for post-m enarchal
 female patients;
‚Ä¢NPCCSS (refer to Section 14);
‚Ä¢NPC-c db score (refer to Section 14);
‚Ä¢SARA
 (refer to Section 14);
‚Ä¢9HPT (refer to Section 14);
‚Ä¢CGI
-S and CGI-I (refer to Section 14);
‚Ä¢Quality of Life scoring (refer to Section  14);
‚Ä¢Review of concomitant therapy;
‚Ä¢Review of AEs that may have occurred following the PICD signature;
‚Ä¢IMP return: Patients will be required to return all unused IMP (and relevant  
packaging [used/empty b ottles]) to the site staff. The site staff should aim to follow up 
on the reasons for any missing IMP or other discrepancies noted after performing the  
relevant IMP accountability;
‚Ä¢Dispensing of sufficient arimoclomol to continue treatment;
‚Ä¢Arimoclomol administration.
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 76 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Should any of the blood samples collected for the purposes of the study be compromised or 
destroyed in error, a repeat sample should be taken during the visit. Care should be taken to ensure that the maximum amount of blood drawn does not exceed what is stated in the PICD.  
13.3.6. VISIT 10 
Visit 10 should take place at the site 36 months (¬±8 weeks) after patient randomisation.  
The following procedures should be performed: 
‚Ä¢Physical examination (refer to Section 15.2.4 for the list of parameters);
‚Ä¢Patient weight;
‚Ä¢Vital signs
 (refer to Section 15.2.4 f or the list of parameters);
‚Ä¢Blood sample for:
oHaematology (refer to Section  15.2.2 for the list of parameters);
oClinical chemistry (refer to Section 15.2.3 for the list of parameters);
oBiomarkers
 analysis (refer to Section 18).
‚Ä¢Pregnancy test (urine) for post-m enarchal
 female patients;
‚Ä¢NPCCSS (refer to Section 14);
‚Ä¢NPC-c db score (refer to Section 14);
‚Ä¢SARA
 (refer to Section 14);
‚Ä¢9HPT (refer to Section 14);
‚Ä¢CGI
-S and CGI-I  (refer to Section 14);
‚Ä¢Quality of Life scoring (refer to Section 14);
‚Ä¢Review of concomitant therapy;
‚Ä¢Review of AEs that may have occurred following the PICD signature;
‚Ä¢IMP return: Patients will be required to return all unused IMP (and relevant  
packaging [ used/empty bottles]) to the site staff. The site staff should aim to follow up 
on the reasons for any missing IMP or other discrepancies noted after performing the  
relevant IMP accountability;
‚Ä¢Dispensing of sufficient arimoclomol to continue tr eatment;
‚Ä¢Arimoclomol administration.
13.3.7. V
ISIT 11 
Visit 11 should take place at the site 42 months (¬±8 weeks) after patient randomisation.  
The following procedures should be performed: 
‚Ä¢Physical examination (refer to Section  15.2.4 for the list of parameters);
‚Ä¢Patient weight;
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 77 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢Vital signs (refer to Section 15.2.4 for the list of parameters);
‚Ä¢Blood sample for:
oHaematology (refer to Section  15.2.2 for the list of parameters);
oClinical chemistry (refer to Section 15.2.3 for the list of parameters);
oBiomarkers
 analysis (refer to Section 18).
‚Ä¢Pregnancy test (urine) for post-m enarchal
 female patients;
‚Ä¢NPCCSS (refer to Section 14);
‚Ä¢NPC-c db score (refer to Section 14);
‚Ä¢SARA
 (refer to Section 14);
‚Ä¢9HPT (refer to Section 14);
‚Ä¢CGI
-S and CGI-I  (refer to Section 14);
‚Ä¢Quality of Life scoring (refer to Section 14);
‚Ä¢Review of concomitant therapy;
‚Ä¢Review of AEs that 
may have occurred following the PICD signature;
‚Ä¢IMP return: Patients will be required to return all unused IMP (and relevant
packaging [ used/empty bottles]) to the site staff. The site staff should aim to follow up
on the reasons for any missing IMP or other discrepancies noted after performing the
relevant 
IMP accountability;
‚Ä¢Dispensing of sufficient arimoclomol to continue tr eatment;
‚Ä¢Arimoclomol administration.
13.3.8. VI
SIT 12 
Visit 12 should take place at the site 48 months (¬±8 weeks) after patient randomisation.  
The following procedures should be performed: 
‚Ä¢Physical examination (refer to Section 15.2.4 for the list of parameters);
‚Ä¢Patient weight;
‚Ä¢Vital signs
 (refer to Section 15.2.4 for the list of parameters);
‚Ä¢Blood sample for:
oHaematology (refer to Section  15.2.2 for the list of parameters);
oClinical chemistry (refer to Section 15.2.3 for the list of parameters);
oBiomarkers
 analysis ( refer to Section 18).
‚Ä¢Pregnancy test (urine) for post-m enarchal female patients;
‚Ä¢NPCCSS (refer to Section 14);
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 78 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢NPC-c db score (refer to Section 14);
‚Ä¢SARA
 (refer to Section 14);
‚Ä¢9HPT (refer to Section 14);
‚Ä¢CGI
-S and CGI-I  (refer to Section 14) ;
‚Ä¢Quality of Life scoring (refer to Section 14);
‚Ä¢Review of concomitant therapy;
‚Ä¢Review of AEs that 
may have occurred following the PICD signature;
‚Ä¢IMP return: Patients will be required to return all unused IMP (and relevant
packaging [ used/empty bottles]) to the site staff. The site staff should aim to follow up
on the reasons for any missing IMP or other discrepancies noted after performing the
relevant 
IMP accountability;
‚Ä¢Dispensing of sufficient arimoclomol to continue treatment;
‚Ä¢Arimoclomol administration.
13.3.9. V
ISIT 13 
Visit 13 should take place at the site 54 months (¬±8 weeks) after patient randomisation.  
The following procedures should be performed: 
‚Ä¢Physical examination (refer to Section 15.2.4 for the list of parameters);
‚Ä¢Patient weight;
‚Ä¢Vital signs
 (refer to Section 15.2.4 f or the list of parameters);
‚Ä¢Blood sample for:
oHaematology (refer to Section  15.2.2 for the list of parameters);
oClinical chemistry (refer to Section 15.2.3 for the list of parameters);
oBiomarkers
 analysis (refer to Section 18).
‚Ä¢Pregnancy test (urine) for post-m enarchal
 female patients;
‚Ä¢NPCCSS (refer to Section 14);
‚Ä¢NPC-c db score (refer to Section 14);
‚Ä¢SARA
 (refer to Section 14);
‚Ä¢9HPT (refer to Section 14);
‚Ä¢CGI
-S and CGI-I  (refer to Section 14);
‚Ä¢Quality of Life scoring (refer to Section 14);
‚Ä¢Review of concomitant therapy;
‚Ä¢Review of AEs that may have occurred following the PICD signature;
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 79 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢IMP return: Patients will be required to return all unused IMP (and relevant
packaging [used/empty bottles]) to the site staff. The site staff should aim to follow upon the reasons for any missing IMP or other discrepancies noted after performing therelevant IMP accountability;
‚Ä¢Dispensing of sufficient arimoclomol to continue treatment;
‚Ä¢Arimoclomol administration.
13.3.10. VISIT  14 (End of Extension Phase/Withdrawal during Extension Phase)  
Visit 14 s hould take place at the site 60 months (¬±8 weeks) after patient randomisation  or 
within 4  weeks of patient withdrawal during the extension phase of the study. 
The following procedures should be performed: 
‚Ä¢Physical examination (refer to Section 15.2.4 for the list of parameters);
‚Ä¢Patient weight;
‚Ä¢Vital signs
 (refer to Section 15.2.4 for the list of parameters);
‚Ä¢Blood sample for:
oHaematology (refer to Section  15.2.2 for the list of parameters);
oClinical chemistry (refer to Section 15.2.3 for the list of parameters);
oBiomarkers
 analysis (refer to Section 18).
‚Ä¢Pregnancy test (urine) for post-m enarchal
 female patients;
‚Ä¢NPCCSS (refer to Section 14);
‚Ä¢NPC-c db score (refer to Section 14) ;
‚Ä¢SARA
 (refer to Section 14);
‚Ä¢9HPT (refer to Section 14);
‚Ä¢CGI
-S and CGI-I (refer to Section 14);
‚Ä¢Quality of Life scoring (refer to Section 14);
‚Ä¢Review of concomitant therapy;
‚Ä¢Review of AEs that may have occurred following the PICD signature;
‚Ä¢IMP return: Patients will be required to return all unused IMP (and relevant  
packaging [used/empty b ottles]) to the site staff. The site staff should aim to follow up 
on the reasons for any missing IMP or other discrepancies noted after performing the  
relevant IMP accountability.
Shoul
d any of the blood samples collected for the purposes of the study be compromised or 
destroyed in error, a repeat sample should be taken during the visit. Care should be taken to ensure that the maximum amount of blood drawn does not exceed what is stated in the PICD. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 80 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  13.4. UNSCHEDULED VISIT  
The patient can return to the site  for an unscheduled visit should the patient experience an 
unacceptable rate of progression or should there be any safety concerns  or should the patient‚Äôs 
weight require reassessment in the clinic (in order to confirm if a dose reduction is required). 
The following procedures should be performed: 
‚Ä¢Blood sample for:
oHaematology (refer to Section 15.2.2 for the list of parameters);
oClinical chemistry (refer to Section  15.2.3 for the list of parameters) .
‚Ä¢NPCCSS (refer to Section  14);
‚Ä¢Concomitant therapy;
‚Ä¢AEs that may have occurred following the PICD signature;
‚Ä¢IMP (arimoclomol or placebo) dispensing and return  will take plac e in the event that a
patient meets the early escape clause and criteria,  or a dose reduction has occurred
oIMP dispensing:
ÔÇßBlinded phase: Patients will be dispensed enough IMP for treatment.
ÔÇßExtension phase : Patients will be dispensed sufficient arimoclomol to
continue treatment .
oPatients will be required to return all unused IMP (and relevant
packaging [used/ empty blister packs  or used/ empty bottles ]) to the site staff.
The site staff should aim to follow up on the reasons for any missing IMP orother dis crepancies noted after performing the relevant IMP accountability .
‚Ä¢IMP (arimoclomol or placebo) administration (depending on the study phase ‚Äì blindedphase or extension phase);
‚Ä¢Blood samples for POP  PK at the discretion of the Investigator  (refer to Section  17.2.2).
Should any of the blood samples collected for the purposes of the study be compromised or destroyed in error, a repeat sample should be taken during the visit. Care should be taken to ensure that the maximum amount of blood drawn does not exceed what is st ated in the PICD.  
13.5. WITHDRAWAL/PREMATURE STUDY DISCONTINUATION 
Should the patient discontinue prematurely and choose to withdraw from the study, the patient will be asked to attend the site for the relevant visit: Withdrawal during the  blinded phase of 
the study (refer to Section  13.2.6) or withdrawal during the extension phase of the study (refer 
to Section  13.3.6).  
The Investigator should document the reason for study discontinuation in the eCRF. 
In the case of an ongoing AE, appropriate safety evaluations should be repeated more 
frequent ly and/or additional tests performed at any time when clinically indicated or at the 
discretion of the Investigator. All ongoing AEs and SAEs will be followed up until resolution , 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 81 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  until the condition stabilizes, until the event is otherwise explained  or until the patient is lost to 
follow up. If the patient is lost to follow up, then this should be noted in the eCRF. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 82 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  14. ASSESSMENTS OF CLINICAL STATUS
14.1. SPECIFICATION OF CLINICAL STATUS PARAMETERS  
The following will be assessed: 
‚Ä¢NPC  Disease Severity Scores;
‚Ä¢SARA;
‚Ä¢9HPT;
‚Ä¢CGI-S;
‚Ä¢CGI-I;
‚Ä¢Quality of Life scoring.
14.2. METHODS AND TIMING  
Refer to APPENDIX II: Study Flow Chart: Blinded Phase Study Period: Patients less than 12 
ye
ars of age, APPENDIX III: Study Flow Chart: Blinded Phase Study Period: Patients 12 Y ear s 
of Age and Older  and A PPENDIX IV: Study Flow Chart: Extension Phase: ALL Patients  f or 
the respective Study Flow Charts documenting the timing of the relevant a ssessments. 
14.2.1. Niemann -P ick D isease Type C Disease Severity S cores 
The NPC disease severity and disease status scores (NPCCSS, NPC-c db score [refer to Table  
14-1
]) will be completed. The NPCCSS template and NPC cdb template will be provided for 
use in this study.
Table 14- 1:  Niemann -Pick D isease Type C  Disease Severity S coring Mod el s 
Disease Severity Scoring Model  Reference 
NPC clinical severity scale (NPCCSS)  Yanjanin  et al., 2010 ‚Äì NPCCSS scoring sheet 
version 1.0 dated  01 April  2016 is used for 
CT-ORZY -NPC -002 study.  
NPC -cdb score (V1.0 dated 01 February 2013) Stampfer  et al., 2013 ‚Äì modified version used
for CT -ORZY- NPC -002 study.  
NPC -cdb: Niemann -Pick type C Clinical Database. 
14.2.2. Scal
e for Assessment and Rating of Ataxia 
The SARA will be completed as per  
http://www.rehabmeasures.org/Lists/RehabMeasures/PrintView.aspx?ID=1242. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 83 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  14.2.3. Nine -hole Peg Test  
The 9HPT  will be completed as per 
http://www.rehabmeasures.org/Lists/RehabMeasures/PrintView.aspx?ID=925. 
14.2.4. Clinical Global Impression Scale ‚Äì Severity  and Clinical Global 
Impression Scale ‚Äì Improvement  
The CGI -S and CGI -I will be completed as per Guy, 1976 which has been modified to exclude 
‚Äúnot assessed‚Äù. 
14.2.5. Quality of Life  
Quality of Life scoring (EQ 5D Y; proxy version) will be completed by the patien t‚Äôs 
parent[s]/legal guardian[s] . 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 84 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  15. ASSESSMENTS OF SAFETY
15.1. SPECIFICATION OF SAFETY PARAMETERS  
The following safety parameters will be assessed:  
‚Ä¢AEs;
‚Ä¢Haematology and clinical chemistry;
‚Ä¢Physical examination and vital signs;
‚Ä¢ECG.
AEs will be recorded from the time of consent until to the end of the extension phase of the 
study (main study), end of the study (paediatric substudy) or patient withdrawal.  
Laboratory parameters will be recorded during the Blinded P hase study period at baseline 
(Visit 1), 7-14 days after the commencement of continuous dosing, at 3, 6 and 12 months 
(placebo versus arimoclomol), during the Extension P hase at 18 months and every 6 months 
thereafter until End of Extension Phase at 60 months. 
Vital signs will be recorded during the Blinded P hase study period at baseline (Visit  1), 
7-14 days after the commencement of continuous dosing, at 3, 6, 9, and 12 months (placebo
versus arimoclomol), during the Extension P hase at 18 months and every 6  months thereafter
until End of Extension Phase at 60 months.Physical examination and ECG will be recorded during the Blinded P hase study period at 
baseline (Visit 1), 6 and 12 months (placebo versus arimoclomol). Physical examination will 
also be performed during the Extension P hase at 18  months and every 6  months thereafter until 
End of Extension Phase at 60 months. 
15.2. METHODS AND TIMING  
Refer to APPENDIX II: Study Flow Chart: Blinded Phase Study Period: Patients less than 12 
years of age, APPENDIX III: Study Flow Chart: Blinded Phase Study Period: Patients 12  Y ears 
of Age and Older  and A PPENDIX IV: Study Flow Chart: Extension Phase: ALL Patients  for 
the respective Study Flow Charts documenting the timing of the relevant assessments. 
15.2.1. Ad verse Events  
AEs (disease related and /or treatment related) reported by the patients (and/or their 
parent[s]/legal guardian[s]) or noticed by the site staff will be recorded in the eCRF (refer to 
Section  15.3 for more information).  The site will also perform telephone follow up with the 
patient (or patient‚Äô s parent[s]/legal guardian[s]) to follow up on the status of the patient and 
whether the patient has experienced any new A Es or the worsening of any existing A Es (refer 
to Section s 13.2.1 and 13.3.2 for more detail).  
15.2.2. Haematology 
Haematology s amples will be sent to a central laboratory for analysis. Details of the central 
laboratory, related procedures and assays are described in the Central Laboratory Manual.  
The following haematology tests will be performed: 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 85 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢Haemoglobin;
‚Ä¢Red blood cell (RBC) count;
‚Ä¢Platelet count;
‚Ä¢White blood cell (WBC) count;
‚Ä¢Absolute neutrophil count (ANC);
‚Ä¢Differential leukocyte count (bands, neutrophils, basophils, eosinophils, monocytes,
and lymphocytes, expressed as percentage of WBC).
15.2.3. Clinical Chemistry  
Clinical chemistry  samples will be sent to a central laboratory for analysis. Details of the central 
laboratory, related procedures and assays are described in the Central Laboratory Manual.  
The following s erum clinical chemistry tests will be performed:  
‚Ä¢Sodium;
‚Ä¢Potassium;
‚Ä¢Chloride;
‚Ä¢Magnesium;
‚Ä¢Iron;
‚Ä¢Calcium;
‚Ä¢Phosphate;
‚Ä¢Creatinine  (serum) (refer also to Section  11.3 for the review of Visit 2 results);
‚Ä¢Blood urea nitrogen;
‚Ä¢Triglycerides;
‚Ä¢High -density lipoprotein (HDL)/low -density lipoprotein (LDL);
‚Ä¢Cholesterol;
‚Ä¢ALT;
‚Ä¢AST;
‚Ä¢Total bilirubin;
‚Ä¢Gamma -glutamyltransferase  (GGT);
‚Ä¢Alkaline phosphata se (AP);
‚Ä¢Lactate dehydrogenase (LDH);
‚Ä¢Albumin.
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 86 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  15.2.4. Physi cal Examination and Vital Signs  
Physical examinations during the study will include  the assessment of skin, head, neck, 
lymphatic, abdomen, respiratory, cardiovascular/peripheral vascular, central nervous and 
musculoskeletal systems as appropriate to determine general condition.  
Vital signs will include supine blood pressure, pulse rate, res piratory rate and temperature (ear). 
New or worsening clinically significant abnormalities will be reported as an AE.  
15.2.5. Electrocardiogram  
A twelve -lead ECG will be recorded over at least 10  seconds after the patient has rested supine 
on a bed for at least 5  minutes. The ECG report must be reviewed by the Investigator and any 
clinical ly relevant findings should be reported in the eCRF. Any new or worsening clinically 
significant abnormalities will be followed up with the patient and reported as an AE. 
15.3. ADVERSE E VENT REPORTING  
It is the Investigator‚Äôs responsibility to ensure compliance with reporting of AE s from his/her 
site. 
Safety data will b e collected from the time of  written informed consent and ends at the end of 
the extension phase of the study (main study), end of the study (paediatric substudy)  or patient 
withdrawal . All ongoing AEs and SAEs will be followed up until resolution, until the condition 
stabilizes, until the event is otherwise explained or until the patient is lost to follow up.  
Any AE (including an AE that leads to death) that occurs after the end of the extension phase 
of the study (main study) or end of the study (paediatric substudy), which the Investigator 
assesses as related to a study procedure and/or medicinal product, should also be reported as an AE or SAE.  
All A Es should be followed until they are resolved or a clinically- stable endpoint is reached if 
they are consi dered chronic.  
15.3.1. Definition  of an Adverse Event  
An Adverse Event  (AE) is defined as: Any untoward medical occurrence in a patient  or clinical 
investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.  
An AE can therefore be any unfavourable and unintended sign (including an abnormal 
laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. 
An AE can also refer to an untoward response to the administration of the IMP, but can also 
occur as a result of the protocol -required procedures or be unrelated to both and include 
worsening of pre-existing conditions, for example. 
AEs include the following: 
‚Ä¢Suspected adverse medication reactions;
‚Ä¢Reactions from medication overdose, abuse, sensitivity, or toxicity;
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 87 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢Apparently unrelated illnesses, including the worsening of a pre- existing illness;
‚Ä¢Injury or accidents;
Note: If a documented medical condition is known to have caused the injury or accident, only the accident 
should be reported as an AE;
‚Ä¢New or aggravated clinically relevant abnormal medical finding at a physical
examination as compared with previous assessments;
‚Ä¢Laboratory abnormalities or other abnormal assessments (e.g. physical examination,vital signs, ECG) that require clinical inte rvention or further investigation (beyond
ordering a repeat [confirmatory] test) unless they are associated with an alreadyreported clinical event.
15.3.2. Definition of a Serious Adverse Event  
A Serious Adverse Event  (SAE) is defined as any untoward medical occurrence that at any 
dose: 
‚Ä¢Results in death;
Note : Death is an outcome of an AE, and not an AE in itself. Event which led to death should be recorded 
with fatal outcome. In reports of death due to ‚ÄúDisease Progression‚Äù, where no other information is
provided, the death will be assumed to have resulted from progression of the disease under investigation.
All deaths occurring on the study or up to an including the end of the extension phase  of the study or
patient withdrawal must be reported.
‚Ä¢Is life -threatening;
A life -threatening event places  the patient at risk of death at the time of the even t. It does not refer to an
event which hypothetically might have caused death if it were more severe).
‚Ä¢Requires inpatient hospitalization  or prolongation of existing hospitalization ;
Note : In general, h ospitalization  signifies that the patient has been detained (usually involving at least an
overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have
been appropriate in the physician‚Äôs office or outpatient setting. Complications that occur duringhospitalization  are A Es. If a complication prolongs h ospitalization  or fulfils any other serious criteria,
the event is serious. When in doubt as to whether other events meet the serious criteria, the event is to be
considered serious. When in doubt as to whether ‚Äú hospitalization ‚Äù occurred or was necessary, the AE
should be considered serious.
Hospitalisation for elective treatment of a pre -existing condition that did not worsen from baseline is not
considered an AE.
‚Ä¢Results in persist ent or significant disability/incapacity;
Note : The term ‚Äúsignificant disability‚Äù means a substantial disruption of a person‚Äôs ability to conduct
normal life functions. This definition is not intended to include experiences of relatively minor medical
significance such as uncomplicated headache, nausea, vomiting, hospital, influenza, and accidental
trauma (e.g., sprained ankle) which may interfere or prevent everyday life functions, but do not constitute a substantial disruption.
‚Ä¢Is a congenital anomaly/bir th defect;
‚Ä¢Is an important medical event(s) that may not be immediately life threatening or result
in death or hospitalization but that may jeopardize the patient or require intervention to
prevent one of the above outcomes. Examples of such events are int ensive treatment in
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 88 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  an emergency room or at home for allergic bronchospasm; blood dyscrasias or 
convulsions that do not result in hospitalization ; or development of drug dependency or 
drug abuse. Medical and scientific judgement should be exercised in deciding whether expedited reporting is appropriate in such instances. 
15.3.3. Recording and R eporting  of Adverse Events  
All A Es and SAEs, as defined above, encountered during the clinical study will be reported in 
the appropriate section of the CRF/ eCRF. Information will include the following: 
‚Ä¢Duration of the AE (onset/resolution dates);
‚Ä¢Relationship to the IMP (refer to Section  15.3.3.6);
‚Ä¢Severity (refer to Section  15.3.3.5);
‚Ä¢Concomitant therapy given (or other action taken);
‚Ä¢Action taken with respect to the IMP.
If an AE increases in severity it will be recorded as a new record with the same AE identifier.  
AE data should be obtained through observation of the patient, from any information 
volunteered by the patient (and the patient ‚Äôs parent[s]/legal guardian[s])  and through patient 
(and the patient ‚Äôs parent[s]/legal guardian[s]) questioning. The patien t may be asked ‚ÄúDo you 
have any health problems?‚Äù or ‚ÄúHave you had any health problems since your last site  visit?‚Äù  
15.3.3.1. Reporting of Signs and Symptoms versus a Diagnosis 
Recording a diagnosis (when possible) is preferred to record  a list of associated signs an d 
symptoms. However, if a diagnosis is known but there are associated signs or symptoms not 
generally attributed to the diagnosis, the diagnosis and each sign or symptom must be recorded separately.  
15.3.3.2. Disease Progression  
Disease progression can be considered  as a worsening of a patient‚Äôs condition that is being 
studied. It may be reflected by an increase in the severity of the condition or an increase in the symptoms. Disease progression during the blinded phase of the study may result in the patient meeting the early escape clause and criteria (refer to Section  10.5.2). Disease progression and 
any events that are unequivocally due to disease progression should be recorded only in the CRF/ eCRF and should not be reported as an AE. 
15.3.3.3. Death  
All deaths that occur during the AE Reporting period (refer to Section 15.3.4) must be reported as follows: 
‚Ä¢Death due (or clearly due to) to disease progression should be documented in theCRF/eCRF  but should not be reported as an SAE;
‚Ä¢Death that is not due (or not clearly due) to disease progression should be documentedin the CRF/ eCRF and as a SAE within 24 hours of the investigator‚Äôs knowledge of the
event (refer to Section  15.3.3.7).
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 89 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  15.3.3.4.  Pregnancy 
Should a pregnancy occur in a female patient  or the partner of a male patient, it must be reported 
i
n accordance with the procedures described in Section  15.3.3.7 . Pregnancy in itself is not 
regarded as an AE.  
Female patients who become pre gnant during the study should be withdrawn (refer to 
Section  10.5.1). 
15.3.3.5. Definition of Se verity of Adverse Events 
Severity of any AE will be graded according to National Cancer Institute ( NCI) CTCAE 
V
ersion 4.03 (14 June 2010), where applicable. 
If an AE occurs that is not listed in the CTCAE, the Investigator will evaluate its severity 
using the definitions in Table 15-1. 
Ta
ble 15-1: Definition of Severity of Adverse Events  
Mild  Grade 1  ‚Äì Does not interfere with patient‚Äôs usual function 
(awareness of symptoms or signs, but easily tolerated [acceptable]).  
Moderate  Grade 2  ‚Äì Interferes to some extent with patient ‚Äôs usual function 
(enough discomfort to interfere with usual activity [disturbing]).  
Severe  Grade 3  ‚Äì Interferes significantly with patient ‚Äôs usual function 
(incapacity to work or to do usual activities [unacceptable ]) 
Life Threatening  Grade 4  ‚Äì Results in risk of death, organ damage, or permanent 
disability (unacceptable) 
Death  Grade 5  ‚Äì Event has a fatal outcome 
Note:  Severe  is a measure of intensity whereas an event must meet one of the criteria for serious even ts listed in 
Section  15.3.2  to be considered serious ;  thus, a severe reaction is not necessarily a serious  reaction. For example, 
a headache may be severe in intensity, but would not be classified as serious unless it m et one of the criteria for 
serious events listed in Section  15.3.2. An AE that is assessed as Grade  3 (severe) or Grade 4 (potentially life -
threaten ing) should not be confused with a SAE.  
15.3.3.6. Definition of Relationship of AEs to a Medicinal Product and/or Study Procedure 
The Investigator must assess the possible relationship between the AE and the IMP  and/or 
study procedure  and/or the patient‚Äôs underlying condition and record that assessment in the 
CRF/ eCRF. The Investigators is to make his/her own assessment of each SAE to be recorded 
on the CRF/ eCRF and on the SAE form. 
The Investigator should provide a Yes or No assessment as to whether there is a reasonable 
possibility that the event may have been caused by the IMP  and/or study procedure. 
KemPharm Denmark  A/S will evaluate all SAE s with respect to seriousness, causality and 
expectedness. The expectedness of an S AE considered to be related to the IMP will be 
determined according to the IB . 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 90 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  The relationship should be assessed according to the criteria below: 
Definitely 
Related  AEs that are temporally linked and for which the study product is the 
most likely explanation, which disappear or decrease when not using study product and reappear when using study product 
Probably Related  AEs that are temporally linked and for which the study product is more 
likely to be the explanation than other causes, which may improve when not using study product 
Possibly Related  AEs that could equally well be explained by study product or other 
causes, which are usually temporally linked and may improve when not using study product but do not reappear when using study product 
Unlikely Related  AEs that may be temporally linked, but which are much more likely to 
be due to other causes than study product and which do not get worse with continuing use of product 
Not Related AEs that can be clearly explained by extraneous causes and for which 
there is no plausible association with study product, or AE s for which 
there is no temporal relationship 
15.3.3.7. S
AE Reporting Procedure for Investigators 
The Investigator must report (by fax, telephone or email) all initial and follow -up SAE reports 
to the safety vendor within 24 hours of awareness of an SAE. Please refer to the SAE Reporting 
Contact Details document.  
If
, for any reason, it is not possible  to complete all sections of the SAE form within 24  hours, 
transmission of the form must not be delayed,  and the outstanding information should be sent 
on a follow-up SAE form. In addition, the event must be documented in the CRF/eCRF.  
Information on SAEs will be recorded on a SAE form. Blank copies are included in the study Investigator‚Äôs File.  
This report should contain as much information as possible and must include an assessment of  
available information on seriousness, severity, cau sal relationship to the IMP or trial procedure, 
the action taken, the outcome to date, and a narrative description of the course of the event.  
Photocopies of the subject‚Äôs medical records should not be sent in lieu of completion of the  
SAE Form. Medical records, laboratory reports etc. should only be sent to the Safety vendor  
upon request. Importantly, when subject records are shared outside the site, all subject  
identifiers, with the exception of the subject number, shall be redacted on the copies of the  
medical records before submission. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 91 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  15.3.3.8. Follow-up SAE Reports 
For all SAEs where important or relevant information is missing, active follow -up should be 
undertaken. Investigators or other site personnel should inform  the safety vendor  of any follow -
up information on a previously reported SAE immediately but no later than 24 hours after they 
become aware of the SAE.  The follow -up information must be presented on an SAE form 
marked as follow -up. It is necessary only to provide the new information, with the SAE for m 
signed by an Investigator. 
The Investigator will ensure that all the necessary information is provided within the timelines 
stipulated by safety vendor when the request for information is made. 
Follow- up reports (as many as required) should be completed and faxed following the same 
procedure above. 
15.3.3.9. Reporting Serious Adverse Events to the Independent Ethics Committee/ 
Institutional Review Board  
The Investigator is responsible for informing local Independent Ethics Committees  (IEC s)/ 
Institutional Review Board  (IRBs)  of the applicable safety reports in compliance with local 
regulations. Copies of all correspondence relating to reporting of any safety reports to the 
IEC/IRB  should be maintained in the Investigator‚Äôs Files and provided t o Worldwide Clinical 
Trials . 
The Sponsor, or its designee s, Worldwide Clinical Trials  or safety vendor , will inform 
Investigators, central IECs /IRBs  and regulatory authorities of applicable safety reports, as 
required . 
15.3.3.10. Reporting of Suspected Unexpected Serious Adverse Reactions 
A suspected unexpected serious adverse reaction  (SUSAR) is an SAE, the nature or severity of 
which is not consistent with the reference safety information  (RSI) of the study drug in the IB 
and for which there is at least a reasonable possibility of a causal relationship with the study 
drug. 
The Sponsor shall ensure that all relevant information about SUSARs that are fatal or 
life-threatening is recorded and reported as soon as possible to the concerned authorities, 
central IECs/IRBs and Investigators, and in any case no later than seven days after knowledge by the Sponsor of such a case, and that relevant follow -up information is subsequently 
communicated within an additional eight days. 
All other SUSARs shall be reported to the concerned authorities, central IES/IRBs  and 
Investigators as soon as possible but within a maximum of fifteen days of first knowledge by 
the Sponsor. The Sponsor will report all SUSARs via the EudraVigilance Clinical Trials  (CT) Module or Council for International Organizations of Medical Sciences  (CIOMS ) 
forms.  
The Investigator is responsible for informing local IECs/IRBs of the applicable safety reports in compliance with local regulations. Copies of all correspondence relating to reporting of any safety report s to the IEC/IRB should be maintained in the Investigator‚Äôs Files and provided to 
Worldwide Clinical Trials  for filing . 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 92 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  15.3.4. Adverse Event Reporting Period  
ALL A Es that occur  from the time  of written informed consent to the end of the extension 
phase of the study (main study), end of the study (paediatric substudy)  or patient withdrawal,  
will be recorded in the CRF/eCRF. All ongoing AEs and SAEs will be followed up until 
resolution, until the condition stabilizes, until the event is otherwise explained or unt il the 
patient is lost to follow up.  
All new AE s or the worsening of any ongoing events from the time of informed consent will 
be recorded on the AE pages of the CRF/eCRF.  
All A Es experienced by a patient, irrespective of the suspected causality, will be m onitored 
until the event has resolved, any abnormal laboratory values have returned to baseline or 
stabilised at a level acceptable to the Investigator and Medical Monitor, until there is a satisfactory explanation for the changes observed, or until the pa tient is lost to follow -up.  
Any untoward event that occurs after the AE reporting period but which the Investigator assesses as possibly related to  the IMP or  a study procedure should also be reported as an AE  
or SAE . 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 93 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  16. ASSESSMENTS OF IMAGING
16.1. SPECIFICATION OF IMAGING PARAMETERS  
The following will be performed: 
‚Ä¢Ultrasound (liver and spleen).
16.2. METHODS AND TIMING  
An ultrasound will be performed in order to document changes in the size of the liver and 
spleen and any clinical relevant findings. 
Refer to  APPENDIX II: Study Flow Chart: Blinded Phase Study Period: Patients less than 12 
years of age and APPENDIX III: Study Flow Chart: Blinded Phase Study Period: Patients 
12 Years of Age and Older  for the respective Study Flow Chart s doc umenting the timing of the 
relevant assessment.  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 94 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  17. ASSES SMENTS OF PHARMACOKINETICS
17.1. SPECIFICATION OF PHARMACOKINETIC PARAMETERS
The
 following PK parameters will be assessed only for patients less than 12  years of age: 
‚Ä¢AUC 0-8;
‚Ä¢Cmax;
‚Ä¢Ad
ditional assessments of arimoclomol concentration  can be performed in the event of
unexpected PK -profiles  (refer to S ection  11.2.1).
For POP  PK of arimoclomol and metabolites (if relevant)  assessed for ALL patients:  
‚Ä¢PK data collected at all visits will be incorporated into a POP PK  model.
17.2. METHODS AND TIMING FOR ASSESSING , RECORDING AND 
ANALYSING PHARMACOKINETIC PARAMETERS  
17.2.1. Patients less than 12 years of A ge: Pharmacokinetic Profiling to confirm 
Dose Selection  
The PK samples  will be collected through venipuncture and the sampling time points are as 
follows: 
‚Ä¢Pre-dose (immediately prior to administration of the single dose of arimoclomol)  and
30 min  (¬±5 min) , 1 hour (¬±10  min) , 2 hours (¬±10  min) , 4 hours (¬±30  min)  and 8 hours
(¬±30  min) following dosing.
The same watch/clock should be used for all time measurements.  
The following information should be noted down: 
1. The precise time of the blood sampling;
2. The precise time of the administration of food and liquid(s);3. The type of liquid(s) administered;4.The selected route for the single dose administration of  arimoclomol including any type
of liquid/soft foodstuff used for the administration (as applicable).
The patient will be required to fast as follows:  
1. Food: At least 2  hours before the single dose administration and at least 2  hours
following the single dose administration;
2.Liquids: Non- protein and non- fat liquids (e.g. juice) are allowed for up to 1 hour before
the single dose administration and from 1 hour following the single dose
administration ;
3.Water can be administered at any time during the PK  procedure.
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 95 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  In the event that unexpected PK -profiles are obtained which are clinical significant and could 
potentially impact the safety of the patient (e.g. risk of accumulation), the independent assessor 
can recommend additional PK sampling to be performed. If agreed by the Sponsor‚Äôs medical responsible person and the Principal Investigator, up to a maximum of 6 additional samples 
(corresponding to the full PK analysis set) can be taken at a subsequent visit prior to randomisation. 
Further instruction on PK sampling are described in a separate Central Laboratory Manual. The volume of blood taken per ven ipuncture sample is no more than 1 m L.  
Care should be taken to ensure that the maximum amount of blood drawn does not exceed what 
is stated in Section  7.3 and in the PICD. 
17.2.2. Population Pharmacokinetic Samples: All Patients  aged >2 Years  
The POP PK samples will be collected through venipuncture and the sampling time points are as follows: 
‚Ä¢Visits  3 and 5
 : 3 hours (¬±1 hour) following dosing;
‚Ä¢Visits  4, 6, and 8: 1.5 hours (¬±30 min) , 3 hours (¬±30 min) and 4.5-6 hours following
dosing. Note: The last POP PK sample should be taken as late as possible but alwaysbefore  the subsequent dose of IMP;
The same watch/clock should be used for all time measurements.  
The f
ollowing information should be noted down: 
1.The precise time of the administration of  the last 2 IMP  doses prior to POP PK
sampling ;
2. The precise time of the blood sampling;
3.The selected route for the IMP administration  including any type of liquid/soft foodstuff
used for the administration (as applicable).
Further instruction on PK sampling are described in a separate Central Laboratory Manual. 
The volume of blood taken per venipuncture sample is no more than 1 m L.  
Care should be taken to ensure that the maximum amount of blood drawn does not exceed 
what is
 stated in Section 7.3 and in the PICD. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 96 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  18. ASSESSMENTS OF BIOMARKERS
18.1. SPECIFICATION OF B IOMARKER P ARAMETERS  
The biomarker parameters (as listed in Table 18-1) w ill  be assessed. 
Table 18- 1:  Niemann -Pick D isease Type C Biomarkers 
NPC Biomarkers  Sample  
Blood Sample  Skin Punch Biopsy  
NPC1 active protein  X X 
NPC1 protein function: Cholesteryl esterification  X 
Oxyst
erol ( cholestane- 3Œ≤,5Œ±,6Œ≤ -triol) X 
Un-esteri
fied cholesterol  X X 
HSP70  X 
Glyc
osphingolipids  X 
Sphingo
id bases X 
Lyso -SM-
509 X 
18.2. MET
HODS AND TIMING  
Biological markers related to the NPC  disease progression will be assessed in blood and skin 
punch biopsy samples. Samples will be sent to the designated  central laboratory for analysis. 
Details of the central laboratory, related procedures and assays are described i n a separate 
Central Laboratory Manual.  
All biomarkers will be assessed during the blinded phase of the study (refer to  APPENDIX II: 
Study Flow Chart: Blinded Phase Study Period: Patients less than 12 years of age and 
APPENDIX III: Study Flow Chart: Blinded Phase Study Period: Patients 12  Years of Age and 
Older  for the respective Study Flow Charts documenting the timing of the relevant 
assessments).  During the extension phase of the study, the following biomarkers will be 
analysed  (refer to APPENDIX IV: Study Flow Chart: Extension Phase: ALL Patients  for the 
Study Flow Chart documenting the timing of the relevant assessments) :  
a.Oxysterol (cholestane- 3Œ≤,5Œ± ,6Œ≤-triol);
b.Un-esterified cholesterol;
c.HSP70;
d.GSLs;
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 97 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  e. Lyso-S M-509.
The sampling procedure is summarised in Figure 18-1. 
F
igure 18- 1:  Biomarker S am pling P rocedure 
18.2.1. Skin P
unch Biopsy  
A punch skin biopsy is a short procedure ( 1-2 minutes)  to remove a small piece of skin tissue. 
Skin punch biopsies are usually done while the child is fully awake, although the area of skin 
where 
the biopsy is taken will be numbed. The punch skin biopsy instrument is gently 
inserted into your child‚Äôs skin, rotated and a small circle of skin is carefully removed (refer 
to Figure 18-2).
Figure 18- 2:  Skin Punch Biopsy P rocedure 

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 98 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  The skin punch biopsy is defined as ‚Äúminimal risk‚Äù procedure in children participating in 
clinical research which represents an opportunity to understand, prevent, or alleviate a serious problem.  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 99 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  19. ASSESSMENTS OF OTHER ENDPOINTS
19.1. SPECIFICATION OF OTHER PARAM ETERS  
‚Ä¢Treatment failures;
‚Ä¢Change in use of NPC  medication ;
‚Ä¢Patient acceptability/palatability of the IMP .
19.2. METHODS AND TIMING  
The difference in number of treatment failures (defined as patients meeting early escape clause 
and criteria) at 12  months will be assessed.  
The change in use of NPC  medication (including miglustat therapy) will be assessed at 
12 months and at 18 months and at every 6  months thereafter until End of Extension Phase at 
60 months. 
The patient‚Äôs acceptability/palatability of the IMP will be assessed during the blinded phase 
study period using the hedonic scale at 7-14 days after the commencement of continuous 
dosing, 3, 6 and 12 months. The hedonic scale is a validated scale developed to test palatability 
of food ( Chen  et al. , 1996) and has been extensively used to assess palatability of flavoured 
medications ( Matsui , 2007). The patient (the patient‚Äôs parents[s]/legal guardians[s]) will be 
asked to use the hedonic scale to rate the palatability of the IMP based on the patient‚Äôs reaction 
to the IMP. 
Telephone follow up (monthly calls during the first 6  months of the blinded phase and every 
3-4 months following the start of the extension phase)  will include assessment of whether the
patient has experienced any difficulties in taking the IMP.
Refer to APPENDIX II: Study Flow Chart: Blinded Phase Study Period: Patients less than 12 
years of age, APPENDIX III: Study Flow Chart: Blinded Phase Study Period: Patients 12  Y ears 
of Age and Older  and A PPENDIX IV: Study Flow Chart: Extension Phase: ALL Patients  for 
the respective Study Flow Charts documenting the timing of the relevant assessments. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 100 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  20. EV ALUATION OF RESULTS
20.1. SAMPLE SIZE AND STU DY POWER 
No formal statistical calculation of sample size has been used.  
However, the following has been considered to try to ensure that a suitable number of patients 
will be recruited. I n the ASIS study (Protocol Number ASIS -001: A retrospective, non-
interventional study of the data of patients diagnosed with NPC  in order to confirm ASIS as a 
disease progression predictive model/tool) (15 patients) the mean rate of progression was 3.6 points per year and the SD  was 2.2. Assuming this SD , a study with 30 patients randomised 
to arimoclomol and 15 patients randomised to placebo has 80% power to detect a difference 
between arimoclomol and placebo of approximately 2 units on the NPCCSS at the 5% 
significance level.  This would be based on a simple two- sample  t-test. Use of covariates and a 
repeated measurements model is expected to improve the power/allow a smaller difference to be detected.   
20.2. STATISTICAL METHODS  
Statistical analyses will be performed by Larix A/S . Statistical analyses will be carried out 
using SAS
¬Æ, Version 9.3 or later, SAS Institute, Cary, Northern Carolina, United States of 
America ( USA).  
The statistical methods summarised below,  for the 12-month blinded phase study period and 
the extension phase of the study, will be described in detailed statistical analysis 
plan(s) (SAP [s]) which will be finalized prior to relevant database‚Äôs  lock. Any deviations from 
the planned analysis as described in the SAP (s) will be justified and recorded in the final 
clinical study report. 
20.2.1. General Considerations 
Descriptive analyses will be performed. Data will be summarised as follows: Continuous variables by descriptive statistics (number of patients  [N], mean, SD, minimum, median and 
maximum); categorical data by absolute and relative frequencies  (n and %). 
Unless indicated otherwise, summary statistics will be reported for observed data only. Missing data will not be imputed  for reporting summary statistics .  
Baseline is defined as the latest assessment prior to randomisation . If a baseline value is 
missing, no change from baseline will be calculated. 
20.2.2. Other Considerations  
For MCID, t he CGI -S and CGI -I will be used as an anchor to estimate a threshold for 
determining the point at which change on the NPCCSS is considered meaningful.  For both clinic ian assessments a 1 -categorical change (reduction in severity by 1- category and 
improvement by 1- category respectively) between baseline and end of treatment will be used 
to provide an estimate on each anchor. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 101 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  20.2.3. Populations for Analysis 
Summaries will be presented for all patients who were entered into the study and assigned a 
patient study number. 
The Full Analysis Set (FAS) will include all patients who are randomised and who have at least 
one post -baseline assessment of NPCCSS. This will be used as the primary analysis set for 
efficacy.  
A Per Protocol (PP) set will also be used to present efficacy data. This will include only patients 
who have taken at least 80% of their randomised medication up to the 6- month assessment, 
and have an assessment at 6  mont hs or beyond (it will exclude all patients with less than 
6 months of follow up data). The 80% of medication criterion will be reviewed and re -
confirmed at the time of the blind review of the database. Patients without a confirmed 
diagnosis of NPC , accordi ng to the study inclusion criteria, will also be excluded from the 
PP analysis set.  Patients who receive the wrong treatment in error will be excluded from these 
efficacy analyses.  
A Completers Ana lysis S et (CAS) will also be used to present efficacy data.  This will include 
only patients who have taken at least 80% of their randomised medication up to the 12-month assessment and have, as a minimum, assessments at baseline and at 12  months (+/ -8 weeks). 
Patients without a confirmed diagnosis of NPC , if any, will also be excluded from the CAS . 
Patients who receive the wrong treatment in error will be excluded from these efficacy analyses.  
‚Ä¢The safety set  will in
 clude all patients who receive any IMP, regardless of whether that
was their correct medication, or not. The safety set will be used for all safety analyses.
The precise details of how the safety data will  be presented for the under 12 -year olds will be 
described in the SAP .  
20.3. BASELINE CHARACTERISTICS  
The following demographic and baseline charac teristics will be summarised: 
‚Ä¢Demographics (date of birth, sex and race);
‚Ä¢Medical history (including concomitant diseases );
‚Ä¢NPC  disease history  (NPC -cdb disease history data)  including date of initial NPC
diagnosis, data of fillipin staining result  (if applicable ), cholestane triol/oxysterols (if
applicable), DNA disease confirmation (date, mutation/s), date of first NPC
symptom (s) (and description), history of neurological manifestations and past
treatments.
20.4. EVALUATION OF PRIMARY ENDPOINT  
The primary analysis is by a general linear mixed model for repeated measurements . The 
primary endpoint is the change from baseline to 12 months in the 5 domain NPCCSS. The 5 domain NPCCSS  score is derived as the sum of scores from the ambulation, speech, swal low, 
fine motor skills and cognition domains. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 102 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  The model will be fitted with treatment, miglustat level and visit as fixed effects along with a 
treatment -by-visit interaction term. The estimated treatment effect will be taken from the 
treatment -by-visit interaction term at 12  months. 
The a
nalysis model is: 
ùëåùëåùëñùëñùëñùëñùëñùëñ=ùõΩùõΩ0‚àôùë¶ùë¶ùëñùëñùëñùëñ0+ùëáùëáùëñùëñ+ùëÄùëÄùëôùëô+ùëâùëâùëñùëñ+ùëáùëáùëâùëâùëñùëñùëñùëñ+ùë†ùë†ùëñùëñùëñùëñ+ùëíùëíùëñùëñùëñùëñùëñùëñ 
where  
Yijk is the 5 domain NPCCSS endpoint for the jth patient of treatment group i  at visit k 
yij0 is the baseline value for the jth patient of treatment group i 
ùõΩùõΩ0 is the unknown fixed slope for the baseline covariate 
Ti is the unknown fixed effect of treatment i 
Ml is the unknown fixed effect of miglustat level l  
Vk is the unknown fixed effect of visit k  
TVik is the unknown fixed interaction effect of treatment i  and visit k  
sij is the effect associated with the jth patient of treatment i  
eijk is the error (residual) associated with the jth patient of treatment i at visit k  
sij and eijk are assumed to be independent from each other and follow a multivariate normal 
distribution. The covariance matrix for e  is chosen to be the unstructured variance -covariance 
matrix, it assumes pair -wise correlations are not constrained by the data.  
The estimated treatment effect is taken from the TV ik interaction term at Visit 6 (i.e. 12 months). 
Missing data will not be imputed for the primary endpoint analysis. If a baseline value is missing, no change from baseline will be calculated. 
The model allows for the calculation of the 95% confidence interval  (CI) for the treatment 
effect, and a P -value to test the null hypothesis that the effect of arimoclomol and placebo is 
the same. 
20.5. EVALUATION OF SECONDARY ENDPOINTS  
Key Secondary Endpoints: 
‚Ä¢Responder analysis of patient‚Äôs CGI -I score remains stable or shows improvement at
12 months and descriptive summary of responder rate at 12 months.
‚Ä¢Responder analysis of patient‚Äôs 5 domain NPCCSS  score remains stable or improves
at 12 months and descriptive summary of responder rate at 12 months .
These will be analysed at 12  months using two- tailed chi -squared tests. If chi -squared 
conditions are not met, then a Fisher‚Äôs exact test will be used. A patient who discontinues 
before 12 months will be considered a non-responder. 
‚Ä¢Time to worsening (as defined by reaching the MCID on patient's 5 domain NPCCSS)
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 103 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Kaplan -Meier plots for time to worsening will be produced for each treatment group and 
compared via a log -rank test, stratified for use of miglustat.     
‚Ä¢Proportion of patients  worsening (as defined by reaching the MCID on patient's 5
domain NPCCSS) at 6  and 12 months
‚Ä¢The proportions of patients who have shown worsening by 6 months and by 12 months
will be analysed using two- tailed chi -squared tests on the FAS and will be repeated for
the PP set and the CAS. If chi -squared conditions are not met, then a Fisher‚Äôs exact test
will be used. A patient who discontinues before 6 months (or 12 months, as appropriate)will be considered a patient who has worsened. Change in full scale NPCCSS  score
apart from hearing domains (i.e. Hearing and Auditory Brainstem Response) frombaseline to 12 months : This will be analysed using an analysis of covariance model
including baseline full scale NPCCSS score ( apart from hearing domains ), miglu stat
and randomised treatment as the only covariates.
Other Secondary Endpoints 
‚Ä¢Change in 5 domain NPCCSS at 6 and 18 months and every 6  months thereafter until
End of Extension Phase at 60 months:  The change in 5 domain NPCCSS at 6 months
will be analysed using the same model as for the change in the full NPCCSS ( apart from
heari ng domains ) at 6 months. Data from 18  months and beyond will be summarised
descriptively.
‚Ä¢Change in full scale NPCCSS score apart from hearing domains (i.e. Hearing and
Auditory Brainstem Response) at 6 and 18 months and every 6  months thereafter until
End of Extension Phase at 60 months : This will be analysed descriptively.
‚Ä¢Responder analysis of the CGI -I score remains stable or shows im provement at 6 and
18 months and every 6  months thereafter until End of Extension Phase at 60 months.
‚Ä¢Responder analysis of 5 domain NPCCSS score remains stable or improves at 6 and
18 months and every 6  months thereafter until End of Extension Phase at 60 months .
‚Ä¢Proportion of patients worsening (as defined by reaching the MCID on patient's 5
domain NPCCSS) at 18  months and every 6  months thereafter until End of Extension
Phase at 60 months.
‚Ä¢Changes in each individual domain of the NPCCSS at 6, 12 and 18 months and every
6 months thereafter until End of Extension Phase at 60 months : These will be tabulated
and presented descriptively, including each domain score and its change from baseline.
‚Ä¢Change in the NPC -cdb score (modified "Stampfer Score") at 6, 12  and 18 monts and
every 6  months thereafter until End of Extension Phase at 60 months : This will be
analysed using the same model as for the change in the full NPC CSS (apart from hearing
domains) at 6  months.
‚Ä¢Change in Quality of Life (EQ 5D Y) at 6, 12  and 18 months and every 6  months
thereafter until End of Extension Phase at 60 months : The changes from baseline will
be simply compared by a Mann Whitney (independent samples) test and 95% CI at  each
of 6 and 12 months). Data from 18 months and every 6 months thereafter until End of
Extension Phase at 60 months will be summarised descriptively.
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 104 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  ‚Ä¢Change in the SARA score at 6, 12 and 18 months and every 6  months thereafter until
End of Extension Phase at 60 months : This will be analysed using the same model as
for the change in the full NPCCSS (apart from hearing domains) at 6 months.
‚Ä¢Change in the 9HPT time at 6, 12 and 18 months and every 6  months thereafter until
End of Extension Phase at 60 months : This will be analysed using the same model as
for the change in the full NPCCSS (apart from hearing domains) at 6 months.
‚Ä¢CGI-S score  at 6, 12 and 18 months and every 6  months thereafter until End of
Extension Phase at 60 months:  This will be analysed descriptively showing the
distribution of scores for each treatment group at 6 and 12 months and the overall
distribution of scores at 18 months and every 6 months thereafter until End of Extension
Phase at 60  months.
‚Ä¢CGI-I score  at 6, 12 and 18 months and every 6  months thereafter until End of
Extension Phase at 60 months:  This will be analysed descriptively showing the
distribution of scores for each treatment group at 6 and 12 months and the overalldistribution of scores at 18 months and at every 6  months thereafter until End of
Extension Phase at 60 months.
20.6. EVALUATION OF  EXPLORATORY ENDPOINTS  
‚Ä¢NPC  disease progression rate based on the NPCCSS (apart from hearing domains)
from baseline in the CT -ORZY -NPC -002 study to 6 and 12 months. This will be
analysed using a similar model as for the change in the N PCCSS score  at 6 months.
Specifically, the analysis of covariance models (2  models) will have as response
variables: rate of disease progression between Baseline and (1) 6  months in the
CT-ORZY- NPC -002 study and (2) 12 months in the  CT-ORZY- NPC -002 study. The
covariates in each model (the same in both analyses) will be rate of disease progressionin study CT- ORZY- NPC -001, miglustat use, and randomised treatment.
‚Ä¢The number of patients leaving the blinded phase of the study before 12 months as aresult of early escape will be presented .
‚Ä¢The number of patients who either withdraw from the study before 12 months, or whoneed to jump to escape therapy will be presented .
‚Ä¢Change in use of NPC medication/standard of care (including miglustat therapy) at 12,18 months and eve ry 6 months thereafter until End of Extension Phase at 60 months
will be listed .
Point estimates of treatment differences with 95% CIs and proportions of treatment difference with 95% CIs will be presented for each subgroup where applicable. Exploratory subgroup analyses will be performed based upon: 
‚Ä¢Use (or not) of miglustat at randomisation, age;
‚Ä¢Genotype;
‚Ä¢Age at diagnosis of first neurological symptom, Categories are:
oPre/peri -natal (onset at age <3  months);
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 105 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  oEarly -infantile (at age 3  months to <2 years);
oLate- infantile (at age 2 to <6  years);
oJuvenile (at age 6 -15 years);
oAdolescent/adult (at age >15  years).
‚Ä¢Age at entry to the study e ither <12  years  or ‚â• 12 years ;
‚Ä¢Age at entry to the study either <4 years or ‚â• 4 years;
‚Ä¢Disease severity ( defined as the 5 domain NPCCSS score), genotype , at baseline
divided into 3 severity groups <4, 4-22 and change in>22 ;
‚Ä¢Disease severity defined as the full scale NPCCSS , (apart from hearing domains ) score
at 3 months ( baseline divided into tertiles; 0 - ‚â§18, 19 - ‚â§36, 37 - ‚â§54) ;
‚Ä¢Change in full scale NPCCSS score , (apart from hearing domains ) from baseline ) to
3 months for patients with late infantile phenotype ( age at the start of neurological
symptoms: from  (at age 2  years up  to and including <6  years  old).
20.7. M
ISSING DATA AND SENSITIVITY ANALYSES  
All reasons for missing data will be documented. 
Any patient with missing baseline NPCCSS data will have the median for all patients imputed. 
It is not expected that any patient will have this baseline missing.  
As a first anal ysis accounting for missing data, a multiple imputation approach will be taken, 
as follows: 
1.The missing values are filled in m  times to generate m complete data sets (using
SAS PROC MI).
This is done by fitting m  linear regression models using patients with observed values
for the endpoint and further covariates (these may be baseline covariates ormeasurements of the endpoint at earlier visits or others). Based on the fitted regressionmodel, a new regression model is simulated from the Bayesian posterior predictivedistribution of the regression parameters and is used to impute the missing values;
2. T he m complete datasets are analysed by using standard statistical procedures  (as
relevant for the specific endpoint);
3. T he results from the m analyses are combin ed for statistical infer ence (using
SAS PROC MIANALYZE).
The method described above assumes that the missing values are ‚Äúmissing at random‚Äù (MAR); 
that is, the probability that an observation is missing may depend on the observed  data, but not 
on the missing  data. This is particularly important to account for patients who progress quickly 
who need to jump to the ‚Äúescape‚Äù section of the protocol and for whom their heightened disease severity will be recorded (and form the reason for them to jump to the escape therapy).  
As a second analysis accounting for missing data, a non- parametric approach will be taken, as 
follows: 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 106 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  1.Patients who withdraw early will be assig ned ‚Äúworst‚Äù scores for their 12 -month
NPCCSS (i.e. worse than all patients, regardless of their treatment assignment) ;
2.Transformation of baseline and post -baseline values for all patients (regardless of
treatment groups) to standardized ranks ( i.e., ranks divided by the number of patients
ranked plus 1, mean ranks in case of ties);
3.Determination of residuals from the linear regression of the NPCCSS standardized
ranks on baseline NPCCSS standardized ranks;
4.Application of the two- sided Wilcoxon- Mann -Whitney test to these residuals. The
standardized test statistic with a continuity c orrection of 0.5 is asymptotically standard
normally distributed under the null hypothesis.
For the c linical global imp ression of severity (CGI -S) at 6 and 12  months, the cumulative 
distribution of total NPCCSS score s apart from hearing domains (probabilit y of attaining each 
score level, or worse) will be plotted, stratified by patients in each clinical global impression category and by treatment. 
Cumulative distribution plots for c linical global impression of improvement (CGI -I) from 
baseline to 6 and 12 months will be plotted similarly.  
All efficacy analyses (using and not using missing data imputation methods) will be repeated 
and presented using the PP analysis set  and CAS , as defined in Section  20.2.3 and to be 
reviewed and confirmed in the blind review of the SAP . 
20.8. EVALUATION OF CLINICAL STATUS  
The clinical status parameters listed in Section  14.1 will be summarised.  
20.9. EVALUATION OF SAFETY 
The safety parameters are listed in Section  15.1. 
All AEs will be displayed in summary tables, by MedDRA system organ class and preferred term. Other safety data (including laboratory data) data will be summarised using appropriate descriptive statistics.  
20.10. EVALUATION OF IMAGING  
The imaging parameters listed in Section  16.1 will be summarised.  
20.11. EVALUATION OF PHARMACOKINETICS  
The PK parameters listed in Section  17.1 will be summarised.  POP PK will also be modelled 
and analysed separately to the clinical study report. 
20.12. EVALUATION OF BIOMARKERS  
The biomarker parameters listed in Section  18.1 will be summarised . 
20.13. EVALUATION OF OTHER ENDPOINTS  
The parameters other endpoints as listed in Section 19.1 will be summarised.  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 107 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  20.14. INTERIM ANALYSIS  
Two interim analys es are planned. One will be carried out after all ongoing patients have 
received 12 months of blinded treatment and another will be carried out after all ongoing 
patients have received 12  months of open- label treatment with arimoclomol. An interim 
analysis may be performed prior to completion of the trial to support a potential regulatory submission.  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 108 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  21. OBLIGATIONS OF THE PRINCIPAL INVESTIGATOR
The study will be performed in accordance with: 
‚Ä¢The protocol;
‚Ä¢The Declaration of Helsinki  (WMA , 2013);
‚Ä¢International Conference on Harmonisation Harmonised Tripartite Guideline for Good
Clinical Practice  (ICH -GCP)  (ICH E6(R2) , 1996);
‚Ä¢All local regulations.
21.1. INDEPENDENT ETHICS COMMITTEE/ INSTITUTIONAL REVIEW 
BOARD 
It is the responsibility of the Investigator to obtain approval  of the trial protocol/amendments 
from the  IEC/IRB . Prior to the initiation of the study, the Investigator/ Worldwide Clinical 
Trials  will submit the following documents to the appropriate IECs /IRBs  for approval: 
‚Ä¢The study protocol and any amendments;
‚Ä¢The P ICD and any other written documents to be provided to the patient (and the
patient ‚Äôs parent[s]/legal guardian[s]);
‚Ä¢The IB;
‚Ä¢Details of any compensation to patients ;
‚Ä¢The current Curriculum Vitae of the Principal Investigator;
‚Ä¢Any other requested document(s).
A copy of the approval will be sent to Worldwide Clinical Trials  along with all other 
correspondence with the IEC /IRB , including the submission documents. The Investigator 
should file all correspondence with the IEC /IRB  in the Investigator Site File.  
The study will not start until approval of the protocol and the PICD has been obtained from the appropriate IEC /IRB . The letter of approval should be dated and  should specify the protocol 
number and date of the protocol or amendment which was reviewed and approved. It should also specify the date of the PICD that was reviewed and approved. 
A dated list of the voting members of the IEC /IRB  who were present when the protocol was 
reviewed and approved, including their titles/occupations and institutional affiliations should 
be provided where possible by the Investigator to Worldwide Clinical Trials  prior to study 
initiation. The Investigator will make all attempts to ensure that the IEC /IRB  is constituted and 
operates in accordance with the ICH -GCP and any local regulations. 
The Investigator will submit any protocol amendments to the IEC /IRB  (and other local 
authorities, according to local regulations) prior to implementation.  
The Investigator will submit required progress reports to the IEC /IRB  that app roved the 
protocol at least annually, as well as report any SAEs, life- threatening problems or deaths, to 
comply with ICH -GCP. The Investigator must inform the IEC /IRB  of the termination of the 
study. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 109 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  21.2. REGULATORY BODY APPROVAL  
The study will not be started until Worldwide Clinical Trials  has received approval from 
relevant regulatory bodies. Worldwide Clinical Trials  will provide the Investigator with a copy 
of the relevant document on behalf of the Sponsor. 
21.3. INFORMED CONSENT AND SCREENING DATA 
PICDs (including patient assent as per local laws and regulations) will normally be based on a 
master document provided by CRO  or the study Sponsor and must be approved by the study 
Sponsor prior to submission to the IEC /IRB . The content of the PICD should re flect that 
described in Section  4.8.10 of the ICH Guidelines  and any local requirements e.g. IEC /IRB . 
Any changes requested by the  IEC/IRB  must be approved by study Sponsor  prior to the 
documents being used. A copy of the final, IEC /IRB -approved consent form must be submitted 
to the CRO  prior to initiation of this study. The Investigator should file the signed PICDs for 
review by Worldwide Clinical Trials  CRAs.  
Written informed consent (and assent as per local laws and regulations) will be obtained from each patient ( and/or their parent[s]/legal guardian[s]) prior to inclusion in the trial, and prior to 
any study- related assessments are performed, as described in Sections  10.1.  
21.4. CASE REPORT FORMS AND SOURCE DOCUMENT VERIFICATION 
CRFs/ eCRFs of a design mutually agreed upon by the Sponsor and delegate(s)  will be supplied 
to the sites.  CRFs/ eCRFs are the sole property of KemPharm Denmark  A/S and should not be 
made available in any form to third parties, except for authorised representatives of appropriate Health/Regulatory Authorities, without written permission from KemPharm Denmark  A/S. 
A CRF/ eCRF is required an d should be completed for each included (consented) patient. The 
Investigator will be responsible for the accuracy of the data entered into the CRF/ eCRF. All 
data must be entered in  English and must be completed by designated study personnel . The 
completed  CRFs/ eCRFs must be reviewed, and ( electronically  for eCRFs ) signed/dated by the 
Investigator in a timely fashion.  If a change is made on any of the eForms /CRF pages  after the 
Investigator has signed that eForm /CRF , the Investigator must re-sign the eCRF /CRF. 
The relevant completed eForms must be available for review to designated Worldwide Clinical 
Trials  representatives at each scheduled monitoring visit. 
The Investigator will allow designated Worldwide Clinical Trials  representatives and 
regulatory bodies to have direct access to the source documents to verify the data reported in the CRFs/eCRFs.  
Source documents (e.g., medical records, raw data collection forms, pharmacy dispensing records, recorded data from automated instruments, laboratory data) are the originals of any documents used by the Investigator or hospital/institution that allow verification of the existence of the patient and substantiate the integrity of the data collected during the trial.  
Source documents should be available to support all the data recorded in the CRF/ eCRF. The 
Investigator will prepare and maintain adequate and accurate source documents. These documents are designed to record all observations and other pertinent data for each patient included in this clinical trial.  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 110 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  21.5. CONFIDENTIALITY 
Personal data of the patient shall be processed in a manner that ensures it has appropriate 
security.  This includes protection against unauthorised or unlawful processing and against 
accidental loss, destruction or damage and by using appropriate technical or organisational measures. One such measure is by the Investigator  ensuring that the patients‚Äô pers onally 
identifiable information  is replaced through the use of pseudonymisation. 
On the eCRFs or other documents submitted to Worldwide Clinical Trials, patients will NOT be identified by their names but by the assigned patient number and their initials to  ensure 
confidentiality of the patients‚Äô  information and that data minimisation principles are 
maintained.  
If patient names are included in error on copies of documents submitted to Worldwide Clinical 
Trials , the names (except for initials) will be erased or securely destroyed and the assigned 
patient number added to the document. 
The Investigator should keep a separate log (Patient Master List) of patient‚Äôs codes (assigned 
patient number), names, addresses, telephone numbers and hospital numbers (if applic able).  
Documents not intended for submission to Worldwide Clinical Trials  (e.g. signed consent 
forms , completed Patient Master List, etc. ) should be maintained by the Investigator in strict 
confidence and not disclosed to any parties outside of this approved agreement.  eCRFs  should 
be protected by use of strong encryption. 
21.6. STAFF INFORMATION AND RESPONSIBILITIES  
It is the responsibility of the Investigator to ensure that all personnel involved in the study are 
fully informed of all relevant aspects of the study, including detailed knowledge of and training in all procedures to be followed to allow collection of accurate, consistent, complete and 
reliable data.  
The Investigator will provide a list of delegated responsibility to Worldwide Clinical Trials , 
detailing the various study tasks to be performed by each member of his/her study staff. Each staff member should sign in agreement to their performing each of the tasks delegated to them on the list. Worldwide Clinical Trials  should ensure that the staff have  the required knowledge 
and training for the tasks delegated to them.  
21.7. ESSENTIAL DOCUMENT RETENTION  
All clinical information shall be recorded, handled and stored in such a way that it can be accurately reported, interpreted and verified, while ensuring confidentiality of the trial patients‚Äô personal data. Documents that enable both the conduct of the clinical trial and the quality of the data produced to be evaluated; and show whether the trial is, or has been, conducted in accordance with ICH -GCP and appli cable regulatory requirements are considered essential 
documents. 
The Investigator will retain copies of all the essential documents (as defined by ICH -GCP) 
until at least 2  years after the last approval of a marketing application in an ICH region, and 
until there are no pending or contemplated marketing applications in an ICH region, or at least 
2 years have elapsed since the formal discontinuation of clinical development of the IMP. The  
period of document retention is, however, also dependent on the applicable regulatory 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 111 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  requirements (e.g. EEC Directive 91/507 requires retention of patient codes for at least 15 years 
after the completion or discontinuation of a trial and retention of hospital records and other source data for the maximum time permitted by the institution where the study takes place). The Investigator should take measures to prevent accidental or premature destruction of these documents. 
The essential documents include: the signed protocol, copies of the completed CRFs/eCRFs, 
signed PICDs from all patients (and /or the patient ‚Äôs parent[s]/legal guardian[s]) who consented, 
hospital records and other source documents, IEC /IRB  approval and all related correspondence, 
including approved documents, and all other documentation included in the Investigator Site File. 
The Investigator will inform the Sponsor of the storage location of these essential documents and must contact the Sponsor before disposing of any. If the Investigator wishes to assign the files to someone else (e.g. if he/she ret ires) or to remove them to another location, the Sponsor 
Project Manager should be consulted about this change. 
The Sponsor will inform the Investigator in writing when these documents no longer need to 
be retained.  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 112 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  22. STUDY MANAGEMENT
22.1. MONITORING  
Prior to stu dy commencement, the Investigator will be informed of the anticipated frequency 
of the monitoring visits. He/she will also receive a notification prior to each monitoring visit 
during the course of the study. It is expected that the Investigator and/or his /her 
Sub-i nvestigator(s) and other appropriate staff will be available on the day of the visit to discuss 
study conduct. Worldwide Clinical Trials  is responsible for ensuring the proper conduct of the 
clinical trial with regards protocol adherence and validity of the data recorded in the  
CRFs/eCRFs.  
A site initiation visit must  be conducted by the CRO  and the site must be activated prior to the 
commencement of any study activities requiring informed consent (i.e. any invasive screening tests).  
22.2. QUALITY ASSURANCE AND QUALITY CONTROL  
An independent audit of the study may be conducted during the study or after completion. The audit may be conducted by either Worldwide Clinical Trials  or the Sponsor‚Äôs Quality 
Assurance (QA) department or an independent auditor or a regulatory authority. 
22.2.1. Quality Control 
Quality Control (QC) is defined as the operational techniques and activities undertaken within the QA system to verify that the requirements for quality of the trial- related activities have been 
fulfilled.  
QC should be applied to each stage of data handling to ensure that all data are reliable and have been processed correctly.  
22.2.2. Quality Assurance 
Quality Assurance  (QA)  is defined as the planned and systematic actions that are established 
to ensure that the trial is performed,  and the data are generated, documented (recorded) and 
reported in compliance with GCP  and the applicable regulatory requirements. 
22.2.3. Audit  
The Investigator will permit an audit mandated by the S ponsor after reasonable notice. The 
purpose of an audit is to confirm that the study is conducted as per protocol, GCP and applicable regulatory requirements, that the rights and well -being  of patients enrolled have been protected 
and that all data relevant for the evaluation of the IMP have been captured, processed and reported in compliance with the planned arrangements. The Investigator will permit direct 
access to all study doc uments, IMP accountability records, medical records and source data. 
The Investigator and his/her study team will also be available for discussion regarding study progress and procedures during the audit (both during the audit and at the end of the audit f or 
an ‚Äúexit‚Äù discussion). 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 113 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  22.3. DATA QUERY PROCESS  
Sites will enter the data from source documents into the eCRF /CRF  in timely manner and the 
data will be verified for missing data, inconsistencies, and for any necessary medical 
clarifications. Queries arising f rom these checks will be flagged within the eCRF  or by data 
clarification/query forms . The site staff will correct, confirm or clarify the data as appropriate. 
All possible attempts should be made by the site staff to resolve the queries within the request ed 
timeframes. If the site staff are unsure about the meaning of a query, or what data is required, then they should seek clarification from the Worldwide Clinical Trials  CRA assigned to their 
site. 
Once all data queries have been resolved, the study will be declared to be ‚Äúclean‚Äù, and the eCRF will be locked ready for statistical analysis. After clean -file status has been achieved, 
Worldwide Clinical Trials  will provide copies of each patient‚Äôs eCRF to the Investigator for 
archiving. Copies of each patient ‚Äôs eCRF /CRF  will also be archived by the Worldwide Clinical 
Trials . 
The data management, data handling, and analysis will be conducted in accordance with good clinical, scientific and data management principles and in compliance with the Standard 
Operating  Procedures of the relevant KemPharm Denmark  A/S delegates . 
22.4. PROTOCOL DEVIATIONS/AMENDMENTS  
The trial must be conducted in accordance with: 
‚Ä¢The protocol;
‚Ä¢Applicable regulatory requirement(s) or conditions linked to the approval(s) of thestudy;
‚Ä¢Applicable IEC /IRB  requirement or conditions linked to the approval(s) of the study;
‚Ä¢Any particulars or documents, other than the protocol, accompanying the regulatory orIEC/IRB  request or that application.
Any deviation from the protocol that has not been app rove
 d by KemPharm Denmark  A/S and 
the IEC/IRB  could result in a discontinuation from the  study at the site involved. Any 
amendment(s) to the protocol must be approved by both KemPharm Denmark  A/S and the 
IEC/IRB  which granted the original approval of the study prior to their implementation (unless 
only logistical or administrative aspects of the trial are involved).  All substantial amendments 
to the protocol must be approved by the applicable regulatory bodies prior to their implementation. 
However, in the event of any medical emergency, the Investigator is free to institute any 
me
dical procedure he/she deems appropriate. Such events and procedures must be promptly 
reported to the KemPharm Denmark  A/S and Worldwide Clinical Trials  representatives.  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 114 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  22.5. DISCONTINUATION OF THE STUDY 
KemPharm Denmark  A/S reserves the right to stop the study at any time on the basis of new 
information regarding safety or efficacy, or if study progress is unsatisfactory, or for other valid 
administrative reasons. After such a decision is made, the Investigator must inform all patients being screened or followed up as soon as possible. All delivered study materials must be collected and all CRFs/ eCRFs completed to the extent possible. 
22.6. PUBLICATIONS  
The study will be registered at www.clinicaltrials.gov . By signing the study protocol, the 
Investigator agrees with the use of results of the study for the purposes of national and international re gistration, publication and information for medical and pharmaceutical 
professionals. If necessary, the authorities will be notified of the Investigator‚Äô s name, address, 
qualifications and extent of involvement. Except for legal reasons, the Investigators will not reveal the result of the study to a third party whilst the data is not yet in the public domain without a mutual agreement about the analysis and interpretation of the data with KemPharm Denmark  A/S.  
Any manuscript, abstract or other publication or presentation of results or information arising in conne
ction with the study (including ancillary study involving trial patients) must be 
prepared in conjunction with KemPharm Denmark  A/S and mus t be submitted to the 
KemPharm D enmark  A/S for review and comment at least 6  weeks prior to submission for 
publication or presentation. 
Authorship credit should be based on substantial contributions to conception and design, 
acquisition of data, or analysis and interpretations of da ta; and be decided by KemPharm 
Denmark  A/S and the international coordinating Investigator in cooperation. KemPharm 
Denmark  A/S has all editorial rights of the data from this study. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 115 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  23. STUDY TIMETABLE
‚Ä¢Planned start of the study (first patient in  [FPI]): Q2 2016 
‚Ä¢Planned end of the main study (12-month blinded phase ):  Q2 2018
‚Ä¢Planned end of the extension phase (48-month follow up): Q2 2022
The end of the study is defined as the last visit of the last patient.  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 116 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  24. REFERENCES
Bayley N. Test Review: Bayley Scales of Infant and Toddler Development: Third Edition. San 
Antonio, TX: The Psychological Corporation. 2006. 
Chen AW, Resurreccion AVA, Paguio LP. Age appropriate hedonic scales to measure food 
preferences of young children. J Sens Stud. 1996;11:141-163. 
Clinical Trial Facilitation Group  (CTFG). Recommendations related to contraception and 
pregnancy testing in clinical trials. Final version 2014-09-15. Delaney KA, Rudser KR, Yund BD, Whitley CB, Haslett PA, Shapiro EG. Methods of 
neurodevelopmental assessment in children with neurodegenerative disease: Sanfilippo syndrome. JIMD Rep. 2014;13:129-37. 
Gelsthorpe ME, Baumann N, Millard E, et al . Niemann -Pick type C1 I1061T mutant encodes 
a functional protein that is selected for endoplasmic reticulum- associated degradation due to 
protein misfolding. J Biol Chem. 2008 Jan:283(13):8229-36. Gumus E, Haliloglu G, Karha n AN,  et al. Niemann -Pick disease type C i n the newborn period: 
a single- center experience.  Eur J Pediatr. 2017 Dec;176(12):1669-1676. 
Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US 
Department of Heal th, Education, and Welfare Public Health Service Alcohol, Drug Abuse, 
and Mental Health Administration; 1976. Howie SR. Blood sample volumes in child health res earch: review of safe limits. Bull World 
Health Organ. 2011 Jan 1;89(1):46-53. Huang JY, Peng SF, Yang CC, et al . Neuroimaging findings in a brain with Neimann- Pick type 
C disease.  J Formos Med Assoc. 2011 Aug;110(8):537-42. 
ICH. E6(R2) Guideline for Good Clinical Practice. 1996 
Imrie J, Dasgupta S, Besley GT, et al . The natural history of Niemann- Pick disease type C in 
the UK.  J Inherit Metab Dis. 2007 Feb;30(1):51- 9. 
Ingemann L, Kirkegaard, T. Lysosomal Storage Diseases and the Heat Shock Response: 
Convergences and Therapeutic Opportunities. J Lipid Res 2014. Nov;55(11):2198-210. 
Kirkegaard  T. Emerging therapies and therapeutic concepts for lysosomal storage diseases. 
Expert Opinion on Orphan Drugs. 2013; 1(5): 385-404. Lloyd- Evans E, Platt FM.  Lipids on trial: the search for the offending metabolite in Niemann-
Pick type C disease.  Traffic. 2010 Apr;11(4):419-28. 
Lloyd- Evans E, Morgan AJ, He X, Smith DA, Elliot -Smith E, Sillence DJ,  et al. Niemann -Pick 
disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium. 
Nat Med. 2008 Nov;14(11):1247-55. 
Mahmood I. Prediction of drug clearance in children from adults: a comparison of several 
allometric methods. Br J Clin Pharmacol. 2006 May; 61(5): 545‚Äì557. Matsui D. Assessing the palatability of medications in children. Paed Perinat Drug Ther. 
2007;8:55-60. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 117 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  McKay Bounfor d K and  Gissen P. Genetic and laboratory diagnostic approach in Niemann 
Pick di sease type C. J Neurol. 2014; 261(Suppl 2): 569‚Äì575.  
Mendon√ßa B, Sargent B, Fetters L. C ross-cultural validity of standardized motor development 
screening and assessment tools: a systematic review.  Dev Med Child Neurol. 2016 
Dec;58(12):1213-1222. 
Neef, D W, J aeger, A M, et al . Heat s hock t ranscription  factor  1 as a therapeutic target i n 
ne
urodegenerative diseases. Nat Rev Dr ug Discov 2011; 10(12) : 930-944. 
National Ca ncer Institute Common Terminol ogy Criteria for Adv erse Events (CTCAE) 
Version 4.03 NCI, NIH, DHHS. 14 June 2010: 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf  
Patterson MC, Hendriksz CJ, Walterfang M, et al.  Recommendations for the diagnosis and 
m
anagement of Niemann- Pick disease type C: An update. Mol Genet Metab. 2012 
J
ul;106(3):330-44. 
Porter FD, Scherrer DE, Lanier MH, et al. Cholesterol Oxidation Products Are Sensitive and 
S
pecific Blood- Based  Biomarkers for Niemann- Pick C1 Disease. Sci Transl Med. 2010 Nov 
3;
2(56):56ra81. 
Rehabilitation Institute of Chigcago, Center for Rehabi l itation Outcomes Research, 
Northwestern University Feinberg School of Medicine Department of Medical Social Sciences 
 from:  
Acc
essed Informatics group. Nine-h ole Peg test (9HPT). Available  
http://www.rehabmeasures.org/Lists/RehabMeasures/PrintView.aspx?ID=925
. 14 
January 2015. 
Reunert J, Fobker M, Kannenberg F, et al. Rapid Diagnosis of 83 Patients with Niemann Pick 
Type C Disease and Related Cholesterol Transport Disorders by Cholestantriol Screening. 
E
BioMedicine. 2015 Dec 22;4:170-5. 
Rehabilitation Institute of Chigcago, Center for Rehabilitation Outcomes Research, 
N
orthwestern University Feinberg School of Medicine Department of Medi cal  Social Sciences 
Informatics group. Scale for Assessment and Rating of Ataxia (SARA).  Available from: 
http://www.rehabmeasures.org/Lists/RehabMeasures/PrintView.aspx?ID=1242.  
Accessed 
14 January 2015. 
S
tampfer M, Theiss S, Amraoui Y, et  al. Niemann Pick disease type C clinical database: 
C
ognitive and coordination decifits are early disease indicators. Orphanet J Rare Dis. 2013 Fe b 
22;8:35. 
Sun X, Marks DL, Park WD, e t a l. Niemann- Pick C variant detection by altered sphingolipid 
trafficking and correlation with mutations within a specific domain of NPC1. Am J Hum Genet. 
2001 Jun;68(6):1361-72. 
Te Vruchte D, Spea k AO, Wallom KL, et al . Relative acidi c compartment  volume as a 
lysosomal storage disorder‚Äìassociated biomarker. J Clin Invest. 2014 Mar 3;124(3):1320-8. 
Vanier  MT. Niemann -Pi ck disease type C. Orphanet J Rare Dis. 2010 Jun 3;5:16. 
Vanier MT . Complex lipid trafficking in Niemann -Pick disease type C. J Inherit Metab Dis. 
2015 Jan;38(1):187-99. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 118 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Watanabe Y, Akaboshi S, Ishida G, et al.  Increased levels of GM2 ganglioside in fibroblasts 
from a patient with juvenile Niemann -Pick disease type C. Brain Dev.  1998 Ma r;20(2):95-7. 
World Medical Association  (WMA) . Declaration of Helsinki  ‚Äì Ethical  Principles for Medical 
Research Involving Human Subjects. 2013. as adopted by the 64th World Medical Assembly 
General Assembly, Fortaleza, Brazil, October 2013 
Wraith JE, NP -C Gui delines Working Group, Baumgartner MR, Bembi B, Covanis A, Levade 
T, et al. Recommendations on the diagnosis and management of Niemann -Pick disease type C. 
Mol Genet Metab. 2009 Sep-Oct;98(1-2):152-65. 
Yanjanin N, V√©lez JI, Gropman A, et al . Linear clinical progression, independent of age of 
onset, in Niemann- Pick disease, type C.  Am J Med Genet B Neuropsychiatry Genet. 2010 Jan 
5; 153B(1):132-40.  Yu T, Chung C , S
 hen D, et al. Ryanodine receptor antagonists adapt NPC1 proteostasis to 
ameliorate lipid storage in Niemann -Pick type C disease fibroblasts. Hum Mol Genet. 2012 Jul 
15;21(14):3205-14. Zampieri  S, Bembi B, Rosso N, et al . Treatment of Human Fibroblasts Carrying NPC1 
Mis
sense Mutations with MG132 Leads to an Improvement of Intracellular Cholesterol 
Trafficking . JIMD Rep.  2012;2:59-69.  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 119 of 173 
Final Version 11.0; 21- Jun-2022  CONFIDENTIAL  25. APPENDICES
25.1. APPENDIX I : BMI FOR AGE - WORLD HEALTH ORGANISATION 

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 120 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 121 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 122 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  

Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 123 of 173 
Final Version 11.0; 21- Jun-2022  CONFIDENTIAL  25.2. APPENDIX I I: STUDY FLOW CHART : BLINDED PHASE  STUDY PERIOD: P ATIENTS LESS THAN 12 YEARS OF 
AGE  
STUDY PHASE  SCREENING  PK RANDOM -
ISATION  BLINDED PHASE  STUDY PERIOD  END OF BLINDED 
PHASE[x] UNSCHEDULED 
VISIT[y] 
Vis it 1 Visit 2  Visit  3 Visit 4  Visit  5 Visit  6 NA 
PROCEDURES  NA NA NA 7-14 days
after start of
continuous
treatment[w]3 m
onths 
(¬±4 weeks) 
after 
randomisation  6 months 
(¬±4 weeks) 
after 
randomisation  9 months 
(¬±4 weeks) 
after 
randomisation  12 months 
(¬±4 weeks) after 
randomisation or  
within 4  weeks or 
withdrawal during 
blinded phase  NA 
Informed Consent  X 
Inclusion/Exclusion 
Criteria  X 
Demographics[a] X 
NPC  Diagnosis[b] X 
NPC  Disease History[c] X 
Medical History (including Concomitant Disease)  
X 
Physical Examination[d] X# X X 
Weight  X# X X X X X 
Vital Signs[e] X# X X X X X 
ECG[f] X# X X 
Skin Punch Biopsy for Biomarkers Analysis  X# X X 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 124 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  STUDY PHASE  SCREENING  PK RANDOM -
ISATION  BLINDED PHASE  STUDY PERIOD  END OF BLINDED 
PHASE[x] UNSCHEDULED 
VISIT[y] 
Vis it 1 Visit 2  Visit  3 Visit 4  Visit  5 Visit  6 NA 
PROCEDURES  NA NA NA 7-14 days
after start of
continuous
treatment[w]3 m
onths 
(¬±4 weeks) 
after 
randomisation  6 months 
(¬±4 weeks) 
after 
randomisation  9 months 
(¬±4 weeks) 
after 
randomisation  12 months 
(¬±4 weeks) after 
randomisation or  
within 4  weeks or 
withdrawal during 
blinded phase  NA 
Haematology[g] X# X X X X X 
Clinical Chemistry[h] X# X X X X X 
Blood Sample for 
Biomarker Analysis[i] X# X X 
Pregnancy test [j] X X 
Ultrasound (Liver and Spleen)
[k] X# X X 
NPCCSS[l] X# X X X X X 
NPC -cdb score[m] X X X 
SARA[n] X X X 
9HPT[n] X X X 
CGI-S & CGI -I[n] X X X X X 
Quality of Life Scoring[n]  X# X X 
Concomitant Therapy[o] X 
Adverse Events[p] X 
Single Dose Arimoclomol Administration
[q] X 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 125 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  STUDY PHASE  SCREENING  PK RANDOM -
ISATION  BLINDED PHASE  STUDY PERIOD  END OF BLINDED 
PHASE[x] UNSCHEDULED 
VISIT[y] 
Vis it 1 Visit 2  Visit  3 Visit 4  Visit  5 Visit  6 NA 
PROCEDURES  NA NA NA 7-14 days
after start of
continuous
treatment[w]3 m
onths 
(¬±4 weeks) 
after 
randomisation  6 months 
(¬±4 weeks) 
after 
randomisation  9 months 
(¬±4 weeks) 
after 
randomisation  12 months 
(¬±4 weeks) after 
randomisation or  
within 4  weeks or 
withdrawal during 
blinded phase  NA 
PK sampling[r]  X 
Randomisation[s] X 
IMP Dispensing[t] X$ X X X X* (X) 
IMP Return[t] X X X X (X) 
IMP Administration[t] X 
POP PK Sampling[u]  X X X X 
Patient Acceptability/ 
Palatability[u] X X X X 
Telephone Follow up[z] X (every month [¬±7 days])  
#The following assessments do not need to be repeated at Visit  1 if these assessments have been performed within 7 days of Visit  1: Physical examination including body weight 
and height,  vital signs,  ECG, skin punch biopsy, haematology, biochemistry, blood sample for biomarker analysis, ultrasound (liver and spleen), NPC  Disease Severity Scores 
and Quality of Life scoring.  
aDemographics  i ncludes date of birth, sex and race. 
bNPC d iagnosis  based on date of initial symptom(s) and symptom(s) description, date of clinical diagnosis and symptoms clinical status, date of confirmed genetic 
NPC  diagnosis, DNA sequence analysis and, if applicable , date of fillipin staining result and cholestane tri ol/oxysterols . 
cNPC d isease history  including date of first NPC  symptom, history of neurological manifestations and past treatments.
dPhysical examinations  dur ing the study will include the  assessment of skin, head, neck, lymphatic, abdomen, respiratory, cardiovascular/peripheral vascular, central 
nervous and musculoskeletal systems as appropriate to determine general condition.  
eVital signs  w ill include supine blood pressure, pulse rate, r espiratory rate and temperature (ear).  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 126 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  fA twelve -l ead ECG  will be recorded over at least 10  seconds after the patient has rested supine on a bed for at least 5  minutes. 
gHaem atology s amples to be sent to a central laboratory for analysis.  
hClinic al che mistry  samples to be sent to a central laboratory for analysis.  
iBiomarker s amples to be sent to a central laboratory for analysis.  
j Urine pregnancy test  for post -menarchal female patients.  
kUltrasound of  the liver and spleen to document changes in the size  of the liver and spleen and any clinical relevant findings.  
lNPC clinical severity scale  ( NPCCSS) : Refer to NPCCSS template provided for use in the study.
mNPC- cd b score: Refer to the modified N PC-cdb template provided for use in the study.  
nSARA: Refer to SARA template provided for use in the study. 
9
HPT : Refer to 9HPT template provided for use in the study.  
CGI -S & CGI -I: Refer to CGI -S and CGI -I templates provided for use in the study.  
Quality of Life  (EQ-5D-Y [Proxy version] ) scoring  will be co mpleted by the patient's parent(s)/legal guardian(s) . 
oConcomitant therapy  in cludes all medication and medical procedures (including any unplanned diagnostic, therapeutic or surgical procedures) ongoing at or starting
after the time of written consent.
pAdverse events (AEs) :  ALL AEs which occur from the time of written informed consent to the end of t he extension phase  of the study or patient withdrawal,  will be
recorded in the eCRF.
qSingle dose arimoclomol administration : P atients less than 12 years of age  will initially receive a single oral dose of arimoclomol, followed by PK sampling.
rPK sampling : F or patients less than 12 years of age  only. PK sampling will be performed following a single dose of arimoclomol: pre -dose (immediately prior to
administration of the single dose of arimoclomol)  and 30  min (¬±5  min), 1  hour (¬±10  min), 2  hours (¬±10 min), 4  hours (¬±30 min) and 8 hours (¬±30 min) following
dosing.
The following information should be noted down:
1. The precise time of the blood sampling;
2. The precise time of the administration of food and liquid(s);
3. The type of liquid(s) administered;
4. The selected route for the single dose administration of arimoclomol including any type of liquid/soft foodstuff used for the  administration (as applicable).
The patient will be required to fast as follows:1. Food: At least 2 hours before the single dose administration and at least 2 hours following the single dose administration;
2. Liquids: Non -protein and non -fat liquids (e. g. juice) are allowed for up to 1 hour before the single dose administration and from 1 hour following the single
dose administration;
3. Water can be administered at any time during the PK procedure.
In the event that the patient requires a dose reductio n, the patient will be dispensed a further single dose of arimoclomol. Single dose PK evaluation will be performed 
following this single dose of arimoclomol in order to confirm the corresponding dose.  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 127 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  Should further dose adjustments be required based on t he single dose PK evaluation, the above procedure will be repeated . 
In the event that unexpected PK -profiles are obtained which are clinical significant and could potentially impact the safety of the patient (e.g. risk of acc umulation), 
the independent assessor can recommend additional PK sampling to be performed. If agreed by the Sponsor‚Äôs medical responsible person and the Principal Investigator, 
up to a maximum of 6 additional samples (corresponding to the full PK analysis set) can be taken at a subsequent visit prior to randomisation.  
sRandomisation  f or patients less than 12 years of age will take place following confirmation of the selected dose scheme after PK analysis.
tIMP dispensing and administration f or patients less than 12  years of age: Follow ing confirmation of the corresponding dose, IMP (arimoclomol or placebo, as per 
the study randomisation) will be shipped to the patient, who will commence dosing upon receipt of it.  
If required, the IMP can be dissolved in 10 mL (i.e. 2 teaspoons) of liquid or in a tablespoon of soft foodstuff. In the dissolved or dispersed state, the IMP  can also be 
administered via a gastric tube (as applicable).   
The patient‚Äôs weight should be measured at each visit and the IMP dose should be adjusted as required and IMP dispensed as relevant.  
During the blinded phase of the study, patients will be dispensed enough IMP for treatment as per the study flow chart.  
$In the event that the IMP (arimoclomol or placebo, as per the study randomisation) is shipped to the patient, the investigator will contact the patient (or patient‚Äôs 
parent[s]/legal guardian[s]) by telephone within 1 week following randomisation to confirm that the IMP has been received, the date that the patient has commenced 
IMP dosing and whether the patient has experienced any diffic ulties in taking the IMP.  
*The patient will be dispensed with sufficient arimoclomol at Visit 6 to continue treatment  (for patients who have not withdrawn from the study).
Early Escape Criteria Met: Should a patient meet the early escape clause and criteria, the patient should be offered  and dispensed treatment with arimoclomol. The 
patient should continue with their current  protocol schedule.  
IMP return:  Patients will be required to return all unused IMP (and relevant packaging [ used/ empty blister packs]) to the site staff. The site staff should aim to follow 
up on the reasons for any missing IMP or other discrepancies noted after performing the relevant IMP accountability.  
uPOP P K Sampling : POP PK sampling will be performed for all patients  as follows:
‚Ä¢V isits  3 & 5 : 3 hours (¬± 1 hour) following dosing.
‚Ä¢Visits  4 & 6 : 1.5 hours  (¬±30  min) , 3 hours (¬±30  min)  and 4.5-6 hours following dosing.  Note: The last POP PK sample should be taken as late as possible but
always before the subsequent dose of IMP .
v Patient Acceptability/Palatability : Refer to the hedonic scale template provided for use in the study.  
w Visit  2 will take place 7 -14 days after the patient has commenced taking the IMP t.i.d.  (continuous treatment). For patients less than 12 years of age, continuous 
treatment will commence following confirmation of the corresponding selected dose scheme.
xEnd of Blinded P hase  (Visit  6): The end of blinded phase  visit (Visit 6) should take place 12 months (¬±4  weeks) after randomisation  or within 4  weeks of patient 
withdrawal during the blinded phase . Withdrawal from study : Should a patient discontinue prematurely and choose to withdraw from the study during the blinded 
phase , all effort should be made to have the patient attend the site for the end of blinded phase  visit (Visit 6) within 4  weeks of patient withdrawal . Should the patient 
(or the patient's parent[s]/legal guardian[s]) refuse to attend the end of blinded phase  visit (Visit 6), the date and reason for study discontinuation (if known)  will be 
recorded in the eCRF as a minimum.  
yUnscheduled visit : T he patient may attend the site for unscheduled visits should the patient experience an unacceptable rate of progression or should there be any 
safety concerns. IMP dispensing and return will take place in the event that a patient meets the early escape clause and  criteria  or a dose reduction has occurred. 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 128 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  zTelephone follow up t o be performed every month (¬±7 days) for 6 months after the start of continuous treatment. Telephone follow -up includes follow -up on the 
status of the patient, whether the patient has experienced any new AEs or the worsening of any existing AEs, whether the patient has had a change in any prescribed 
medication, whether the patient has experienced any difficulties in taking the IMP  and to confirm the weight of the patient .   
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 129 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  25.3. APPENDIX III: STUDY FLOW CHART: BLINDED PHASE  STUDY PERIO D: PATIENTS 12  YEARS OF AGE AND 
OLDER  
STUDY PHASE  SCREENING  RANDOM -
ISATION  BLINDED PHASE STUDY PERIOD  END OF BLINDED PHASE[u] UNSCHEDULED 
VISIT[v] 
Vis it 1 Visit 2  Visit  3 Visit 4  Visit  5 Visit  6 NA 
PROCEDURES  NA NA 7-14 days after
start of
continuous
treatment[t]3 months 
(¬±4 weeks) 
after 
randomisation  6 months 
(¬±4 weeks) 
after 
randomisation  9 months 
(¬±4 weeks) 
after 
randomisation  12 months (¬±4  weeks) after 
randomisation or within 
4 weeks of withdrawal 
during blinded phase  NA 
Informed Consent  X 
Inclusion/Exclusion Criteria  X 
Demographics[a] X 
NPC  Diagnosis[b] X 
NPC  Disease History[c] X 
Medical History 
(including Concomitant 
Disease)  X 
Physical Examination[d] X# X X 
Weight  X# X X X X X 
Vital Signs[e] X# X X X X X 
ECG[f] X# X X 
Skin Punch Biopsy for Biomarkers Analysis  X# X X 
Haematology[g] X# X X X X X 
Clinical Chemistry[h] X# X X X X X 
Blood Sample for Biomarker Analysis
[i] X# X X 
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 130 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  STUDY PHASE  SCREENING  RANDOM -
ISATION  BLINDED PHASE STUDY PERIOD  END OF BLINDED PHASE[u] UNSCHEDULED 
VISIT[v] 
Vis it 1 Visit 2  Visit  3 Visit 4  Visit  5 Visit  6 NA 
PROCEDURES  NA NA 7-14 days after
start of
continuous
treatment[t]3 months 
(¬±4 weeks) 
after 
randomisation  6 months 
(¬±4 weeks) 
after 
randomisation  9 months 
(¬±4 weeks) 
after 
randomisation  12 months (¬±4  weeks) after 
randomisation or within 
4 weeks of withdrawal 
during blinded phase  NA 
Pregnancy test [j] X X 
Ultrasound (Liver and Spleen)
[k] X# X X 
NPCCSS[l] X# X X X X X 
NPC -cdb score[m] X X X 
SARA[n] X X X 
9HPT[n] X X X 
CGI-S & CGI -I[n] X X X X X 
Quality of Life Scoring[n]  X# X X 
Concomitant Therapy[o]  X 
Adverse Events[p] X 
Randomisation X 
IMP Dispensing X$ X X X X* (X) 
IMP Return[q] X X X X (X) 
IMP Administration[q] X 
POP PK Sampling[r] X X X X 
Patient Acceptability/ Palatability
[s] X X X X 
Telephone Follow up[w] X (every month [¬±7 days])  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 131 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  #The following assessments do not need to be repeated at Visit  1 if these assessments have been performed within 7 days of Visit  1: Physical examination including body weight 
and height, vital signs, ECG, skin punch biopsy, haematology, biochemistry, blood sample for biomarker analysis, ultrasound (liver and spleen), NPC Disease Severity Scores 
and Quality of Life scoring.  
aDemographics  i ncludes date of birth, sex and race. 
bNPC d iagnosis  based on date of initial symptom(s) and symptom(s) description, date of clinical diagnosis and symptoms clinical status, date of confirmed genetic 
NPC  diagnosis, DNA sequence analysis and, if applicable, date of fillipin staining result and cholestane tri ol/oxysterols . 
cNPC d isease history  including date of first NPC  symptom, history of neurological manifestations and past treatments.
dPhysical examinations  dur ing the study will include the  assessment of skin, head, neck, lymphatic, abdomen, respiratory,  cardiovascular/peripheral vascular, central 
nervous and musculoskeletal systems as appropriate to determine general condition.  
eVital signs  w ill include supine blood pressure, pulse rate, respiratory rate and temperature (ear).  
fA twelve -l ead ECG  will be recorded over at least 10  seconds after the patient has rested supine on a bed for at least 5  minutes. 
gHaematology s amples to be sent to a central laboratory for analysis.  
hClinical chemistry  s amples to be sent to a central laboratory for anal ysis. 
iBiomarker s amples to be sent to a central laboratory for analysis.  
j Urine pregnancy test for post -menarchal female patients.  
kUltrasound of  the liver and spleen to document changes in the size of the liver and spleen and any clinical relevant findings.  
lNPC clinical severity scale  ( NPCCSS) : Refer to NPCCSS template provided for use in the study.
mNPC- cd b score: Refer to the modified NPC -cdb template provided for use in the study.  
nSARA: Refer to SARA template provided for use in the study.  
9
HPT: Refer to 9HPT template provided for use in the study.  
CGI -S & CGI -I: Refer to CGI -S and CGI -I templates provided for use in the study.  
Quality of Life  (EQ-5D-Y [Proxy version]) scoring will be completed by the patient's parent(s)/legal guardian(s).  
oConcomitant therapy  i ncludes all medication and medical procedures (including any unplanned diagnostic, therapeutic or surgical procedures) ongoi ng at or starting
after the time of written consent.
pAdverse events (AEs) :  ALL AEs which occur from the time of written informed consent to the end of the extension phase of the study or patient withdrawal, will be
recorded in the eCRF.
qIMP  dis pensing and administration :
If required, the IMP can be dissolved in 10 mL (i.e. 2 teaspoons) of liquid or in a tablespoon of soft foodstuff. In the dissolved or dispersed state, the IMP  can also be
administered via a gastric tube (as applicable).
The patient‚Äôs weight should be measured at each visit and the IMP dose should be adjusted as required and IMP dispensed as relevant.During the blinded phase of the study, patients will be dispensed enough IMP for treatment as per the study flow chart.
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 132 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  $Confirmation of eligibility will be dependent on the availability of the relevant central lab results. In the event that conf irmation of eligibility and subsequent 
randomisation of a patient occurs after the screening site visit, IMP (arimoclomol or placeb o, as per the study randomisation) will be shipped to the patient, who will 
commence dosing upon receipt of it. The investigator will contact the patient (or patient‚Äôs parent[s]/legal guardian[s]) by t elephone within 1  week following 
randomisation to confi rm that the IMP has been received, the date that the patient has commenced IMP dosing and whether the patient has experienced any difficulties 
in taking the IMP.  
*The patient will be dispensed with sufficient arimoclomol at Visit 6 to continue treatment (for patients who have not withdrawn from the study).
Early Escape Criteria Met: Should a patient meet the early escape clause and criteria, the patient should be offered  and dispensed treatment with arimoclomol. The 
patient should continue with their curren t protocol schedule.  
IMP return:  Patients will be required to return all unused IMP (and relevant packaging [ used/ empty blister packs]) to the site staff. The site staff should aim to follow 
up on the reasons for any missing IMP or other discrepancies note d after performing the relevant IMP accountability.  
rPOP P K Sampling : POP PK sampling will be performed for all patients  as follows: 
‚Ä¢Visits 3  & 5 : 3 hours (¬± 1 hour) following dosing.
‚Ä¢Visits  4 & 6 : 1.5 hours  (¬±30  min), 3  hours (¬±30  min)  and 4.5-6 hours following dosing.  Note: The last POP PK sample should be taken as late as possible but
always before the subsequent dose of IMP .
sPatient Acceptability/Palatability : R efer to the hedonic scale t emplate provided for use in the study. 
t Visit  2 will take place 7 -14 days after the patient has commenced taking the IMP t.i.d.  (continuous treatment). 
uEnd of Blinded Phase (Visit  6): T he end of blinded phase visit (Visit  6) should take place 12 months (¬±4  weeks) after randomisation or within 4  weeks of patient
withdrawal during the blinded phase.
Withdrawal from study : S hould a patient discontinue prematurely and choose to withdraw from the study during the blinded phase, all effort should be made to have
the patient attend the site for the end of blinded phase visit (Visit 6) within 4  weeks of patient withdrawal . Should the patient (or the patient's parent[s]/legal guardian[s]) 
refuse to attend the end of blinded phase visit (Visit  6), the date and reason for study discontinuation (if known) will be recorded in the eCRF as a minimum.
vUnscheduled visit :  The patient may attend the site for unscheduled visits should the patient experience an unacceptable rate of progression or  should there be any
safety concerns. IMP disp ensing and return will take place in the event that a patient meets the early escape clause and criteria or a dose reduction has occurred.
wTelephone follow up t o be performed every month (¬±7 days) for 6 months after the start of continuous treatment. Telephone follow -up includes follow -up on the
status of the patient, whether the patient has experienced any new AEs or the worsening of any existing AEs, whether the patient has had a change in any prescribed
medication, whether the patient has experienced any difficulties in taking the IMP  and to confirm the weight of the patient .
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 133 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  25.4. APPENDIX I V: STUDY FLOW CHART: EXTENSION  PHASE : ALL PATIENTS  
STUDY PHASE  FOLLOW -UP 
Vis it 7 Visit  8 Visit  9 Visit  10 Visit  11 
PROCEDURES  18 months (¬±4  weeks) 
after randomisation   24 months (¬±8  weeks) 
after randomisation  30 months (¬±8  weeks) 
after randomisation  36 months (¬±8  weeks) 
after randomisation  42 months (¬± 8 weeks) 
after randomisation   
Physical examination[a] X X X X X 
Weight  X X X X X 
Vital Signs[b] X X X X X 
Haematology[c] X X X X X 
Clinical Chemistry[d] X X X X X 
POP PK Sampling[e]  X 
Blood Sample for Biomarker 
Analysis[f] X X X X X 
Pregnancy test[g] X X X X X 
NPCCSS[h] X X X X X 
NPC -cdb score[i] X X X X X 
SARA ji] X X X X X 
9HPT[j] X X X X X 
CGI-S & CGI -I[j] X X X X X 
Quality of Life Scoring[j] X X X X X 
Concomitant Therapy[k]  X X X X X 
Adverse Events[l] X X X X X 
Arimoclomol Dispensing[m] X X X X X 
Arimoclomol Return[m] X X X X X 
Arimoclomol Administration[n] X X X X X 
Telephone Follow up[o] X (every 3 -4 months)  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 134 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  APPENDIX IV: STUDY FLOW CHART: EXTENSION PHASE: ALL PATIENTS (CONTINUED)  
STUDY PHASE  FOLLOW -UP END OF EXTENSION PHASE[q] UNSCHEDULED VISIT[p] 
Vis it 12 Visit  13 Visit  14 NA 
PROCEDURES  48 months (¬±8  weeks) after 
randomisation  54 months (¬±8  weeks) after 
randomisation  60 months (¬±8  weeks) after 
randomisation or within 4 weeks of 
withdrawal during extension phase  NA 
Physical examination[a] X X X 
Weight  X X X X 
Vital Signs[b] X X X 
Haematology[c] X X X X 
Clinical Chemistry[d] X X X X 
POP PK Sampling[e]  (X) 
Blood Sample for Biomarker 
Analysis[f] X X X 
Pregnancy test[g] X X X 
NPCCSS[h] X X X X 
NPC -cdb score[i] X X X 
SARA[j] X X X 
9HPT[j] X X X 
CGI-S & CGI -I[j] X X X 
Quality of Life Scoring[j] X X X 
Concomitant Therapy[k]  X X X X 
Adverse Events[l] X X X X 
Arimoclomol Dispensing[m] X X X 
Arimoclomol Return[m] X X X X 
Arimoclomol Administration[n] X X X 
Telephone Follow up[o] X (every 3 -4 months)  
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 135 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  a. Physical examinations  during the study will include the assessment of skin, head, neck, lymphatic, abdomen, respiratory, cardiovascular/peripheral vascular, central
nervous and musculoskeletal systems as appropriate to determine general condition.
b. Vital signs  will include supine blood pressure, pulse rate, respiratory rate and temperature (ear).
c. Haematology samples to be sent to a central laboratory for analysis.
d. Clinical chemistry  samples to be sent to a central laboratory for analysis.
e. POP PK Sampling : POP PK sampling will be  performed  for all patients  as follows:
Visit 8 and unscheduled visit : 1.5 hours  (¬±30  min), 3  hours (¬±30 min)  and 4.5-6 hours following dosing.  Note: The last POP PK sample should be taken as late as
possible but always before the subsequent dose of IMP .
POP PK sampling at the unscheduled visit is a t the  discretion of the Investigator .
f. Biomarker samples to be sent to a central laboratory for analysis.
g. Urine  pregnancy test for post -menarchal female patients.
h. NPC clinical severity scale  (NPCCSS) : Refer to NPCCSS template provided for use in the study.
i. NPC- cdb score: Refer to the modified NPC -cdb template provided for use in the study.
j. SARA: Refer to SARA template provided for use in the study.
9HPT : Refer to 9HPT template provided for use in the study.
CGI -S & CGI -I: Refer to CGI -S and CGI -I templates provided for use in the study.
Quality of Life  (EQ-5D-Y [Proxy version]) scoring will be completed by the patient's parent(s)/legal guardian(s).
k. Concomitant therapy  includes a ll medication and medical procedures (including any unplanned diagnostic, therapeutic or surgical procedures) ongoing at or s tarting
after the time of written consent.
l. Adverse events (AEs) : ALL AEs which occur from the time of written informed consent to the end of the extension phase of the study or patient withdrawal, will be
recorded in the eCRF.
m. Arimoclomol dispensing: Patients will be dispensed sufficient arimoclomol to continue treatment. When this dispensing does not coincide with a site visit, this supply
of arimoclomol will be shipped to the patient‚Äôs home.
Arimoclomol return:  Patients will be required to return all unused Arimoclomol  (and relevant packaging [ used/empty bottles ]) to the site staff at each visit. The site
staff should aim to follow u p on the reasons for any missing Arimoclomol or other discrepancies noted after performing the relevant Arimoclomol accountability.
n. Arimoclomol administration : If required, arimoclomol can be dissolved in 10 mL (i.e. 2 teaspoons) of liquid or in a tablespoon of soft foodstuff. In the dissolved or
dispersed state, arimoclomol can also be administered via a gastric tube (as applicable).
The patient‚Äôs weight should be measured at each visit and the arimoclomol dose should be adjusted as required and arimoclomol dispensed as relevant.
o. Telephone follow up to be performed every 3 -4 months following the start of the extension phase of the study. Telephone follow -up includes follow -up on the status
of the patient, whether the patient has experienced any new AEs or the worsening of any existing AEs, whether the patient has had a change in any prescribedmedication, whether the patient has experienced any difficulties in taking arimoclomol and to confirm the weight of the patie nt.
p.Unscheduled visit : T he patient may a ttend the site for unscheduled visits should the patient experience an unacceptable rate of progression or should there be an y
safety concerns.
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 136 of 173 
Final Version 1 1.0; 21-Jun-2022 CONFIDENTIAL  q. End of Extension Phase : The end of extension phase visit should take place within 60 months (¬±8 weeks) after randomisation or within 4 weeks of withdrawal during
extension phase.
Withdrawal from study : Should a patient discontinue prematurely and choose to withdraw from the study during the extension phase, all effort should be made to
have the patient attend the site for the end of extension phase visit within 4 weeks of patient withdrawal. Should the patient (or the patient's parent[s]/legal guardian[s])
refuse to attend the end of extension phase visit, the date and reason for study discontinuation will be recor ded in the eCRF as a minimum.
Protocol CT -ORZY -NPC -002 Arimoclomol in Niemann -Pick disease type C  Page 137 of 173 
Final Version 11.0; 21- Jun-2022  CONFIDENTIAL  25.5. APPENDIX V: PAEDIATRIC SUBSTUDY 
The sub-study is ongoing as a separate trial and does not contribute to 
the primary or secondary endpoints of the main trial . Therefore the 
details are not included here. 